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Introduction 
1 Introduction 
 
The growth hormone (GH)/insulin-like growth factor (IGF)-axis is a key endocrine 
regulatory system of growth and differentiation of cells, tissues and organs as well as 
the whole organism 1. IGF binding proteins (IGFBPs) represent a crucial part of this 
axis and are capable to essentially modulate IGF-I and IGF-II actions via different 
mechanisms as well as to act IGF-independently 2,3.  
The so far known six structurally related, high-affinity IGF binding proteins  
(IGFBP-1 to -6) are distributed in a highly defined fashion in various organs and 
tissues, and in biological fluids 4. Their functions have been studied extensively in 
vitro, revealing a broad spectrum of actions for a given IGFBP. In order to unravel 
IGFBP actions in vivo, several mouse models lacking or overexpressing specific 
IGFBPs have been generated by transgenic technology in the last decade. However, 
the biological relevance of IGFBPs in vivo is only partially understood 5. 
IGFBP-2 is the second most abundant IGFBP in the circulation and has been identi-
fied as an inhibitor of postnatal growth in mice in vivo 6. The growth inhibitory effect of 
IGFBP-2 was even more pronounced in the context of GH and IGF-I excess in GH 
transgenic giant mice, than in animals with normal GH and IGF-I levels. The stimula-
ted growth of the kidneys, the adrenal glands, and the carcass observed in GH trans-
genic mice was most potently reduced by IGFBP-2 excess 7.  
Further findings implicate IGFBP-2 as a good candidate to modulate GH/IGF actions 
on the adrenal gland and on the kidney or to act by GH/IGF-independent mecha-
nisms. IGFBP-2 attracted particular attention in the context of adrenal physiology and 
pathology since 1) IGFBP-2 is co-regulated with IGF-II, an important factor inducing 
proliferation of adrenocortical cells and steroidogenesis 8; 2) overexpression of 
IGFBP-2 and secretion into the circulation are characteristic for adrenocortical 
carcinomas 9; and 3) overexpression of IGFBP-2 in mouse adrenocortical tumor cells 
(Y-1) increased their tumorigenic potential, i.e., stimulation of anchorage-dependent 
and -independent proliferation and changes in cellular morphology 10. 
Further, an involvement of IGFBP-2 in several physiological and pathological 
conditions of the kidney has been suggested, since 1) serum IGFBP-2 levels are 
correlated with the degree of renal dysfunction and are inversely correlated with 
height in children suffering from chronic renal failure 11; 2) overexpression of IGFBP-2 
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in murine mesangial cells (MMC) avoids IGF-I-induced proliferation of those cells 12;  
3) IGFBP-2 is overexpressed in cyst epithelia in human multicystic renal dysplasia 13. 
 
GH transgenic mice represent a widely used experimental model for growth 
research. Phenotypical characterization of GH transgenic mice revealed a typical 
spectrum of alterations, including increased somatic growth and visceromegaly 14. 
GH transgenic mice exhibit enlarged adrenal glands associated with corticosterone 
hypersecretion 15,16, so that studies concerning growth regulation of adrenocortical cells 
easily can be combined with a functional read-out, i.e., plasma corticosterone secretion. 
The GH transgenic mouse further represents a valuable animal model for progressive 
glomerulosclerosis, chronic renal failure, and acquired cystic kidney disease (ACKD) 17. 
 
The objective of this study was to characterize IGFBP-2 effects on growth and 
function of the adrenal gland and the kidney in normal and GH-stimulated conditions. 
Quantitative morphological and functional studies were performed on a collective of 
mice of four different genetic groups. The groups were generated by an experimental 
cross of hemizygous transgenic mice overexpressing murine IGFBP-2 under the 
transcriptional control of the cytomegalovirus (CMV) promoter with hemizygous 
transgenic mice overexpressing bovine GH under the transcriptional control of the rat 
phosphoenolpyruvate carboxykinase (PEPCK) promoter.  
In particular, the following questions were addressed: 1) Whether adrenal enlargement 
observed in G mice is due to cellular hyperplasia, hypertrophy, or both. 2) How 
corticosterone hypersecretion is linked with these changes. 3) Whether adrenal 
enlargement and function are affected by IGFBP-2. 4) Which compartments of the 
kidney are involved in GH/IGF-I-induced renal hypertrophy. 5) Whether IGFBP-2 
overexpression affects GH/IGF-I-induced glomerular hypertrophy and damage.  
6) Whether overexpression of IGFBP-2 affects tubular cells under normal and  
GH/IGF-I-stimulated conditions.  
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2 Literature 
 
2.1 Overview of the components of the GH/IGF-axis  
 
The GH/IGF-axis displays a complex, interrelated and interactive system consisting 
of the peptide hormone GH, the peptide growth factors IGF-I and IGF-II, their specific 
receptors as well as a series of binding proteins, and multiple related proteases 1,18. 
 
2.1.1 Growth hormone 
 
GH belongs to a large family of cytokine peptides. It is synthesized and stored 
exclusively by somatotroph cells within the anterior pituitary 19, and is secreted in a 
pulsatile manner 20,21. Its amino acid sequence is highly conserved between different 
species, e.g., rat (r) and murine (m) GH show 95% and 92% identity with bovine (b) 
GH, respectively 22. GH expression and secretion is mainly regulated by two 
hypothalamic peptides, the growth hormone-releasing hormone (GHRH) and the 
somatotropin release-inhibiting factor (SRIF, somatostatin) 23. Apart from the neuro-
endocrine regulation, various other hormones, including GH, IGF-I, ghrelin, as well as 
the metabolic status affect GH synthesis and release 24,25. For example, IGF-I inhibits 
GH release by attenuating both the GH pulse frequency and amplitude 26.  
 
2.1.2 Growth hormone receptor and growth hormone binding protein 
 
The GH receptor (GHR) is a specific, high affinity cell-surface receptor that is 
activated by GH binding and mediates GH effects. When binding to its receptor, one 
GH molecule interacts with two GHR molecules, causing receptor dimerization 19. 
Post receptor signaling initially occurs through phosphorylation of the associated 
tyrosine kinase Janus Kinase 2 (JAK2) 27. GHR expression is highly tissue specific 
and regulated by numerous factors, including the developmental stage and nutritional 
status 28,29. Further, various hormones have been shown to affect GHR expression 
30,31. 
The GH binding protein (GHBP) is the slightly modified, soluble form of the GHR 
extracellular ligand binding domain and occurs in serum 32. GHBP binds up to 60% of 
circulating GH 33 and is suggested to act as a reservoir, buffering the secretory peaks 
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of GH 19. Binding increases half-life of serum GH from about 20 minutes to several 
hours, mainly by decreasing renal clearance 34.  
GH is able to influence GHR/BP expression dose-dependently 31 and in a tissue-
specific fashion, as shown by in vitro and in vivo studies. In mice, hepatic GHR/BP 
mRNA levels are positively correlated with increased GH levels, whereas pituitary 
GHR/BP mRNA levels are not affected 35. In contrast, in the kidney, GH binding sites 
are down-regulated by high serum GH levels 36.  
 
2.1.3 Insulin-like growth factors 
 
Together with their cognate receptors and binding proteins, IGF-I and IGF-II com-
pose the IGF-system 37. IGF-I and IGF-II are growth and differentiation promoting 
single-chain polypeptides, which share significant structural homology with insulin 38 
and act as endocrine as well as auto-/paracrine growth factors 39. Both IGF-I and 
IGF-II bind with high affinity to specific cell surface receptors (see 2.1.4), but are also 
able to interact with the insulin receptor and exhibit biological effects similar to those 
of insulin 40. IGF-I is synthesized and released from multiple tissues. Postnatally, the 
vast majority of circulating IGF-I originates from GH-induced expression and 
secretion of the liver 41,42, as proposed by the somatomedin hypothesis 1,43. IGF-I 
expression further depends on tissue type and developmental and physiological or 
pathological status. Contrary to IGF-I, expression of IGF-II is not stimulated by GH 40. 
 
2.1.4 Insulin-like growth factor receptors 
 
The type I IGF receptor (IGF-IR) and type II IGF receptor (IGF-IIR) represent specific 
cell-surface receptors, which mediate the effects of the IGFs 2. According to the cur-
rent view of IGF-IR and IGF-IIR functions, pre- and postnatal IGF signaling is mainly 
mediated through the IGF-IR 44,45, whereas the IGF-IIR mediates IGF binding, endo-
cytosis and lysosomal degradation, thereby acting as a growth inhibitor 46.  
The tetrameric IGF-IR consists of two extracellular, ligand-binding α-subunits and two 
transmembrane and cytoplasmatic, tyrosine residues containing β-subunits, linked by 
disulfide bonds 47. IGF-IR binds IGF-I with KD of 0.2-1 x 10-9 M, whereas its affinity to 
IGF-II and insulin is about 2-15 fold and 100-1000 fold lower, respectively 48.  
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IGF binding to the α-subunit of the IGF-IR causes autophosphorylation of different 
tyrosine kinases of the β-subunits 49,50. The postnatal expression of IGF-IR is 
influenced by the nutritional status and various hormones 47, and by pathological 
conditions, especially in the kidney 51,52. 
The mammalian IGF-IIR is identical to the cation-independent mannose 6-phospate 
(M6P) receptor (M6PR) and is thus referred as the IGF-IIR/M6PR. It binds IGF-I and 
IGF-II, but no known signal transduction mechanism is initiated by the IGF-IIR/M6PR 
45,53. An exception of the current view was recently given by Pantaleon et al. 45, who 
demonstrated an involvement of the IGF-IIR/M6PR in the regulation of growth of 
early mouse embryos. 
The IGF-IIR/M6PR binds IGF-II with high affinity (KD = 0.02-0.7 x 10-9 M) and IGF-I 
with 100-500 fold lower affinity, further, it binds various other ligands, including glyco-
proteins bearing the M6P recognition marker 54. The expression of IGF-IIR/M6PR is 
developmentally regulated 45. It is high in multiple fetal tissues, and declines 
dramatically in most tissues during the late gestational and/or in the early postnatal 
period 55-57. 
 
2.1.5 Insulin-like growth factor-binding proteins 
 
The insulin-like growth factor-binding proteins (IGFBPs) comprise a family of six 
homologous peptides (IGFBP-1 to -6) that bind IGF-I and IGF-II with high affinity 4,44. 
Together with nine IGFBP-related proteins (IGFBP-rP 1 to -9), which are able to bind 
the IGFs with low affinity 58, they create an IGFBP superfamily 59-61.  
The IGFBPs occur in circulation, several other biological fluids and tissues in a 
specific pattern 4. The expression of the different IGFBPs is tightly regulated in a 
development- and tissue-specific manner, depending on various factors, such as 
metabolic situation, hormones, and pathologic conditions 9,62.  
The IGFBPs bind IGFs with high affinity (KD ~ 10-10 M), thereby creating complexes of 
distinct molecular weight. In serum, approximately 75-80% of the IGFs are bound to 
IGFBP-3 comprising a 150 kDa ternary complex consisting of one molecule each of 
IGF-I or IGF-II, IGFBP-3, and a non-IGF binding glycoprotein, termed acid labile 
subunit (ALS) 2,63. A smaller proportion (20-25%) of the serum IGFs is bound to the 
other IGFBPs, forming a 45 kDa binary complex, and less than 1% is found in an 
unbound form 4. IGFBP-5 is able to form a 45 kDa binary complex or to form a 
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ternary complex of 130 kDa together with ALS 64. IGFBP-2 is the second most 
abundant IGFBP in circulation 4.  
IGFBPs are capable of inhibiting or enhancing IGF effects, but also exert IGF-inde-
pendent effects 3. IGF-dependent effects of IGFBPs refer to their ability of binding 
IGFs, thereby sequestering the IGFs from their receptors and manipulating their bio-
availability, as well as supporting transport and storage of the IGFs 65. IGFBP-binding 
prolongs half-life of serum IGFs from less than ten minutes of unbound IGFs to 20-30 
minutes in the 45 kDa complex and to 12-15 hours in the ternary complex 66,67. IGF-
independent effects derive from the ability of the IGFBPs to interact with proteins 
other than the IGFs, including ALS, insulin, components of the cell surface, ECM 
proteins, and potentially, intracellular components 65,68.  
Specific proteases are able to cleave every IGFBP. The IGFBP fragments show no or 
drastically reduced affinity to the IGFs, resulting in an altered bioavailability of the 
IGFs 69. The group of proteases is heterogeneous and includes kallikrein-like serine 
proteases, cathepsins and matrix metalloproteinases 70. 
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2.2 Studying the role of the GH/IGF-axis in growth processes 
 
The various components of the GH/IGF-axis are multifarious interacting and complex 
interrelated, thereby exhibiting pleiotropic effects on anatomic structures - from the 
single cell over tissues and organs to the whole organism 1,18. Growth of a 
mammalian organism is a phenomenon effected predominately by proliferative 
events, outbalancing apoptosis and increasing total cell number, with some additional 
contributions of cell hypertrophy and deposition of extracellular matrix 71. Beside its 
role in regulating physiological growth processes, the GH/IGF-axis is involved in 
various pathological growth processes, with diverse components of this axis being 
dysregulated 72-74. In many physiological and pathological situations, it is difficult to 
predict, which individual members of the GH/IGF-axis are responsible for growth or 
altered growth, and which ones are only co-regulated without an intrinsic effect on 
growth processes 72,75,76.  
Genetically modified mice represent a powerful tool for studying the contribution of 
individual members of the GH/IGF-axis to growth processes in vivo. Those animals, 
which either overexpress a particular gene or harbor a knockout of a particular gene, 
provide an unique opportunity for performing gain of function, or partial or complete 
loss of function studies regarding a particular gene 76,77. Beside genetically modified 
mouse models, mouse strains that carry spontaneous mutations, leading to a partial 
or complete deficiency of an individual member of the GH/IGF-axis are of interest for 
studying the role of various components of the GH/IGF-axis in the regulation of 
growth and differentiation. 
 
2.2.1 Studying the role of GH in growth processes 
 
2.2.1.1 GH transgenic and GH deficient mouse models 
 
The murine metallothionein-I (MT) promoter-hGH transgenic mouse, generated by 
Palmiter et al. in 1982 78, was one of the first transgenic animals. Since then, several 
strains of transgenic mice overexpressing heterologous GH genes under the trans-
criptional control of various regulatory elements have been developed 79. Frequently 
used promoters are the transcriptional regulatory elements from the MT gene 80 or 
the rat phosphoenolpyruvate carboxykinase (PEPCK) gene 81. GH gene sequences 
 
-8- 
Literature 
from several species, including human, rat, cow, and sheep, have been incorporated 
into the mouse genome. Different GH fusion genes introduced into the mouse 
genome are summarized by Wanke et al. 82 and Kopchick et al. 83. 
GH transgenic mice display high serum levels of heterologous GH and increased 
serum IGF-I levels 84,85. For example, a MT-hGH transgenic mouse strain was repor-
ted to exhibit heterologous GH levels ranging from 1.2 to 900 µg/ml, as well as about 
two- to three-fold increased serum IGF-I levels 79. The most obvious phenotypical 
effect of GH transgene expression is the markedly stimulated overall body growth. 
From three weeks of age onwards, GH transgenic mice display an increased body 
weight, which is almost doubled in adult animals versus wild-type controls 86,87, as 
well as visceromegaly and disproportionate skeletal gigantism 88,89. 
GH transgenic mice demonstrate a typical spectrum of pathomorphological altera-
tions of inner organs, with the kidney and liver being predominantly affected 14,82. 
Renal alterations result in chronic renal failure progressing to end-stage renal 
disease (see 2.4.3.1). The liver of GH transgenic mice is overproportionally enlarged 
in relation to body size. Sequential histological studies revealed a characteristic 
sequence of liver changes. Initial alterations are characterized by hepatocellular 
hypertrophy and single cell necroses. Subsequent stages include hypertrophic and 
regressive liver cell changes, oval cell proliferation, and focal growth of hepatocytes 
exhibiting no tendency to megalocytic change. Apart from non-neoplastic changes, 
hepatocellular tumors, including both adenoma and carcinoma, occur age-depen-
dently at a high frequency in GH transgenic mice 14,90.  
Further, transgenic GH male mice demonstrate stimulated skin growth, which results 
from an interaction of elevated GH levels with male sex hormones 91. Life expectancy 
is significantly reduced in GH transgenic mice, primarily due to renal failure 92. 
 
GH deficiency has been detected in several mouse strains, harboring spontaneous 
genetic mutations. GH deficient mice are growth retarded from two weeks of age 
onwards resulting in dwarfism 75. Further, they usually show reduced fertility or are 
infertile, display additional severe endocrine alterations, and exhibit significantly 
prolonged longevity 93,94. 
Snell dwarf mice (dw/dw) 95 carry a missense mutation in the gene encoding Pit-1, 
which is a pituitary-specific transcription factor that is responsible for differentiation of 
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somatotrophs, lactotrophs, and thyrotrophs during fetal development of the pituitary 
gland 96. Snell dwarfs lack both GH and thyroid-stimulating hormone 75. 
Ames dwarf mice (df/df) carry a missense mutation at the Prop-1 (Prophet of pit-1) 
locus. The gene product of Prop-1 is responsible for the development of Pit-1 positive 
cells 97. The lack of Pit-1 positive cells in df/df mice apparently produces the same 
defects in pituitary development as in dw/dw mice, and thus, the phenotype of Ames 
dwarfs resembles that of Snell dwarfs 75. 
So called ´little´ mice (lit/lit) bear a homozygous autosomal recessive lit mutation 98 
and exhibit an isolated GH deficiency. The mutation consists of a single nucleotide 
substitution of the GH releasing hormone receptor gene. lit/lit mice possess only 
residual GH activity. Their pituitary and serum GH levels are reduced to less than 5% 
of normal 75.  
Although of significant importance for a variety of studies, these spontaneous dwarf 
mice are not considered as ideal models to study the GH/IGF-axis in postnatal 
growth, as they exhibit combined pituitary hormone deficiencies or possess residual 
GH activity. Therefore, several investigators chose GHR knockout mice (see under 
2.2.2.1) to study the effects of missing GH activity 75,99. 
 
2.2.1.2 Effects of GH on somatic growth  
 
GH promotes postnatal growth processes, whereas pre- and perinatal growth is GH 
independent 100 despite the presence of the GHR 101,102. In the postnatal period, GH 
effects can be mediated directly through activation of the GHR, indirectly either by 
stimulating IGF-I expression and release from the liver into the bloodstream - as 
proposed in the somatomedin hypothesis by Salmon and Daughaday in 1957 103 -, or 
by stimulating the local production of IGF-I in different organs 43,104. 
 
In humans, prolonged hypersecretion of GH before puberty can yield gigantism 18. 
GH hypersecretion in adults, mostly caused by pituitary adenomas 105, leads to a 
condition known as acromegaly 106. Acromegalic patients are characterized by 
increased serum levels of GH and IGF-I and show a number of anatomic alterations, 
including acral and soft tissue overgrowth, skin thickening, and thyroid enlargement 
106. In contrast, hyposecretion or no secretion of GH before puberty results in dwar-
fism. Adult patients with GH deficiency exhibit increased adiposity and decreased 
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lean body mass 107, and a reduced life expectancy, despite apparently sufficient 
replacement therapies . 
GH exerts a broad variety of biological actions 108. Apart from promoting postnatal 
growth and differentiation, GH affects lipid, protein, carbohydrate, and mineral meta-
bolism 19,106, and is assumed to modulate emotion, stress response, and behavior 109. 
Acromegalic human patients develop severe hyperinsulinemia, impaired glucose 
tolerance, insulin resistance, and as many as 50% of the acromegalic patients 
develop overt diabetes mellitus 110,111. Hyperinsulinemia associated with normoglyce-
mia is a consistent finding in GH transgenic mice 86,112. The reason for the apparent 
discrepancy in diabetogenesis between GH transgenic mice and human acromegalic 
patient is not clear 83. Like acromegalic patients, PEPCK-bGH transgenic rabbits 
exhibit an acromegalic phenotype and frequently develop diabetes mellitus 113.  
 
2.2.1.3 Effects of GH on other components of the GH/IGF-axis 
 
GH levels influence serum and tissue concentrations of various other components of 
the GH/IGF-axis. Serum IGF-I levels are increased by GH excess and decreased in 
GH deficiency states 114,115. Furthermore, serum GH levels and hepatic IGF-I mRNA 
and protein concentrations are positively correlated 104,116, whereas IGF-I mRNA 
levels of other organs are only partially GH-dependent or GH-independent 75,104. 
Altered GH levels influence the expression and abundance of IGFBPs 59. Hepatic 
mRNA as well as serum levels of IGFBP-2 are reduced by GH excess, but unaltered 
in GH deficiency states 117-119. IGFBP-3 serum levels are elevated by GH 119,120, 
whereas IGFBP-3 liver mRNA levels are not affected 117,120. An indirect effect of 
elevated IGF-I is discussed, which might protect IGFBP-3 from proteolysis by forming 
a ternary complex 121, or might promote the recruitment of IGFBP-3, attached to cell 
membranes 117. Hepatic ALS mRNA and serum levels are increased due to elevated 
GH levels 63,117.  
 
2.2.2 Studying the role of GHR/BP in growth processes 
 
In order to evaluate the biological effects of GHR/BP on growth processes, different 
GHR/BP knockout mouse strains were generated 75,99. Disruption of the GHR/BP 
gene causes failure of GHR/BP binding and signal transduction in homozygous (-/-) 
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mice resulting in the inability to utilize GH 122,123. GHR/BP -/- mice exhibit normal birth 
weights 75, but show a dwarfing phenotype from two weeks of age onwards weighing 
about 40%  to 45% of normal controls. GHR/BP -/- mice exhibit increased serum GH 
levels and drastically reduced IGF-I levels. Besides dwarfism, those mice demon-
strate delayed sexual maturity and increased longevity 123.  
The GHR/BP knockout mouse is discussed as a model for the human Laron 
syndrome (LS) 123,124, although the model differs in some aspects from human LS 
patients. Human LS patients tend to become obese and hypoglycemic, while 
GHR/BP -/- mice stay lean and normoglycemic. Insulin levels were found to be 
elevated in some LS patients, possibly due to obesity, while GHR/BP -/- mice show 
severely decreased insulin levels as compared to control mice 123,125. 
 
2.2.3 Studying the role of the IGFs in growth processes 
 
2.2.3.1 IGF-I and IGF-II transgenic mice 
 
Overexpression of hIGF-I under the transcriptional control of the MT promoter in 
transgenic mice stimulates somatic growth from four weeks of age onwards and 
results in an about 1.4-fold elevated body weight, as compared to non-transgenic 
siblings 85,126. MT-hIGF-I transgenic mice display an approximately 50% increase of 
serum IGF-I concentrations, as compared to controls 126. Due to the negative 
feedback regulation on pituitary GH synthesis by transgene-encoded serum IGF-I, 
endogenous serum GH levels and, as a consequence, hepatic endogenous IGF-I 
mRNA levels are reduced 126. Serum IGF-I concentrations in hIGF-I transgenic mice 
are markedly lower than those of GH transgenic mice, which is discussed to be at 
least partially responsible for the less stimulated body growth of hIGF-I transgenic 
mice 2. 
hIGF-I transgenic mice exhibit a selective organomegaly, with kidneys, carcass, 
brain, and pancreas being mostly affected, but no apparent increase in skeletal 
growth as seen in GH transgenic mice 84,126. Despite nephromegaly, IGF-I transgenic 
mice show no glomerulosclerotic lesions and only a moderate glomerular hyper-
trophy. The difference in renal pathology between GH- and IGF-I transgenic mice is 
discussed to be due to high serum GH levels and approximately doubled serum IGF-I 
levels in GH transgenic mice, as compared to IGF-I transgenic mice 84,127.  
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Several IGF-II transgenic mouse strains have been generated, harboring different 
IGF-II fusion genes 128. Analysis of the various IGF-II transgenic mouse strains 
revealed that the postnatal overproduction of IGF-II may affect body and/or organ 
weights, depending on the expression level and tissue specificity of IGF-II overpro-
duction as well as on the use of heterologous or homologous IGF-II coding regions. 
Several studies show a correlation between the sites where the transgene is 
expressed and the observed alterations in organ growth suggesting local actions of 
transgene-encoded IGF-II 128,129.  
In several IGF-II transgenic mouse strains, increased serum IGF-II levels correlate 
negatively with serum IGF-I levels, probably through a negative feedback regulation 
of IGF-II on pituitary GH synthesis and concomitant reduction of IGF-I expression 130. 
Another explanation for reduced serum IGF-I levels discussed, is the possibility that 
elevated serum IGF-II levels displace IGF-I from serum IGFBPs, leading to an 
accelerated plasma clearance rate of IGF-I 131. Serum IGFBP levels were not 
affected by IGF-II overexpression, except for IGFBP-2, which serum levels were 
correlated positively with IGF-II levels in several IGF-II transgenic mouse strains. The 
authors suggest that IGF-II is a major regulator of IGFBP-2 129. 
 
2.2.3.2 IGF-I and IGF-II knockout mice 
 
The knockout (-/-) of IGF-I or IGF-II in genetically engineered mice results in 
drastically reduced prenatal growth 132-135. Newborn mice lacking IGF-I or IGF-II show 
birth weights 40% and 60% lower than wild-type littermates 132.  
IGF-I -/- mice present a high neonatal death rate. In surviving animals, the postnatal 
absence of IGF-I impairs the body growth rate. At an age of seven to eight weeks, 
IGF-I knockout mice weigh only about 30% of controls emphasizing the relevance of 
IGF-I for normal postnatal growth 132. Further, mice lacking IGF-I demonstrate 
developmental defects in brain, muscle, bone and lung, and are infertile 132,136. The 
phenotype of IGF-I -/- mice resembles that of a known case of IGF-I gene deletion in 
a human patient. Deletion of the IGF-I gene in the human patient caused intrauterine 
and postnatal growth retardation leading to an extreme short stature 136.  
In contrast to IGF-I -/- mice, mice lacking IGF-II do not have an increased neonatal 
death rate and show normal postnatal growth rates 132. These findings support the 
hypothesis that IGF-II at physiologic concentrations has no relevance in postnatal 
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growth of mice 137. However, IGF-II -/- mice do not catch-up the prenatal growth 
deficit 133.  
Double knockout mice, lacking both IGF-I and IGF-II are more severely affected than 
single mutants, lacking either IGF-I or IGF-II. Their birth weight is decreased to 
approximately 30% of that of normal littermates indicating that the two ligands act, at 
least partially, independently. Those double knockout mice die within minutes after 
birth due to respiratory failure 132. 
 
2.2.3.3 Mice carrying a conditional knockout of the hepatic IGF-I gene 
 
Two different strains of liver IGF-I deficient (LID) mice were generated by gene 
targeting using the Cre/loxP system 138. LID mice display a hepatocyte-specific 
inactivation of the IGF-I gene resulting in hepatic IGF-I mRNA levels that are reduced 
to approximately 5% of control values 41,42. Contrary, IGF-I mRNA levels in non-
hepatic tissues are normal, with exception of spleenic IGF-I mRNA levels, which in 
one strain are also significantly reduced 42. As a consequence of hepatic IGF-I 
knockout, circulating IGF-I levels in LID mice are reduced by 75%, indicating that the 
liver is the main source of IGF-I in circulation. Serum GH concentrations in LID mice 
are elevated, which is supposed to result from the lack of IGF-I-mediated feedback 
regulation 41,42.  
Despite the reduction of serum IGF-I levels, LID mice show normal somatic growth 
and development. However, LID mice demonstrate disproportionate organ growth, 
including significantly increased liver and decreased kidney weight 41,42. These 
results demonstrate that liver-derived IGF-I is not required for postnatal somatic 
growth, which directly challenges the somatomedin hypothesis 42. However, this 
conclusion must be regarded critically, since increased circulating GH levels might 
compensate for the lack of serum IGF-I 6. Further studies revealed, that LID mice 
exhibit four-fold elevated serum insulin concentrations and muscle-specific insulin 
insensitivity 139 suggesting that IGF-I, together with GH and insulin, plays a role in 
maintaining a balanced carbohydrate metabolism 140.  
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2.2.4 Studying the role of the IGF-IR and IGF-IIR in growth processes 
 
In order to study the role of the IGF-IR and IGF-IIR in growth processes, IGF-IR- and 
IGF-IIR knockout mice have been generated. IGF-IR -/- mice exhibit a dwarfing 
phenotype with birth weights of approximately 45% of that of controls, and appear to 
be normally proportioned. They exhibit histological abnormalities, consisting of cellu-
lar hypoplasia, chiefly in skeletal muscle, internal organs, and the stratum spinosum 
of the skin. IGF-IR knockout mice die immediately after birth due to respiratory failure 
132,135. In heterozygous knockout mice (IGF-IR +/-), growth as well as IGF-IR mRNA 
levels are normal, suggesting effective up-regulation of the second (wild-type, intact) 
IGF-IR allele. Thus, a single functional wild-type allele of the IGF-IR is sufficient to 
assure normal IGF-IR expression and growth 132,135. In contrast, the reduction of the 
level of IGF-IR by either targeted partial invalidation of the IGF-IR gene or deletion of 
the essential exon 3 of the IGF-IR gene in genetically engineered mice, causes a 
modest postnatal growth deficit from four to five weeks of age onwards, with the 
weight differences affecting all tissues to a similar degree 141,142. In those mice, 
transcripts of mutated alleles are present, but cannot be translated into functional 
protein, thus leading to approximately by half reduced IGF-binding sites. These 
findings support the current view that the levels of IGF-IR protein are regulated on 
the transcriptional stage 142.  
 
Mouse mutants inheriting maternally a targeted disruption of the imprinted IGF-IIR 
gene (IGF-IIR knockout mice), which normally is only expressed from the maternal 
allele, have about 2- to 4.4-fold increased serum IGF-II levels and about 2-fold 
increased IGF-II protein contents in extracts of whole embryos 53,143,144. The authors 
explain the elevated IGF-II concentrations of IGF-IIR knockout mice by a failure of 
IGF-II binding and degradation. The phenotype is characterized by fetal overgrowth 
(135% of normal birth weight), generalized organomegaly, kinky tail, postaxial 
polydactyly and edema. The enlargement of organs was reported to be attributed to 
cellular hyperplasia, but not to cellular hypertrophy 53. IGF-IIR knockout mice usually 
die during the late fetal or perinatal period. A small minority of IGF-IIR knockout mice 
survives, depending on the genetic background. Since the paternal IGF-IIR allele is 
transcriptionally silent, the paternal transmission of the IGF-IIR mutation does not 
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affect the viability of heterozygous offspring, which are indistinguishable from wild-
type siblings 53. 
 
2.2.5 Studying the role of IGFBPs in growth regulation 
 
For evaluating the specific roles of the IGFBPs on growth processes in vivo, several 
mouse models lacking or overexpressing specific IGFBPs have been generated by 
transgenic technology.  
In contrast to the inactivation of ligands or receptors of the GH/IGF-I-axis, the knock-
out approach applied to IGFBPs presents rather disappointing results 76. IGFBP-2 
knockout mice exhibit a reduction in spleen weight of adult males as the only anato-
mic alteration 145. Mice lacking IGFBP-4 are slightly smaller than control animals, and 
the genetic ablation of IGFBP-6 does not result in any apparent phenotypical 
changes 146. This phenomenon is discussed to be due to functional redundancy of 
the members of the IGFBP family, which prevent the appearance of dramatic 
phenotypes 76.  
The alternative approach, overexpression of IGFBPs, has been far more successful 
in generating phenotypical changes 76. Phenotypic analysis revealed features that 
are common for most IGFBPs, such as growth retardation, but also effects that are 
specific for individual IGFBPs 5. Transgenic mice, overexpressing IGFBP-1 exhibit 
several organ-related alterations, with the brain and kidney being most affected (see 
under 2.4.2.4) as well as disturbed glucose homeostasis. IGFBP-2 transgenic mice 
are presented in depth below. IGFBP-3 transgenic mice display no alterations in 
somatic growth, but show significantly increased weights of heart, liver, and spleen. 
Surprisingly, the selective organomegaly develops in organs different from the sites 
of major IGFBP-3 transgene expression 76. Findings in transgenic mice overexpres-
sing IGFBP-4 under the control of the H-2Kb promoter suggest that IGFBP-4 is a 
potential growth inhibitor of lymphoid tissues 147. Local overexpression of IGFBP-4 in 
smooth muscle cells of transgenic mice resulted in decreased weights of bladder, 
aorta, and stomach as a consequence of hypoplasia of smooth muscle cells, and did 
not affect body weight 148. Overexpression of IGFBP-5 under the control of the 
calcein promoter in transgenic mice results in a transiently impaired osteoblast 
function, in a decrease in trabecular bone, and osteopenia 149. Local overexpression 
of IGFBP-5 in mammary gland epithelial cells of transgenic mice leads to impaired 
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mammary development, due to a decreased number of mammary gland epithelial 
cells 150. Transgenic mice, overexpressing IGFBP-6 under the control of the glial 
fibrillary acidic protein promoter show high IGFBP-6 levels in the circulation and 
brain. They display reduced body weights at juvenile age as well as a reduced brain 
size, impaired ovary function and reduced litter sizes 151. 
 
IGFBP-2 transgenic mice 
Transgenic mice overexpressing homologous IGFBP-2 under the control of the 
cytomegalovirus (CMV) promoter show an expression of transgenic IGFBP-2 mRNA 
in numerous organs with exception of the liver 152. They exhibit markedly elevated 
IGFBP-2 protein levels in several organs including kidney and adrenal gland. Serum 
IGFBP-2 levels are about three-fold increased in IGFBP-2 transgenic mice, if 
compared to their non-transgenic littermates, whereas serum concentrations of IGF-I, 
IGF-II, IGFBP-3, and -4 are not altered.  
Phenotypic effects of IGFBP-2 overexpression in transgenic mice include reduced 
body weight gain from 23 days of age onwards. The reduction of body weight is 
mainly determined by decreased carcass weight, whereas absolute and/or relative 
(to body weight) organ weights are only partially and slightly reduced. Among the 
organs, pancreas, spleen, and liver are most prominently reduced in weight. Further 
evidence for a role of IGFBP-2 as a growth inhibitor in vivo derives from normal mice 
selected for low eight-week body weight, in which growth reduction is associated with 
increased hepatic IGFBP-2 mRNA expression and serum IGFBP-2 levels 153. 
Interestingly, the phenotype of IGFBP-2 transgenic mice is inverse to that of IGF-I 
transgenic mice 126, indicating that in vivo, the growth inhibiting effect of IGFBP-2 
maybe due to the suppression of IGF-I effects 152.  
 
Crossbreeding of IGFBP-2 transgenic mice with transgenic mice overexpressing 
bovine (b) GH demonstrated that the growth inhibiting effect of IGFBP-2 is even more 
pronounced in high than in normal GH/IGF-I conditions 7. Five-week-old double 
(IGFBP-2 and bGH) transgenic animals exhibit body weights that range at the level of 
non-transgenic controls demonstrating that IGFBP-2 overexpression normalizes GH-
stimulated body growth in mice at this age. At an age of 15 weeks, the body weight of 
double transgenic mice is drastically reduced, as compared to bGH transgenic mice, 
ranging at an intermediate level between the body weight of controls and that of bGH 
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transgenic littermates. Various organs and tissues are differently affected by the 
growth inhibiting effect of elevated IGFBP-2. In double vs. bGH transgenic mice for 
example, the weight reduction of the adrenal gland and the kidney is even 
overproportional when compared to the reduction of body weight, pointing out the 
relevance of the GH/IGF-axis in regulation of adrenal gland and kidney growth  
in vivo.  
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2.3 The GH/IGF-axis and the adrenal gland 
 
Apart from adrenocorticotropin (ACTH), which is the primary regulator of adrenocorti-
cal growth and function, the GH/IGF-axis is intimately involved in the developmental 
and functional regulation of the adrenal gland 154. Both in vitro and in vivo studies 
demonstrated effects of single components of the GH/IGF-axis on fetal and adult as 
well as on neoplastic adrenal tissue. 
 
2.3.1 Effects of GH on adrenal growth and function 
 
In vivo, GH excess causes adrenal enlargement and corticosterone hypersecretion in 
various species. Administration of porcine (p) GH to barrows increases adrenal 
weight 155. Transplantation of GH-producing tumors in rats leads to a 300% increase 
in adrenal weight and elevates serum corticosterone levels despite unaltered ACTH 
levels 156. Chronic overexpression of hGH or bGH in transgenic mice results in ad-
renal enlargement 79, and increased serum corticosterone and plasma ACTH levels 
15,16, whereas GH-deficiency in mice is associated with size reduction of adrenal 
glands 157 and unaltered corticosterone levels 118. In children affected by isolated GH-
deficiency, an elevated ACTH-induced steroidogenesis has been observed during 
short-term treatment with recombinant hGH 158. Since the GH receptor is found in the 
adrenal gland of several species, including mouse, rat and man, a direct effect of GH 
on adrenal tissue is discussed by several authors 159-161.  
However, hGH does not have a direct effect on basal or ACTH-induced steroido-
genesis in fetal and adult human adrenocortical cells (HAC) 162,163. Likewise, bGH is 
unable to induce steroidogenesis in murine adrenocortical tissue in vitro 15. 
 
2.3.2 Expression of the IGFs in the adrenal gland and their effects on adrenal growth 
and function 
 
The IGFs play a crucial role in growth and function of the adrenal gland. They exhibit 
mitogenic and differentiating effects on both fetal and adult adrenocortical tissue 154, 
and are assumed to act predominantly in a para-/autocrine manner at the 
adrenocortical level 164.  
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2.3.2.1 IGFs and the fetal adrenal gland 
 
Fetal adrenal tissue of different species, including man 154,165, rhesus monkey 166, 
sheep 167, and rat 168 contains high levels of IGF-II mRNA and IGF-II protein. As 
shown in the fetal human and fetal rhesus monkey adrenal gland, the expression of 
IGF-II is restricted to the cortex 166,169. Contrary, IGF-I mRNA and IGF-I protein is 
absent, or found only at minimal levels in the fetal adrenal gland. Similarly, in fetal 
HAC, mRNA levels encoding IGF-II are highly abundant, whereas IGF-I mRNA is  
not detectable 169. Since the adrenal gland grows rapidly from midgestation until term 
170, a central role of IGF-II in promoting growth of the fetal adrenal gland is postulated 
154.  
IGF-II expression in the fetal adrenocortex is regulated by numerous hormones and 
factors, such as GH, IGF-I, IGF-II and TGFβ 165,169. However, pituitary ACTH has 
been shown to be the major promoter of adrenocortical IGF-II mRNA expression 154. 
In fetal HAC, IGF-II mRNA concentrations are increased by ACTH in a time- and 
dose-dependent manner 165. In rhesus monkey fetuses, elevated serum ACTH levels, 
which are achieved by in uteri metyrapone treatment, cause significantly increased 
adrenal IGF-II mRNA levels, as compared to untreated controls 166.  
 
Depending on the species, IGF-I and/or IGF-II exhibit mitogenic and differentiating 
effects on the fetal adrenocortex. In vitro, both hIGF-I and hIGF-II stimulate 
proliferation of fetal HAC in a dose-dependent fashion 169. In fetal rat adrenal cells, 
only IGF-II but not IGF-I acts mitogenic, pointing out the relevance of IGF-II in the 
fetal growth of the rat adrenal gland 171. In vivo, increased adrenal IGF-II levels are 
associated with stimulated growth of the fetal rhesus monkey adrenal gland, due to 
hypertrophy of adrenocortical cells of the definitive, transitional and fetal zones, 
whereas the adrenal medulla is unaffected 166. 
IGF-I and IGF-II show differentiating effects in fetal HAC, likely through interaction 
with the IGF-IR 154. IGF-II augments ACTH-stimulated cortisol and androgen 
synthesis through up-regulation of several adrenal steroidogenic key enzymes 172,173. 
Both IGF-I and IGF-II directly up-regulate basal expression of the steroidogenic key 
enzyme cytochrome P450 17α-hydroxylase 163.  
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2.3.2.2 IGFs and the adult adrenal gland 
 
The expression and presence of the IGFs in the adult adrenal gland differs from that 
in the fetal adrenal gland 174. In the adult human adrenal gland, IGF-II mRNA is 
almost undetectable, whereas IGF-I expression is comparably high in adult and fetal 
adrenals 175. Likewise, IGF-I is expressed in the adrenal gland of adult mice, whereas 
no IGF-II mRNA is detectable 8.  
Contrary, in vitro adult HAC secrete IGF-I and IGF-II, which might be due to culture 
conditions 176. IGF-I and IGF-II secretion of adult HAC is stimulated by ACTH 176, but 
not by hGH 162 . Similarly, in adult bovine adrenocortical cells (BAC), IGF-I secretion 
can be stimulated dose-dependently by ACTH 177.  
 
IGF-I and IGF-II stimulate growth and steroidogenesis of the adult adrenal gland. In 
vivo, infusion of IGF-I into guinea pigs causes an increase in the fractional weight of 
the adrenal glands. This effect is more pronounced with long R3 IGF-I, an IGF-I 
anaogue with reduced affinity to IGFBPs 178. hGH and bGH transgenic mice with 
increased systemic and adrenal IGF-I levels, display adrenal enlargement as well as 
elevated plasma corticosterone and ACTH levels 16,79,159. Since hGH has no direct 
steroidogenic effect on adult HAC 162, IGF-I is likely to be responsible for the adrenal 
changes in hGH and bGH transgenic mice. PEPCK-hIGF-II transgenic mice, 
exhibiting increased IGF-II serum levels and adrenal IGF-II transgene expression, 
display an elevated adrenal weight resulting from an increased volume of the zona 
fasciculata 129. hIGF-II transgenic mice exhibit two-fold elevated serum corticosterone 
concentrations, but unaltered plasma ACTH levels, as compared to non-transgenic 
control mice, excluding direct effects of hIGF-II on the hypothalamic or pituitary level 
8. Several lines of evidence indicate that in the adrenal gland, the IGFs act primarily 
at the local level in a paracrine/autocrine fashion 176. In the transgenic mouse models 
mentioned above, however, it remains unclear, whether the IGFs act on the adrenal 
gland in an endocrine or rather a paracrine/autocrine fashion 8. 
The steroidogenic effect of IGF-I and IGF-II has been confirmed in vitro. In adult 
HAC, IGF-I and more potently IGF-II stimulates basal as well as ACTH-induced 
steroid biosynthesis in a time- and dose-dependent manner through interaction with 
the IGF-IR 163. The stimulation of steroid biosynthesis is linked to an up-regulation of 
steroidogenic key enzymes, and an increase in ACTH sensitivity due to an elevated 
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ACTH-receptor expression 163,174. IGF-I and IGF-II display comparable effects in adult 
BAC, concerning cortisol secretion 179,180. Furthermore, in adult BAC, IGF-I is 
involved in the regulation of Steroidogenic acute Regulatory Protein (StAR) 179, which 
is assumed to play a key role in the acute steroidogenic response of steroidogenic 
cells 181,182.  
Results obtained from studies using rodent adrenocortical cells differ from those 
obtained with HAC or BAC. In rat adrenocortical cells, IGF-I exhibits an inhibitory 
effect on steroid biosynthesis 183, whereas in murine adrenocortical cells, IGF-I has 
no effect on adrenocortical steroid secretion 15. The discrepancy in the steroidogenic 
potency of IGFs might be due to species differences or to methodic variations bet-
ween the studies. Methodic variations for example, concern incubation times of the 
adrenocortical cells, which are two and four hours in the murine experiment, whereas 
they are up to 48 hours in time course studies using HAC and BAC. The maximum 
stimulation of basal and ACTH-induced cortisol secretion through IGF-I and IGF-II is 
reached after 36 or 48 hours in HAC and BAC.  
 
2.3.3 Role of the IGF-IR and IGF-IIR/M6PR in adrenal growth 
 
The mitogenic and differentiating effects of IGF-I and IGF-II on the adrenal gland are 
assumed to be mediated through interaction with the IGF-IR 154. This is supported by 
bovine and human cell culture studies, demonstrating that both IGF-I and IGF-II 
stimulate steroidogenesis exclusively through activation of the IGF-IR 8,180. The 
physiological role of the IGF-IIR/M6PR in the adrenal cortex remains controversial 164. 
Since loss of heterozygousity at the IGF-IIR/M6PR locus represents a frequent event 
in human adrenocortical tumors, a tumor suppressing role is discussed for the  
IGF-IIR/M6PR 46,184. 
Both the IGF-IR and IGF-IIR/M6PR are expressed in fetal and adult human adrenal 
glands to a comparable extend 175, and are abundant at a similar level in all zones of 
the adult adrenal cortex 185,186. As shown in the fetal rhesus monkey adrenal gland, 
IGF-IR expression is restricted to the definitive, transitional, and fetal zone of the 
adrenal cortex 166. Since IGF-IR expression levels decline to non-detectable levels 
from the end of the second trimester until term 166, the authors propose a growth 
regulative role of the decreasing IGF-IR expression, since 1) the IGF-IR expression 
changes perinatally, whereas no other components of the GH/IGF-axis is altered, and 
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2) the adrenal weight decreases significantly by the first week after delivery 170. 
Besides the developmental regulation, ACTH stimulates adrenocortical expression of 
IGF-IR, as evidenced in vivo in the fetal primate adrenal gland 166 and in vitro in bovine 
adrenocortical cells 187.  
 
2.3.4 Effects of the IGFBPs on adrenal growth 
 
The occurrence of IGFBP mRNA and protein in the adrenal gland has been investiga-
ted in various species. Most detailed information derives from studies in primates. 
Both fetal and adult human adrenal glands express IGFBP-2 at equal levels, as 
determined by Northern blot analysis 175, and, like in fetal rhesus monkey adrenal 
tissue, the relative abundance of IGFBP-2 is greater than that of other IGFBPs 166. 
These results indicate physiological significance of IGFBP-2 in both the fetal and adult 
adrenal gland. Conversely, IGFBP-1 and -3 are expressed in fetal but not adult human 
adrenal tissue, with IGFBP-1 expression levels being low. Furthermore, fetal and adult 
human adrenal tissue express IGFBP-4, -5 and -6 mRNA 175.  
As determined by in situ hybridization, IGFBP-2 and -6 mRNA is localized in 
adrenocortical parenchymal cells in fetal rhesus monkey adrenal tissue. The authors 
therefore suggest an essential role of IGFBP-2 and -6 in the primate fetal adrenal 
gland 166. In contrast, IGFBP-3, -4 and -5 mRNA are not localized in adrenocortical 
parenchymal cells, but in connective tissue surrounding the adrenal gland (IGFBP-3 
and -4), and in endothelial cells of intra-adrenocortical blood vessels (IGFBP-5). 
Although IGFBP-3, -4 and -5 are not localized in parenchymal cells of the 
adrenocortex, a possible paracrine action of these IGFBPs must be considered 166.  
 
Cultured adrenocortical cells secrete IGFBPs, and the in vitro expression pattern 
differs from that in vivo. In the medium of cultured fetal and adult HAC, IGFBP-3 is the 
most abundant IGFBP, whereas IGFBP-6 is not detectable, or at minimal levels 175,188. 
Quantification of the IGF binding capacity in adult HAC medium reveals that IGFBP-3 
accounts for almost half of the IGF binding capacity, whereas IGFBP-2 accounts for 
about 12% 188. Adult BAC secrete a comparable pattern of IGFBPs 189. 
The secretion of individual IGFBPs by adult HAC and BAC can be stimulated through 
ACTH and IGFs 188,189. In adult HAC and BAC, ACTH treatment increases IGFBP-1 
and -3 secretion, whereas incubation with IGFs elevates IGFBP-3 and -5 levels 177,189. 
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The enhanced secretion of IGFBP-1 and -5 by ACTH and IGFs, respectively, is 
paralleled by an increase in IGFBP-1 and -5 mRNA levels in these cells 188.  
Locally expressed IGFBPs are able to modulate effects of the IGFs on adrenocortical 
cells. In HAC and BAC, the divergent steroidogenic potency of IGF-I and IGF-II (see 
2.3.2.2) is caused by different interactions of IGFBPs with IGF-I and IGF -II. So far, it 
remains unclear, which particular IGFBP(s) is (are) responsible for this modulatory 
effect. Since some IGFBPs exhibit a greater affinity for IGF-II 4, the authors assume 
that the stronger steroidogenic potency of IGF-II is due to a preferential binding of  
IGF-II to IGFBPs that are capable of adhering to the cell surface and promote the 
interaction of IGF-II with the IGF-I receptor 174,180. The potency of a single IGFBP to 
modulate IGF-stimulated steroidogenesis has been shown for IGFBP-1, which 
potentiates IGF-I effects 190. 
 
In vivo, a characteristic change of the adrenal IGFBP pattern is associated with human 
adrenocortical carcinogenesis. In human adrenocortical neoplasms, IGFBP-2 
concentrations are significantly higher in malignant than in benign tumors. Despite 
elevated levels of IGFBP-2 protein in malignant adrenocortical tumor tissue, no 
increase of IGFBP-2 mRNA levels is detectable, suggesting the influence of post-
transcriptional mechanisms in the regulation of IGFBP-2 protein levels. In contrast to 
IGFBP-2, no change in the secretion of other IGFBPs is found in human adrenocorti-
cal tumors 191. Patients with metastasized adrenocortical carcinomas exhibit increased 
plasma IGFBP-2 levels, which correlate positively with tumor burden and inversely 
with survival 192. In vitro studies using Y-1 mouse adrenocortical tumor cells provide 
further evidence for a role of elevated IGFBP-2 in adrenocortical tumorigenesis. 
Overexpression of IGFBP-2 in transfected tumor cells is associated with significant 
morphological alterations, enhanced cell proliferation, and increased colony formation, 
as compared to control cells 10.  
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2.4 The GH/IGF-axis and the kidney 
 
The GH/IGF-axis plays a central role in renal growth and function. It is closely 
involved in growth and differentiation of the kidneys during nephrogenesis and 
development, but also in pathological processes of various renal disease states 193. 
Furthermore, single components of the GH/IGF-axis show effects on glomerular 
hemodynamics as well as on distinct tubular functions. Both locally expressed and 
circulating components of the GH/IGF-axis affect the kidneys, and the kidneys 
influence systemic levels of individual members of the GH/IGF-axis by eliminating 
them from circulation 18. 
 
2.4.1 Spatial distribution of the GH/IGF-axis in the kidney 
 
Within the kidney, the expression of components of the GH/IGF-axis is highly 
organized and differs among the anatomical segments of the nephron 194. Studies on 
the spatial distribution were performed predominantly in rats and mice, whereas less 
information is available about the expression pattern in human nephrons. Available 
data suggest that there are some species differences in the renal expression pattern 
of components of the GH/IGF-axis 195. In rats and mice, the renal expression of mem-
bers of the GH/IGF-axis is known to be altered in physiologic adaptive processes and 
in a number of experimental renal disease states 18. 
 
2.4.1.1 Spatial distribution of GHR in the kidney 
 
The GHR gene is expressed in the proximal tubule and the thick ascending limb of 
the loop of Henle (TALH), as demonstrated by in situ hybridization of rat kidneys 196. 
Since IGF-I mRNA is not expressed in the proximal tubule, or only at minimal levels, 
the authors assume direct GH effects on this nephron segment 196. This assumption 
is confirmed by in vitro studies demonstrating that GH stimulates gluconeogenesis in 
canine proximal tubular cells without induction of IGF-I expression 197. In the proximal 
tubule, GHR and ALS (acid-labile subunit, see 2.1.5) are co-expressed, with both 
GHR mRNA and ALS mRNA levels are influenced by circulating GH levels. Since 
IGF-I and IGFBP-3 are not expressed in this nephron segment, a local intrinsic 
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function of ALS is speculated, independent of forming a 150 kDa complex together 
with one molecule each of IGF-I or IGF-II and IGFBP-3 198.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Expression of components of the GH/IGF-axis in the rat nephron. The figure 
differentiates between proteins and mRNAs. Rec, Receptor; ?, in vitro finding, but not confirmed by 
in vivo studies. According to Feld and Hirschberg 18. 
 
 
In the rat TALH, expression of the GHR is co-localized with the expression of IGF-I 
and IGF-IR. This constellation suggests that GH may act indirectly via local induction 
of IGF-I, which in turn acts through the IGF-IR by autocrine and/or paracrine modes 
196. The thick ascending limb of the loop of Henle is the only segment of the nephron, 
in which the triplet of GHR, IGF-I and IGF-IR is expressed 18.  
Interestingly, in both the rat and human glomerulus, GHR expression has not been 
detected in vivo, which is important in sight of interpretations of GH actions in renal 
disease models 18. Likewise, in glomeruli from C57B1/SJL mice, GHR mRNA is not 
detectable, however, GHBP is expressed 199. In contrast to in vivo situations, in vitro 
studies demonstrate GHR/GHBP expression in human mesangial cells. In those 
cells, physiological doses of GH dose-dependently elevate GHR/GHBP gene 
transcription, whereas supraphysiological doses result in its down-regulation 31. The 
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authors discuss dedifferentiation of glomerular cells under cell culture conditions as 
an explanation for the different GHR/GHBP expression of mesangial cells in vivo and 
in vitro 18,31.  
 
2.4.1.2 Spatial distribution of the IGFs, IGF-IR and IGF-IIR/M6PR in the kidney 
 
The renal expression of IGF-I and IGF-II varies greatly between species. The human 
kidney does not express IGF-I, whereas IGF-I mRNA is present in the rat kidney 
18,195,200. IGF-I expression is not detectable within the rat glomerulus in vivo 200, 
however, in vitro, rat and mouse glomerular mesangial cells express IGF-I 201,202. The 
difference in IGF-I expression of rat mesangial cells between in vivo and in vitro 
situations is explained by dedifferentiation of those cells in the cell culture 
environment 18.  
No or only minimal IGF-I mRNA content is detectable in rat proximal and distal tubule 
epithelial cells 200,203. Contrary, IGF-I protein is found in proximal tubular epithelial 
(PTE) cells, being localized along the brush border and the basolateral membrane 
but not in cytoplasm. Thus, IGF-I protein detected in PTE cells most probably reflects 
bound IGF-I originating from the circulation and/or ultrafiltrate 204.  
The rat TALH and collecting duct epithelia contain IGF-I mRNA and protein, with the 
greatest IGF-I expression within the kidney being localized in medullary collecting 
duct epithelia 196,204. 
The human kidney expresses IGF-II, which is apparently limited to the vascular 
compartment and the medullary interstitium 205. Conflicting data exist about the 
expression of IGF-II in the rat kidney. Chin & Bondy 196 did not detect IGF-II mRNA in 
the rat kidney, whereas Evan et al. 206 reported the occurrence of IGF-II mRNA, 
localized in the wall of the renal microvasculature.  
 
The IGF-IR is expressed in rat glomeruli, which provides the basis for effects of IGF-I 
on glomerular function and growth. Glomeruli express IGF-IR even at a higher den-
sity than other parts of the nephron 200. Since the glomerulus does not express IGF-I, 
as demonstrated by in vivo studies, the activation of glomerular IGF-IR by circulating 
but not by auto-/paracrine acting IGF-I is assumed 18. Furthermore, rat glomeruli also 
contain IGF-IIR/M6PR mRNA 206 and IGF-IIR/M6PR protein 207.  
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IGF-IR and IGF-IIR/M6PR are expressed in rat PTE cells. The IGF-IIR/M6PR is 
localized exclusively in the apical part of PTE cells just below the brush border, but 
not in the basolateral part of the cells 208. In contrast, the IGF-IR is abundant in both 
the apical and the basolateral part of PTE cells, with the higher concentration being 
located in the basolateral part 209. However, functional studies in isolated-perfused 
rabbit proximal tubules indicate a greater sensitivity of apical IGF-IR. The stimulation 
of apical IGF-IR occurs at a 100-fold lower IGF-I concentration than of basolateral 
IGF-IR. Further, the magnitude of the maximal response (phosphate transport) of 
apical compared to basolateral IGF-IR to IGF-I stimulation is 3-fold greater 210.  
In vivo, IGF-IR expression is further proved in the epithelium of rat TALH, distal 
tubules, and the collecting ducts 18,196.  
 
2.4.1.3 Spatial distribution of the IGFBPs in the kidney 
 
The IGFBPs are expressed in a specific spatial distribution within the kidney, sugges-
ting that they tightly regulate IGF effects in a site-specific manner. Noticeably, rats 
and mice demonstrate comparable renal expression patterns of the IGFBPs 18.  
In the glomerulus, both rats and mice express IGFBP-2 in the parietal epithelium of 
the Bowman’s capsule and podocytes and IGFBP-5 in the glomerular mesangium 
206,211,212. Mice show an additional minor IGFBP-1 mRNA occurrence in the parietal 
epithelium of the Bowman’s capsule 212. Rat glomeruli additionally express IGFBP-4 
at a minor level 213. 
Mouse PTE cells contain high IGFBP-4 mRNA concentrations, and low IGFBP-1 and 
-5 mRNA levels 212. The expression of IGFBP-4 mRNA 211,213 and IGFBP-5 mRNA 214 
is also detectable in rat PTE cells.  
In the epithelium of the thin limb of the loop of Henle of mice, IGFBP-2 mRNA and 
IGFBP-2 protein is demonstrable 212. Similarly, IGFBP-2 mRNA has been detected in 
this nephron segment in rats 206,211. Epithelial cells of the thick ascending limb of the 
loop of Henle of both mice and rats contain IGFBP-1 mRNA and IGFBP-1 protein 
204,211,212. Further, mouse and rat distal tubule epithelial cells express IGFBP-1 and  
-5, while collecting duct epithelium contains IGFBP-1, -2, and -4 mRNA 211,212.  
The expression of IGFBP-3 is restricted to the cortical interstitium and to fibroblasts 
of large vessels and the ureter in the rat kidney. IGFBP-6 is expressed only weakly in 
the interstitium 211.  
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2.4.2 Renal processing of GH and IGFs  
 
2.4.2.1 Processing of GH in the kidney 
 
Besides effects of members of the GH/IGF-axis on the kidney, the kidney plays an 
important role in the turnover of the ligands. About 60% of GH is bound to GHBP, 
being prevented from renal degradation 33. Unbound GH is handled similar to other 
microproteins by the kidney and undergoes glomerular ultrafiltration with a high 
sieving coefficient of 0.6, subsequent tubular absorption and lysosomal degradation, 
and minimal urinary excretion 215,216. The kidney is the major organ causing plasma 
GH turnover 217,218. Glomerular ultrafiltration of GH is the rate-limiting step in GH 
metabolism, which explains why renal dysfunction leads to increased serum GH 
levels and half-life of GH 18,219.  
 
2.4.2.2 Processing of the IGFs in the kidney 
 
Due to their low molecular mass, unbound IGFs undergo renal ultrafiltration with a 
sieving coefficient that approaches 1.0. Since more than 99% of the circulating IGFs 
are bound in 150 and 45 kDa complexes, their renal ultrafiltration is extremely low, 
and the healthy kidney plays only a modest role in degradation of circulating IGF-I 220-
222. Contrary, human patients and animals suffering from the nephrotic syndrome 
show an increased renal ultrafiltration of IGF-I, along with other growth factors 223 and 
stimulatory proteins 224.  
Notably, in nephrotic rats, IGF-I is ultrafiltrated mainly in conjunction with IGFBP-2, 
and the concentration of IGF-I and IGFBP-2 is strongly increased in the proximal 
tubular fluid 220. In vitro, proximal tubular fluid of nephrotic rats stimulates proliferation 
of opossum kidney (OK) cells 225 as well as the secretion of collagen type I and IV of 
mouse proximal tubular epithelial cells (PTE), confirming its ability of promoting 
tubulointerstitial fibrosis in vivo 220. As demonstrated in mouse PTE, the effects of 
proximal tubular fluid of nephrotic mice are largely due to ultrafiltrated IGF-I and the 
activation of IGF-IR, indicating biological significance of ultrafiltrated IGF-I 220.  
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2.4.3 Role of components of the GH/IGF-axis in renal growth  
 
The GH/IGF-axis is intimately involved in renal development. The components of the 
GH/IGF-axis, with exception of GH, are expressed in a varying degree in the embryo-
nic metanephros as well as in fetal and postnatal renal tissue 18.  
Beside its role in physiologic renal growth, the GH/IGF-axis plays an essential role in 
various adaptive and pathological growth processes of the kidney. Different human 
renal diseases states are characterized by altered expression of components of the 
GH/IGF-axis. Several rodent animal models have been established in order to study 
the role of the GH/IGF-axis in the pathogenesis of various renal diseases. These 
models include genetically engineered mice, lacking or overexpressing members of 
the GH/IGF-axis, unilateral and subtotal nephrectomized rodents, rodents with 
spontaneous or with induced diabetes mellitus, and nutritionally induced glomerulo-
sclerosis of rodents 18.  
 
2.4.3.1 Role of GH in renal growth processes 
 
Systemic overexpression of GH in transgenic mice - either due to ectopic expression 
of heterologous GH transgenes or to stimulation of endogenous GH release by 
expression of a GHRH transgene (GH-releasing hormone) - regularly leads to a 
typical spectrum of renal alterations and results in chronic renal failure progressing to 
end-stage renal disease 17. Both, morphological and clinical-chemical findings 
indicate renal failure as the primary cause of shortened lifespan of GH transgenic 
mice 92. 
Detailed studies revealed a characteristic sequence of kidney alterations in GH 
transgenic mice. Initial changes include renal hypertrophy and hypertrophy of the 
glomeruli, which are overproportionally enlarged in relation to both kidney and body 
weight, indicating that the glomeruli may exhibit individual growth responses to GH 82. 
Glomerular enlargement in GH transgenic mice is progressive with age and associa-
ted with the development of glomerulosclerotic lesions. Hypertrophic changes of GH 
transgenic mouse glomeruli include mesangial extracellular matrix expansion due to 
an increased extracellular matrix synthesis and a decreased extracellular matrix 
degradation 226, and proliferation of both endothelial and mesangial cells. However, 
there is no change in the number of podocytes, which demonstrate hypertrophy and 
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foot process effacement 227. These early podocyte changes are associated with 
albuminuria. Concomitant with an age-related further increase of glomerular size in 
GH transgenic mice, severe maladaptive podocyte lesions including detachment of 
podocytes from the glomerular basement membrane do occur. The resultant denu-
dation of the glomerular basement membrane is associated with severe proteinuria, 
glomerular hyalinosis, synechia formation, and collapse of glomerular capillaries 227. 
These lesions progress to glomerular obsolescence that is associated with atrophy of 
the adjacent tubule and interstitial fibrosis. Thus, the progressive kidney lesions in 
GH transgenic mice appear to be attributable to a considerable extent to podocyte 
damage resulting from the limited capacity of this highly specialized cell type 228 to 
keep up with progressing overall glomerular growth. End-stage renal lesions are 
characterized by a marked atrophy of nephrons, interstitial fibrosis, and pronounced 
tubulocystic alterations. Remnant glomeruli demonstrate diffuse-segmental or focal-
global sclerosis and/or hyalinosis 82,229.  
The nephropathological alterations of GH transgenic mice, therefore, represent a 
valuable and well characterized model to study the pathogenesis of glomerulosclero-
sis and the mechanisms involved in the progression of chronic renal failure. Further, 
advanced kidney lesions of GH transgenic mice provide a model for aquired cystic 
kidney disease 17. 
 
Similar renal effects of GH excess are also detectable in various other species. Rats 
treated with GH, and rats bearing GH-secreting tumors develop renal and glomerular 
hypertrophy, glomerulosclerosis, and severe proteinuria 230,231. In dogs, GH treatment 
for 14 weeks causes enlarged kidneys, glomerular hypertrophy and mesangial 
thickening, suggesting that the development of pathological changes of the kidney 
due to overexposure to GH is not restricted to rodents 232. Likewise, PEPCK-bGH 
transgenic rabbits develop severe glomerulosclerotic and tubulointerstitial lesions 113. 
Contrary, in healthy humans, short-term administration of recombinant hGH causes 
only a transient, slight proteinuria 18. Even acromegalic patients, showing high serum 
GH and IGF-I concentrations for long periods, exhibit only minor renal changes, 
including increased kidney weight, and moderate proteinuria 233,234. Single cases of 
acromegalic patients have been reported with glomerulosclerotic lesions 235,236. The 
renal enlargement of acromegalic patients is partially reversible by the reduction of 
GH secretion through either surgery or somatostatin treatment 233.  
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In contrast, dwarf rats, which are selectively deficient for GH exhibit reduced renal 
mass and glomerular tuft volume, as compared to normal rats 237. Furthermore, GH 
absence prevents from development of renal and glomerular hypertrophy and 
glomerulosclerosis. Thus, GH-deficient rats do not develop spontaneous age-related 
glomerulosclerosis 238. Likewise, subtotally nephrectomized GH-deficient rats 239 or 
subtotally nephrectomized normal rats that are treated with a somatostatin analogue 
240 do not develop compensatory renal and glomerular growth. Similarly, adult 
uninephrectomized mice that are treated with a specific GHR antagonist are 
prevented from renal and glomerular hypertrophy, which occur in untreated mice. 
Noteworthy, both GHR antagonist treated and untreated mice exhibit equal serum 
GH levels 241. Additionally, renal and glomerular hypertrophy following the induction 
of experimental diabetes in rodents, can be abolished by eliminating GH secretion or 
blockade of GHR 19. 
 
Circulating GH levels were found to correlate with the degree of nephropathological 
changes in various rodent models 83. For example, co-expression of bGH and GH 
antagonist genes at different levels in transgenic mice results in renal alterations, 
which reflect the relative expression levels of each transgene 83. The lifespan of GH 
transgenic mice negatively correlates with serum GH levels, and the lifespan of those 
animals is shortened primarily due to chronic renal failure 92. Furthermore, the 
severity of spontaneously developing glomerulosclerosis in aging rats is correlated 
with plasma GH levels 238. 
 
2.4.3.2 Role of IGF-I and IGF-II in renal growth processes 
 
IGF levels have been shown to be able to influence the nephron number in the pre-
natal period. In vitro, the nephron population of mouse metanephroi in organ culture 
are increased when exposed to IGF-I 242. Likewise, IGF-II elevates the number of 
nephrons in cultured rat metanephroi in a dose-dependent manner, whereas IGF-I is 
not able to influence nephron numbers 243. Contrary, surviving IGF-I knockout mice 
exhibit a 20% nephron deficit associated with generalized organ hypoplasia at birth 
and growth retardation 244.  
Doublier et al. 243 reported that overexpression of hIGFBP-1 in mice affects nephron 
number. A 15% to 20% nephron deficit associated with intrauterine growth 
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retardation was found in normal mice born from hIGFBP-1 transgenic mothers 
suggesting prenatal growth deficits by hIGFBP-1 overexpression. Furthermore, 
transgenic mice overexpressing hIGFBP-1 from embryonic day 15 onwards and born 
from normal mothers were reported to have normal body and kidney weights at birth, 
however, to show a significant nephron deficit at an age of three months. The 
authors, therefore, suggested postnatally affected nephrogenesis. They explained 
the phenotypes by reduced amounts of circulating IGFs, presumably IGF-II, due to 
transgene hIGFBP-1 expression, although direct hIGFBP-1 effects cannot be 
excluded 243.  
 
In the postnatal period, IGF-I mediates many of the effects of GH in the kidney,  
and both circulating as well as renal IGF-I participates in renal and glomerular  
growth processes via endocrine and auto-/paracrine pathways, respectively 245,246.  
In GH-deficient dwarf rats characterized by low systemic and renal IGF-I levels,  
both the reduced renal mass and glomerular tuft volume can be normalized to a 
similar degree by administration of either IGF-I or GH 237. Moreover, an increase in 
GFR can be induced in those dwarf rats by either IGF-I or GH administration. These 
findings indicate that IGF-I may mimic and/or mediate much of the renal effects of GH 
237.  
Treatment of normal rats with IGF-I or overexpression of IGF-I in transgenic mice 
causes body weight gain and selective growth of certain organs including the kidneys 
85,247, although endogenous GH and IGF-I expression is inhibited in IGF-I transgenic 
mice 126. Proximal tubular epithelial (PTE) cells are the dominant cell type in the renal 
cortex making up 80% of the mass of the kidney, and their growth accounts for most 
of renal hypertrophy 248. IGF-I is a strong mitogen for PTE cells and causes hyper-
plasia of cultured PTE cells of various species, including man 249, mouse 250, rat 251, 
and rabbit 252. The PTE cell proliferative effect of IGF-I is mediated via activation of 
the IGF-IR 250,253. Beside its mitogenic effect, IGF-I has an anti-apoptotic effect on 
PTE cells 254. 
As shown in the rat kidney in vivo, the renal mass increase in IGF-I excess states is 
due to cellular hypertrophy in addition to hyperplasia, as indicated by an increase of 
DNA/protein ratio, mitosis and proliferating cell nuclear antigen expression 255. Like-
wise, in various rodent models, renal hypertrophy associated to increased renal IGF-I 
levels has been shown to be due to a combination of hyperplasia and hypertrophy, or 
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only to hypertrophy of renal cells 256. In compensatory renal growth following 
uninephrectomy in mice and rats, the proximal tubule growth is a hypertrophic, but 
not a hyperplastic growth form, and is mediated by a cell cycle-dependent process 
257. The mechanism in cell cycle-dependent hypertrophy involves the coordinated 
effects of a mitogen and an anti-proliferative agent, e.g., transforming growth factor β 
(TGF-β). The mitogenic stimulus moves quiescent PTE cells into the G1 phase of the 
cell cycle. The anti-proliferative stimulus blocks the PTE cells to cross the restriction 
point and move to the S phase. Having undergone increased protein synthesis and 
growth associated with the early G1 phase, the cells are now “trapped” in a hyper-
trophied state 258. 
Glomerular alterations in IGF-I transgenic mice include glomerular hypertrophy and 
mesangial cell proliferation, but IGF-I transgenic mice did not show progressive 
glomerulosclerotic or tubulointerstitial lesions or albuminuria up to an age of  
19 weeks 84,85. However, the degree of glomerular enlargement does not reach that 
of GH transgenic mice, which exhibit a significantly higher mean glomerular volume 
as well as an increased mean glomerular volume-to-either kidney or -body weight-
ratio than IGF-I transgenic mice 85,127. The absence of glomerulosclerotic lesions in 
only moderately hypertrophied glomeruli of IGF-I transgenic mice is in line with the 
hypothesis that overproportional overall tuft growth and resultant podocyte damage, 
plays a significant role in the initiation and progression of glomerulosclerotic lesions 
in GH transgenic mice 227. In vitro, IGF-I has been shown to promote mesangial cell 
hyperplasia, by acting both as a mitogen 259,260 and as an inhibitor of apoptosis 261 
through activation of the IGF-IR 262. Further, IGF-I is able to induce mesangial cell 
hypertrophy 263. In addition, IGF-I stimulates the expression of extracellular matrix 
components, including proteoglycans and type I and type IV collagen by cultured 
mesangial cells 245,260. 
 
2.4.3.3 Involvement of IGFBPs in renal growth processes and renal disease states 
 
The renal levels of the IGFBPs show changes in normal growth physiology and 
particulary under pathological conditions18. However, it is difficult to predict whether 
altered IGFBPs have intrinsic effects or merely represent an epiphenomenon of 
developmental processes and diseases 5. Contrary, altering the level of IGFBPs, in 
particular that of IGFBP-1, results in a renal phenotype 264. 
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Renal changes have been shown in transgenic mice overexpressing hIGFBP-1 265. 
hIGFBP-1 transgenic mice are characterized by decreased nephron numbers 243 and 
develop glomerulosclerosis without glomerular hypertrophy or hypercellularity 264. At 
three months of age, hIGFBP-1 transgenic mice present a significantly increased 
mesangial extracellular matrix. The expansion of mesangial extracellular matrix is 
related to a marked increase in laminin and type IV collagen and to the appearance 
of type I collagen. Several possibilities are discussed to explain the renal phenotype 
of hIGFBP-1 transgenic mice, including impaired glucose and lipid metabolism, as 
seen in another IGFBP-1 transgenic mouse strain, reduced nephron numbers, 
reduced renal IGF-I bioavailability, and IGF-independent effects of high IGFBP-1 
levels 264. 
 
In several renal disease states, including chronic renal failure (CRF) 11,222,266,267 and 
multicystic renal dysplasia 13 in humans, and the nephrotic syndrome in experimental 
animals 268,269, circulating as well as renal patterns of the IGFBPs are dysregulated 
72. In human patients with CRF and end stage renal disease (ESRD), serum levels of 
intact or fragmented IGFBP-1 to -4 and IGFBP-6 are elevated 266,270, as a 
consequence of multiple factors, including increased synthesis, increased proteolysis 
(of IGFBP-3), and altered renal excretion 11.  
Children suffering from CRF commonly display severe growth retardation and tissue 
catabolism resulting from an excess of serum IGFBPs and concomitant reduction of 
IGF-I bioavailability 11,266. Those children demonstrate by half reduced serum concen-
trations of unbound and presumably bioactive IGF-I, as compared to healthy controls 
222. Their total serum IGF-I concentrations tend to cluster in the normal-low range 11, 
despite elevated plasma GH levels due to a prolonged half-life and an increased 
production of GH 271,272. In children with CRF, serum concentrations of unbound IGF-I 
are inversely correlated with serum IGFBP-1 and -2 levels 222. More, IGFBP-2 is the 
only binding protein, which has been shown to be inversely correlated with the height 
of prepuberal children with CRF. Further, compared to other IGFBPs, IGFBP-2 serum 
concentrations are most markedly elevated and this increase correlates with the 
degree of renal dysfunction 11,266.  
Elevated serum IGFBP-2 levels were also detected in two different nephrotic rat 
models and found to be due to increased hepatic expression of IGFBP-2 268,269. In 
human patients with CRF, serum IGFBP-2 levels do not decrease within 14 days 
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after renal transplantation, indicating that serum IGFBP-2 levels are not, or only in 
part regulated by an intact kidney function, which is the case for IGFBP-3 and -6 273. 
Elevated serum IGFBP-2 levels are assumed to shift IGF-I from the 150 kDa (ternary) 
to 45 kDa (binary) complexes, resulting in an augmented renal excretion of IGF-I 194. 
As shown in the proximal tubule fluid of nephrotic rats, the glomerular ultrafiltration of 
IGF-I occurs primarily in association with IGFBP-2 220. 
Multicystic renal dysplasia displays the most common form of renal dysplasia that 
leads to ESRD in children 274. Renal expression of IGFBP-2 and -3 as well as of  
IGF-II are altered in multicystic renal dysplasia. IGFBP-2 is overexpressed in 
multicystic dysplastic kidneys from early gestation fetuses to postnatal stages, with 
both IGFBP-2 mRNA and IGFBP-2 protein being localized to the cyst epithelium. The 
authors speculate that IGFBP-2 may serve to potentiate and target the mitogenic and 
proliferative effects of IGF-II. However, a direct, IGF-independent effect of IGFBP-2 
on the cyst epithelium cannot be excluded 13. IGF-II mRNA is abundantly expressed 
in the mesenchyme surrounding the cysts, whereas IGF-II peptide is present in the 
cyst epithelium, suggesting that IGF-II may act in a paracrine fashion on the 
neighboring cyst epithelium. Expression of IGFBP-3 mRNA, which has been shown 
in metanephric blastema and in the ureteric duct and collection duct epithelia of 
normal developing kidneys, is absent in cyst epithelia maybe due to dedifferentiation 
of cyst epithelial cells 13.  
 
Contrary to the proliferative effect, associated with IGFBP-2 overexpression in cyst 
epithelium in human multicystic renal dysplasia, elevated IGFBP-2 expression in 
murine mesangial cells (MMC) has an IGF-dependent, anti-proliferative effect 12. In 
MMC, IGF-I dose-dependently up-regulates IGFBP-2 expression and secretion, and 
as a consequence of high IGFBP-2 levels, IGF-I is not able to stimulate MMC proli-
feration. When the IGF-I-induced stimulated IGFBP-2 synthesis is inhibited, IGF-I is 
able to enhance proliferation of MMC 12. The authors speculate that the discrepancy 
in glomerulosclerosis development between GH and IGF-I transgenic mice (see 
2.4.3.1 and 2.4.3.2) may be caused by a diverse mesangial expression of endoge-
nous IGFBP-2. They speculate that mesangial cells of IGF-I transgenic mice secrete 
elevated levels of IGFBP-2 in response to elevated IGF-I levels and, thus limit IGF-I 
effects, like mesangial proliferation and extracellular matrix secretion. Contrary, high 
 
-36- 
Literature 
GH levels in GH transgenic mice reduce IGFBP-2 production (see 2.2.1.3), and 
thereby may strongly increase the sensitivity of mesangial cells to elevated IGF-I 12.  
 
In summary, these findings demonstrate that IGFBPs represent essential regulators 
of IGF-actions in different renal cell types. In particular, IGFBP-2 has been implicated 
to modulate proliferative effects on glomerular cells and proximal tubular cells. 
Further, IGFBP-2 is considered to play a central role in regulation/dysregulation of 
IGF-I bioavailability in chronic renal failure. 
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3 Research design and methods 
 
3.1 Animals 
 
3.1.1 Crossbreeding and animal husbandry 
 
Hemizygous transgenic female mice overexpressing murine (m) IGFBP-2 under the 
transcriptional control of the cytomegalovirus (CMV)-promoter were mated with hemi-
zygous transgenic male mice overexpressing bovine (b) GH under the transcriptional 
control of the rat phosphoenolpyruvate carboxykinase (PEPCK)-promoter, generating 
four different genetic groups of offspring. In the present study, male mice of the 
following genetic groups were investigated: non-transgenic controls (C), animals 
harboring the mIGFBP-2 (B) or the bGH (G) transgene, and those harboring both 
transgenes (GB) (Fig. 3.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Breeding regime. Female hemizygous CMV-mIGFBP-2 transgenic (tg) mice were 
crossed with male hemizygous PEPCK-bGH transgenic mice. According to the Mendelian trans-
mission, all experimental groups were produced within the same litters: non-transgenic controls (C),  
single mIGFBP-2 (B) or bGH (G) transgenic mice, and mice carrying both transgenes (GB). 
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mIGFBP-2 transgenic mice were generated as previously described by Hoeflich et al. 
152 and bred onto a C57BL/6 background (Charles River Laboratories, Inc.-Wiga, 
Germany). The generation of bGH transgenic mice is reported elsewhere in detail 81. 
bGH transgenic mice were derived from the 12th generation of sequential crossing 
with NMRI outbred mice (Charles River Laboratories, Inc.-Wiga, Germany). The used 
breeding regime ensures a similar genetic background of the four generated experi-
mental groups.  
All mice were maintained under standard (non-barrier) conditions (21±1°C, 55±3% 
relative humidity; 12/12-hours light/dark cycle) and had free access to standard diet 
(V1534; Ssniff, Germany) and tap water. At an age of three weeks, animals were 
weaned, separated according to gender, marked by piercing the ears, and tail tip 
biopsies were taken for genetic analysis. 
The experimental setup summarized 175 animals. Of the four genetic groups,  
44 mice at 38 days of age and 44 mice at 75 days of age were analyzed for several 
parameters. Age, number, and genotype of animals used for analyses of individual 
parameters are listed in table 3.1. 
Additionally, 44 mice (C: n=15, B: n=11, G: n=10, GB: n=8) of the four genetic groups 
at four months of age were used for plasma corticosterone determination. Plasma 
ACTH levels were measured from 31 mice (C: n=8, B: n=7, G: n=8, GB: n=8) of the 
four genetic groups at an age of four to seven months. To exclude strain-specific 
effects on plasma ACTH levels, this parameter was also investigated in a different 
transgenic mouse strain overexpressing bGH under the control of the MT promoter. 
Blood samples from 6 four-month-old MT-bGH transgenic male mice and 6 male 
littermate controls were used for plasma ACTH determination.  
 
 
Table 3.1 Age, number, and genotype of mice used for the analyses of single 
parameters. n(x) indicates the number of mice of the genotype that is given in brackets; V(cortex, adrenal 
gland), volume of the adrenal cortex; V(medulla, adrenal gland), volume of the adrenal medulla; V(z. fasciculata), 
volume of the zona fasciculata; V(z. glomerulosa) volume of the zona glomerulosa; v(z. fasciculata cells), mean 
volume of zona fasciculata cells; N(z. fasciculata cells, animal), total number of zona fasciculata cells per 
animal; N(glomeruli, animal), number of glomeruli per animal; V(x zone, kidney), volume of a particular (renal) 
zone; V(x nephron segment), volume of a particular nephron segment; v(PTE cells), mean volume of proximal 
tubular epithelial (PTE) cells; N(PTE cells, animal), total number of PTE cells per animal; v(glom) mean 
glomerular volume; WLB, Western ligand blot. 
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Table 3.1 
 
Investigation/ 38 days of age 75 days of age 
Parameter   
 
Body weight 7(C), 7(B), 7(G), 7(GB) 6(C), 8(B), 7(G), 7(GB) 
 
Serum parameters 
IGF-I-, IGFBP-2 concentration 11(C), 11(B), 11(G), 11(GB) 10(C), 12(B), 11(G), 11(GB) 
Clinical-chemical parameters 11(C), 11(B), 11(G), 11(GB) 10(C), 12(B), 11(G), 11(GB) 
 
Adrenal gland weight  3(C), 3(B), 3(G), 3(GB) 
 
Quantitative stereology of the adrenal gland 
V(cortex, adrenal gland), V(medulla, adrenal gland)  3(C), 3(B), 3(G), 3(GB) 
V(z. fasciculata), V(z. glomerulosa)  3(C), 3(B), 3(G), 3(GB) 
v(z. fasciculata cells), N(z. fasciculata cells, animal)  3(C), 3(B), 3(G), 3(GB) 
 
Kidney weight 7(C), 7(B), 7(G), 7(GB) 6(C), 8(B), 7(G), 7(GB) 
 
Quantitative stereology of the kidney 
N(glomeruli, animal) 4(C), 4(B), 4(G), 4(GB) 
V(x zone, kidney)  5(C), 5(B), 5(G), 5(GB) 5(C), 5(B), 5(G), 5(GB) 
V(x nephron segment)  5(C), 5(B), 5(G), 5(GB) 5(C), 5(B), 5(G), 5(GB) 
v(PTE cells), N(PTE cells, animal)  4(C), 4(B), 4(G), 4(GB) 
v(glom)  5(C), 5(B), 5(G), 5(GB) 5(C), 5(B), 5(G), 5(GB) 
 
Glomerulosclerosis index 4(C), 4(B), 4(G), 4(GB) 4(C), 4(B), 4(G), 4(GB) 
 
Urine protein analyses 
Pattern of proteinuria 11(C), 11(B), 11(G), 11(GB) 10(C), 12(B), 11(G), 11(GB) 
Urinary albumin concentration 11(C), 11(B), 11(G), 11(GB) 10(C), 12(B), 11(G), 11(GB) 
 
WLB analysis 3(C), 3(B), 3(G), 3(GB) 
 
Immunohistochemistry 3(C), 3(B), 3(G), 3(GB) 
 
In situ Hybridization 3(C), 3(B), 3(G), 3(GB) 
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3.1.2 Polymerase chain reaction (PCR)  
 
Transgenic mice were identified by polymerase chain reaction (PCR). Tail tip bio-
psies of approximately 0.4 cm length were taken and stored at -80°C until assayed. 
Genomic DNA was extracted using the proteinase K lysis buffer-method 37. The tail 
tips were digested over night in 450 µl lysis buffer and 30 µl proteinase K solution by 
incubation at 56°C in a type 1030 waterbath (Gesellschaft für Labortechnik mbH, 
Germany). Subsequently, the samples were cleared by adding 400 µl of phenol-
chloroform/isoamyl alcohol (C/IA), gently shaking the tubes for 10 min, centrifuging 
them (3 min, 10.000 rpm, RT), and transferring the aquatic, DNA-containing 
supernatant in a new tube. Next, 400 µl C/IA was added to the revealed supernatant, 
tubes were gently shaken for 3 min and again, the supernatant containing the DNA 
was saved in a new tube. This step was repeated once. The DNA was precipitated 
with 40 µl 3 M sodium acetate solution and 700 µl 100% ethanol, became visible and 
was pelleted by shortly vortexing. The pellet of genomic DNA was washed in 70% 
ethanol, dried, and dissolved in 50 µl re-distilled water. 
Subsequently, the sample was prepared for amplification. 19 µl of the Master Mix and 
1 µl of a 1:5 dilution of the genomic DNA solution were mixed carefully in PCR-analy-
sis cups, which were then placed in a thermocycler (Mastercycler gradient®; Eppen-
dorf, Germany) and the program (see 3.1.2.2) was run. As positive control, the DNA 
solution of a known transgenic animal was used in the PCR approach, whereas the 
Master Mix with 1 µl of PCR water instead of DNA solution served as negative con-
trol. For detection of the bGH transgene, 5’ CGG ACC GTG TCT ATG AGA AGC 3’ 
sense (bGH #1) and 5’ GGA AAG GAC AGT GGG AGT GG 3’ anti-sense (bGH #2) 
oligonucleotides were used. For mIGFBP-2 PCR analysis, primers were used as 
follows: 5’ GCG CGG GTA CCT GTG AAA 3’ sense (CMV #3) and 5’ TCC CTC AGA 
GTG GTC GTC ATC 3’ antisense (IGFBP-2 #4). 
After amplification, 4 µl 6x loading dye (MBI Fermentas, Germany) was added to 
each sample. Then the sample was transferred into the sample wells of a 2% 
agarose gel containing 1.0 µl ethidium bromide per 100 ml, and was positioned in a 
Easy Cast™ gel chamber (PeqLab, Germany) filled with 1*TAE running buffer. At the 
beginning of each sample well row, 12 µl PUC Mix Marker #8 (MBI Fermentas, 
Germany) was placed in order to allow estimation of amplified fragment size. 
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Electrophoresis was run for approximately 45 min at 90 V with an output of 
approximately 200 mA. Subsequently, the amplified products were visualized under 
UV light (306 nm) and a Polaroid picture (AGS, Germany) was taken for result 
documentation. bGH transgenic mice showed a distinct fragment with a size of 608 
bp, in mIGFBP-2 transgenic mice, a fragment of 332 bp was acquired (Fig. 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Polaroid picture for PCR result documentation. Bands at 608 bp meet the size 
of bGH fragment. At the beginning of each row, the PUC Mix Marker #8 (M) is placed. The 
identification number of the animals is shown above and underneath the Polaroid print; transgenic 
mice are written in bold numbers. W, PCR water (Quiagen, Germany); P, positive control; N, negative 
control. 
 
Beside the material mentioned in the text above, the following reagents and pro-
grams have been used: 
 
Proteinase K solution: 20 mg/ml diluted in re-distilled water (Roche, Germany): 
 
C/IA    24 vol/1 vol: chloroform/isoamyl alcohol (both Roth, Ger.) 
 
Phenol-C/IA   25 vol/25 vol: phenol (Roth, Germany)-C/IA 
 
Sodium acetate, 3 M 18.6 g/100 ml distilled water 
  M    20   21   22   23  24  25   26   27   28   29   30  31   32   33                W    P   N 
  M      1    2     3     4     5    6     7    8     9    10   11  12  13   14   15  16  17   18  19 
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Lysis buffer:    10 ml Tris, pH 8.0, 1 M 
  40 ml EDTA, pH 8.0, 0.5 M 
    5 ml Sodium chloride, 4 M 
  20 ml SDS, 10 % 
125 ml distilled water 
 
  Tris, pH 8.0, 1 M 
6.06 g Tris-(hydroxymethyl)-aminomethane (Roth, Ger.) 
    ad 50 ml dist. water, adjust pH with 1 N HCl (Merck, Ger.) 
 
  EDTA, pH 8.0, 0.5 M 
    14.89 g EDTA (Roth, Germany) 
    ad 80 ml distilled water, adjust pH with 1 N NaOH 
  
Sodium chloride, 4 M 
    11.69 g Sodium chloride (Merck, Germany) 
    ad 50 ml distilled water 
 
SDS, 10 % 10.0 g SDS (Sigma, Germany) 
    ad 100 ml distilled water 
 
Primer concentration: 100 pmol/µl each (Genzentrum/DNSynthese, Germany) 
dNTPs:   100 mM each (Eppendorf, Germany): 
 
PCR-KIT Master Mix: (Quiagen, Germany) 
  dNTP 1mM   4.0 µl 
  10*Buffer   2.0 µl  
  MgCl2   1.25 µl 
  Primer sense   1.0 µl 
  Primer antisense   1.0 µl 
  PCR water   5.7 µl 
  Q-solution   4.0 µl 
  Taq polymerase  0.125 µl 
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50* TAE stock solution:  
  121 g Tris base (Roth, Germany) 
  28.55 ml glacial acetic acid (Sigma, Germany) 
  50 ml EDTA, 0.5 M, pH 8.0  
  ad 500 ml distilled water 
 
Agarose gel:  2 g agarose (Gibco BRL, Germany)/100 ml 1*TAE buffer,  
  add 1 µl (1 mg/ml) ethidium bromide (Merck, Germany) 
 
 
Program for bGH DNA fragment amplification  
a) 4 min 94°C 
  b) 1 min 94°C 
  c) 1 min 65°C 
  d) 2 min 72°C 
  e) 10 min 72°C 
  f) Hold on 4°C 
Steps b) - d): 35 cycles 
 
 
Program for mIGFBP-2 DNA fragment amplification  
a) 4 min 94°C 
  b) 1 min 94°C 
  c) 1 min 56°C 
  d) 2 min 72°C 
  e) 10 min 72°C 
  f) Hold on 4°C 
Steps b) - d): 35 cycles 
 
-44- 
Research design and methods 
3.2 Urine protein analysis 
 
Urine protein analyses were applied to determine the consequence of expression of 
the bGH and/or IGFBP-2 transgene on kidney function. In order to exclude potential 
differences in urine protein excretion over the day, spot urine samples were taken 
constantly between twelve and one o’clock in the afternoon. The urine samples were 
immediately frozen and stored at -80°C until assayed. Usually, spontaneous urine 
could be obtained. If this was not the case, samples were taken by carefully 
squeezing the bladder with two fingers.  
Details of mice used for urine protein analyses are listed in table 3.1. The pattern of 
proteinuria was determined using sodium dodecyl sulphate- (SDS-) polyacrylamide 
gel electrophoresis (PAGE). The urinary albumin concentration was measured using 
the murine microalbuminuria enzyme linked immunosorbent assay (ELISA)  
Albuwell M™ (Exocell Inc., USA).  
 
3.2.1 Analysis of the pattern of proteinuria by SDS-PAGE 
 
A 12% separating and a 5% stacking SDS-polyacrylamide gel was casted in a Mini-
Protean III gel-casting chamber (Biorad, Germany). A comb for forming sample wells 
was immediately placed in the still fluid stacking gel until fully polymerisation. The 
comb was removed and the gel was placed into a Protean III electrophoresis cell 
(Biorad, Germany), which next was filled with running buffer.  
All urine samples were examined within one week. First, the creatinine concentration 
of the urine samples was measured using an automated analyser technique (Hitachi, 
Merck, Germany). Urine samples were then standardized by dilution with sample buf-
fer to a constant creatinine content of 250 µmol/l. A mouse albumin standard 
(Biotrend, Germany) was diluted 1:100 in sample buffer. Protein was denatured by 
heating the diluted samples and the mouse albumin standard thermoblock TB1 
(Biometra, Germany) for 10 min at 100°C. The samples, an additional broad range 
molecular weight standard (Biorad, Germany), and the mouse albumin standard were 
then loaded onto the gel and electrophoresis was run for 60 min at 200 volt. Sub-
sequently, the gel was stained with the Coomassie blue staining solution for 30 min 
and destained in the Coomassie destaining solution for approximately 1.5 hours until 
clear background. Visible protein bands were registered and gels were digitally 
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photographed for documentation. Finally, gels were dried for long-term storage using 
the DryEase™ Mini-Gel Drying System (Novex, Germany) according to the manu-
facturers protocol. 
 
Beside the material mentioned in the text above, the following reagents have been 
used: 
 
12% SDS-polyacrylamide gel: 
  3.5 ml distilled water 
  2.5 ml Tris/HCl, 1.5 M, pH 8.8 
  100 µl SDS, 10%  
  4.0 ml Acrylamide, 30% (Roth, Germany) 
  50 µl Ammonium persulphate 10% (Biorad, Germany) 
  5 µl Tetraethylethylenediamine (TEMED; Sigma, Germany) 
 
  Tris/HCl, 1.5 M, pH 8.8: 
  18.5 g Tris base 
  ad 100 ml distilled water, adjust pH with 1N HCl  
 
5% SDS-polyacrylamide gel: 
  6.1 ml distilled water  
  2.5 ml Tris/HCl, 0.5 M, pH 6.8 
  100 µl SDS, 10% 
  1.3 ml Acrylamide, 30% 
  50 µl Ammonium persulphate, 10% 
  5 µl TEMED 
 
  Tris/HCl, 0.5 M, pH 6.8: 
  6.075 g Tris 
  ad 100 ml dist. water, adjust pH with 1N HCl 
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Running buffer (stock): 
  30.3 g Tris 
  144 g Glycerol (Merck, Germany) 
  ad 1 l distilled water 
 
Running buffer (ready to use): 
  40 ml running buffer stock solution 
  4.0 ml SDS, 10% 
  ad 400 ml distilled water 
 
Sample buffer:  1 ml distilled water 
  0.25 ml Tris/HCl, 0.5 M, pH 6.8 
  0.2 ml Glycerol 
  0.4 ml SDS, 10% 
  0.125 ml Bromphenol blue, 0.05% (Sigma, Germany)  
 
Coomassie staining solution: 
  625 mg Coomassie Brilliantblau G250 (Merck, Germany) 
  12.5 ml 100% acetic acid (AppliChem, Germany) 
  125 ml 100% ethanol 
  ad 250 ml distilled water 
 
Coomassie destaining solution: 
  17.5 ml 100% acetic acid  
  12.5 ml 100% ethanol 
  ad 250 ml distilled water 
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3.2.2 Determination of urinary albumin concentration by ELISA  
 
For quantitative determination of urinary albumin concentrations, the murine micro-
albuminuria ELISA Albuwell M™ (Exocell Inc., USA) was applied, representing a 
conventional indirect competitive ELISA.  
The murine albumin standard dilutions were prepared due to manufacturers recom-
mendations with a provided diluent. The proper dilution of urine specimens ranged 
from 1:13 to 1:150, as shown by a pilot study. For the first incubation step (30 min), 
50 µl of the standard solutions and the diluted specimens were added to the albumin-
precoated wells of the ELISA plate together with 50 µl of a rabbit anti-murine albumin 
antibody solution. Then, the plate was washed ten times with a Columbus plate 
washer (Tecan AG, Germany). In a second incubation step (30 min), the probe was 
labeled by adding 100 µl of a horseradish peroxidase-conjugated goat anti-rabbit 
antibody. Next, the plate was washed as described above. Subsequently, the 
antibody-conjugate that bound to the albumin of the stationary phase was detected 
through a chromogenic reaction. 100 µl of a provided color developer was added for 
5 to 10 min. The color intensity was measured by determining the absorbance at  
450 nm using a computer-assisted (Magellan; Tecan AG, Germany) microplate 
reader (Sunrise; Tecan AG, Germany). The values of the specimen wells were in the 
linear segment of the calibration curve. 
 
3.3 Serum and plasma parameters 
 
For determination of clinical-chemical serum parameters and serum IGFBP-2 and 
IGF-I levels, blood was collected from mice (see table 3.1) under ether anesthesia by 
puncture of the retroorbital plexus. Serum was separated by centrifugation (10 min, 
10,000 rpm) and stored at -80°C until assayed. Various clinical-chemical serum 
parameters, including sodium, potassium, calcium, chloride, phosphate, total protein, 
creatinine, urea, cholesterol, and triglycerides were determined using an Olympus 
AU400 autoanalyser (Olympus Diagnostica GmbH, Germany) and adapted reagents 
from Olympus Diagnostica GmbH (Germany). The measurement of clinical-chemical 
serum parameters was kindly carried out by Martina Klempt, Institute of Experimental 
Genetics, National Research Center for Environment and Health (GSF), Neuherberg, 
Germany. 
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Serum IGF-I and IGFBP-2 concentrations were quantified as described previously 
275-277 using specific RIAs. The determinations were kindly performed by Martin 
Elmlinger, University Children’s Hospital, Pediatric Endocrinology, Tübingen, 
Germany. For both assays, dilution curves of mouse serum samples were linear and 
paralleled those of human standards.  
Plasma corticosterone levels were measured in 44 mice (C: n=15, B: n=11, G: n=10, 
GB: n=8) at four months of age. The animals were housed singly in opaque cages for 
two weeks before measurement of basal plasma corticosterone levels. Blood sam-
ples were taken between 16.00 and 18.00 hours. Mice were anesthetized individually 
in a glass jar containing saturated ether vapor and retroorbital blood was collected 
within 30 sec of the initial disturbance from the cage. To measure stimulated 
corticosterone levels, the anesthetized animals were treated intraperitoneally with  
1 IU/100 g body weight ACTH (Synacthen®, Ciba-Geigy, Switzerland), and a second 
blood sample was obtained 60 min later. Blood was collected in ice chilled EDTA-
coated Eppendorf tubes containing 200 IU aprotinin (Trasylol®, Bayer AG, Ger-
many). Plasma samples were stored at -80 C until assayed. 
For measurement of basal plasma ACTH concentrations, blood samples were taken 
from additional 31 mice (C: n=8, B: n=7, G: n=8, GB: n=8; four to seven months of 
age) of the four genetic groups between 8.00 and 9.00 hours and between 16.00 and 
17.00 hours. The blood samples from the six MT-bGH transgenic mice and six 
littermate controls were collected in the morning. The blood samples for basal 
plasma ACTH determination were taken from the tail vein of conscious animals, 
because this is the least stressful method of blood sampling, if only a small amount of 
blood is needed and if the animals are used to be handled. Blood samples were 
collected in EDTA-coated tubes. The measurement of plasma corticosterone and 
ACTH concentrations was kindly carried out by Matthias M. Weber, Laboratory of 
Endocrine Research, Medical Department II Köln-Merheim, University of Cologne, 
Germany. 
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3.4 Body and organ weights 
 
The body weight of mice listed in table 3.1 was constantly recorded between twelve 
and one o’clock in the afternoon after urine collection, and was determined to the 
nearest 0.1 g (PM 3000; Mettler, Switzerland). 
The adrenal gland and kidney weight was determined after perfusion fixation of the 
mice (for details, see table 3.1). After fixation, the adrenal glands and kidneys were 
excised and adjacent tissues were carefully removed under a dissecting microscope 
(Stemi DV4, Zeiss, Germany). The adrenal glands were weighed to the nearest  
0.1 mg, the kidneys to the nearest 1.0 mg on a precision balance (AE 200; Mettler, 
Switzerland). 
 
3.5 Tissue preparation 
 
3.5.1 Perfusion fixation  
 
After blood collection under ether anesthesia, the mice were sacrificed by ether 
inhalation. Subsequently, the abdominal cavity and thorax were opened and the 
animals were fixed by orthograde perfusion via the left heart ventricle. The vascular 
system was preflushed with phosphate-buffered saline (PBS, pH 7.4, 37 °C) for  
20 sec and perfused with a 3% glutaraldehyde-PBS solution (pH 7.4, 37 °C) for 5 min 
under a constant pressure of 100 mm Hg. An incision of the inferior vena cava 
served as outlet for the perfusate. After perfusion fixation, the adrenal glands and 
kidneys were postfixed in situ for an additional 48 h in the same fixative.  
 
3.5.2 Immersion fixation  
 
The kidneys for immunohistochemistry and in situ hybridization were collected from 
mice sacrificed by bleeding from the retroorbital sinus under ether anesthesia, and 
cut perpendicular to the longitudinal axis into four slices. The kidney slices were 
placed in tissue-embedding capsules and fixed by immersion in a 4% 
paraformaldehyde-PBS solution (pH 7.2) at 4°C for 12 hours.  
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3.5.3 Materials 
 
The following materials were used for perfusion fixation and immersion fixation: 
 
Phosphate-buffered saline (PBS) 
 0.25 g potassium dihydrogen phosphate (AppliChem, Germany) 
 8.0 g sodium chloride 
 1.46 g di-sodium hydrogen phosphate dihydrate (AppliChem,  
    Germany) 
 ad 1 l distilled water, adjust to pH 7.4 
 
3% glutaraldehyde-PBS solution (pH 7.4): 
  880 ml PBS, pH 7.4 
 120 ml glutaraldehyde, 25% (Serva, Germany) 
 
4% paraformaldehyde-PBS solution (pH 7.2): 
  1000 ml PBS, pH 7.4 
 40 g paraformaldehyde (Serva, Germany) 
 adjust to pH 7.2 with 1 n NaOH 
 
 
 
3.6 Histological techniques 
 
3.6.1 Paraffin histology 
 
The left, perfusion fixed, complete adrenal glands and the immersion fixed kidney 
slices were routinely dehydrated in a Histomaster 2050/DI (Bavimed, Germany) and 
embedded in paraffin (Paraplast®, Tyco Health Care, USA). Approximately 3 to 5 µm 
thick sections were obtained using a HM 315 microtome (Microm GmbH, Germany). 
The sections were mounted on glass slides (Marienfeld, Germany) and stained with 
hematoxylin and eosine (H&E), and Periodic Acid Schiff stain (PAS) according to 
standard procedures (see appendix). 
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3.6.2 Plastic histology 
 
Perfusion fixed, sliced (see below) kidneys were dehydrated in a Citadel 1000 
(Shandon, Germany). In order to avoid distorsion, the kidney slices were fixed with a 
piece of foam-rubber sponge in the tissue-embedding capsules. Subsequently, the 
kidney slices were processed in a hydroxymethylmethacrylate (Fluka Chemie, 
Germany)/methylmethacrylate (Riedel de Haën, Germany) solution at 4°C on a 
shaker for 18 hours. The kidney slices were then shifted into “solution 1”, composed 
of benzoylperoxide (338 mg; Merck, Germany), methylmethacrylate (20 ml), 
hydroxymethylmethacrylate (60 ml), ethyleneglycol monobutylether (16 ml; Merck, 
Germany), and polyethylene glycol 400 (2 ml; Merck, Germany). After immersion at 
4°C on a shaker for four hours, the kidney slices were placed in plastic cups and 
embedded using 60 µl of dimethylanilin (Merck, Germany) in 40 ml of “solution 1” as 
starter for polymerisation. Embedding cups were immediately placed into a water 
bath (4°C) and polymerisation took place at 4°C over night 278. Sections of 1.5 µm 
thickness were cut from the casted blocks on a Reichert-Jung 2050 rotary microtome 
(Cambridge Instruments, Germany). The sections were routinely processed and 
stained with H&E, PAS, and Periodic acid silver methenamine combined with PAS 
(PASM-PAS), respectively. Staining procedures are listed in the appendix.  
 
3.6.3 Epon histology 
 
Since Epon is a trademark of the Shell Company (USA), Serva (Germany) distributes 
the identical chemical substance under the designation “glycid ether 100”. In the 
present study the terms “Epon” and “glycid ether 100” are used synonymous. 
Cubes with a maximal carve length of 1 mm of the renal cortex and complete adrenal 
glands were washed for 3 hours in Sörensen phosphate buffer at room temperature, 
postfixed in 1% osmium tetroxide 279 for 2 hours at 4°C, and washed in Sörensen 
phosphate buffer three times for 2 min at room temperature. Subsequently, the 
specimens were dehydrated through a series of acetone solutions at 4°C before they 
were infiltrated with a 100% acetone/Epon mixture for 1 hour, and twice with pure 
Epon for 30 min, respectively, at room temperature. Then, the Epon infiltrated 
samples were embedded in an Epon-embedding mixture in dried gelatin capsules 
(Plano, Germany). Polymerization took place at 60°C for approximately 48 hours. 
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Epon blocks were trimmed with a TM60 Reichert-Jung milling machine (Leica, Ger-
many) and 0.5 µm semi-thin sections were obtained with a Reichert-Jung "Ultracut E" 
microtome (Leica, Germany).  
 
The following materials were used for Epon histology: 
 
Sörensen phosphate buffer, 0.067 M, pH 7.4 
   80.8 ml solution I 
   19.2 ml solution II 
adjust to pH 7.4 
 
 Solution I: 9.08 g potassium dihydrogen phosphate 
  ad 1 l distilled water 
 
 Solution II: 11.88 g di-sodium hydrogen phosphate dihydrate 
  ad 1 l distilled water 
 
Osmium tetroxide, 1%  
   5.0 ml osmium tetroxide, 2% (Merck, Germany) 
   2.0 ml veronal acetate buffer, pH 7.6 
   2.0 ml hydrogen chloride 0.1 M (Merck, Germany) 
   1.0 ml distilled water 
   0.45 g saccharose (Merck, Germany) 
 
 veronal acetate buffer, pH 7.6: 
  2.95 g sodium veronal (barbitone sodium) (Merck, Germany) 
  1.94 g sodium acetate (Merck, Germany) 
  ad 100 ml distilled water 
 
Epon-embedding mixture 
   3.5 ml solution A and 6.5 ml solution B 
   0.15 ml para-dimethyl aminomethyl phenol (Serva, Germany) 
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 Solution A: 62 ml glycid ether 100 (Serva, Germany) 
  100 ml 2-dodecenyl succinicacid anhydride (Serva, Germany) 
 
 Solution B: 100 ml glycid ether 100  
  89 ml methylnadic anhydride (Serva, Germany) 
 
 
3.7 Stereological investigations of the adrenal glands 
 
Stereological analyses of the adrenal glands were carried out on 12 male mice (n=3 
per genetic group, chosen by random numbers) at the age of 75 days.  
 
3.7.1 Determination of the zonal composition 
 
The left, paraffin-embedded (see 3.6.1) adrenal gland was exhaustively sectioned at 
a nominal thickness of 3 µm on a HM 315 microtome (Microm GmbH, Germany) 
equipped with a section counter. Every 20th section of the series was saved, mounted 
on consecutively numbered glass-slides, and stained with H&E. Morphometric 
evaluation was carried out on a Videoplan® image analysis system (Zeiss-Kontron, 
Germany) coupled to a light microscope (Orhoplan; Leitz, Germany) via a color video 
camera (CCTV WV-CD132E; Matsushita, Japan). The total number of paraffin 
sections sampled per adrenal gland ranged from 14 to 28. On these sections, the 
cross-sectional areas of cortex and medulla were planimetrically determined. 
Furthermore, the cross-sectional areas of the adrenocortical zones were measured 
by point counting at a 340 × final magnification, which was provided by a 10 × 
objective. For calibration, an object micrometer (Zeiss, Germany) was used.  
 
Since in mice the zona fasciculata and zona reticularis are not distinguishable at the 
light microscopic level 280, these zones were calculated jointly and for simplicity will 
henceforth be denoted zona fasciculata only. The volume fractions of the cortex 
(VV(cortex/adrenal gland)) and the medulla (VV(medulla/adrenal gland)) of the adrenal gland were 
estimated following the principle of Delesse 281. They were calculated as the sum of 
cross-sectional areas of cortical and medullary tissue, respectively, divided by the 
sum of cross-sectional areas of the whole adrenal gland 282. The fractional volume of 
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the zona fasciculata in the adrenal cortex (VV(zona fasc./cortex)) was estimated from the 
corresponding point fraction.  
The absolute volume of the adrenal cortex (V(cortex, adrenal gland)) and the medulla 
(V(medulla, adrenal gland)) was obtained as the product of the corresponding volume 
fractions (VV(cortex/adrenal gland) and VV(medulla/ adrenal gland), respectively) and the volume of 
the adrenal gland. The latter was calculated by dividing the weight of the adrenal 
gland by the specific weight, which is reported to correspond to 1.039 mg/mm3 for 
adrenal glands 283. The volume of the zona fasciculata (V(zona fasciculata, cortex)) was 
obtained as the product of VV(zona fasciculata/cortex) and V(cortex, adrenal gland). 
 
3.7.2 Determination of number and size of zona fasciculata cells 
 
For quantitative determination of the changes of the zona fasciculata at a cellular le-
vel, the disector method was applied. The disector is a three-dimensional stereologic 
probe, which allows unbiased assumption-free counting and sizing of particles 284. 
The physical disector, which consists of a pair of physical section planes separated 
by a known distance and an unbiased two-dimensional counting frame, in combina-
tion with systematic point counting was used to estimate the numerical density and 
the mean volume of zona fasciculata cells.  
 
The right, Epon-embedded adrenal glands were analyzed. After trimming of the Epon 
blocks, at least 8 serial semi-thin sections (0.5 µm) comprising the whole organ were 
cut from each adrenal gland with a Reichert-Jung "Ultracut E" microtome (Leica, 
Germany), mounted on consecutively numbered glass-slides, fixed over a flame, and 
stained with toluidine blue and safranine. 
From the stack of serially cut semi-thin sections, one section was drawn at random 
by means of a random number (R) between 2 and 8 (the baseline section was not 
used for sampling) as a reference section in a disector. The second section (look-up 
section) was sampled among no. 2-8 by means of R±3, i.e., the disector height was 
equivalent to the thickness of three semi-thin sections (1.5 µm). Five fields were 
systematically sampled at random in the zona fasciculata of the reference section 
and the corresponding fields were identified in the look-up section (Fig. 3.3). Light 
microscopic images of the selected fields were acquired with a color video camera 
using a 63 × oil immersion objective and color prints were prepared at a constant final 
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magnification (2,300×). A plastic transparency with equally spaced test points (n=70) 
and an unbiased counting frame 285,286, representing an area of 8,800 µm2, was 
superimposed on the printed images (Fig. 3.3).  
All profiles of zona fasciculata cell nuclei sampled in the reference section, which 
were not present in the look-up section, were counted (Q-). On the reference sec-
ions, the number of points hitting zona fasciculata cells (P(zona fasc. cells)) was counted 
as well as the points hitting the zona fasciculata (P(zona fasc.)). The volume density of 
zona fasciculata cells in the zona fasciculata (VV(zona fasc. cells/zona fasc.)) was estimated 
from the corresponding point fraction 282. The operation of counting of Q- (cell nuclei) 
was then repeated by interchanging the roles of the look-up section and the 
reference section, thereby increasing the efficiency by a factor of two.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3: Counting of zona fasciculata cells with the physical disector. A visual field, 
selected by systematic random sampling in the zona fasciculata on the reference section (a) and the 
corresponding visual field on the look-up section (b, 1.5 µm apart) are shown. An unbiased counting 
frame is superimposed on the reference section. Profiles of zona fasciculata cell nuclei were sampled, 
if they were located completely in the frame, or were partially in the frame and intersected or touched 
by the “allowed” (dotted) lines. Profiles of zona fasciculata cell nuclei were not sampled, if they were 
touched or intersected by the “forbidden” (solid) lines. Cell nuclei sampled in the reference section 
were counted (Q-; arrows), if they were not present in the look-up section. 
a b
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Given that zona fasciculata cells have only one nucleus, which is documented in the 
literature 280 and was also observed in this study, no cell is counted twice with this 
procedure. On the average, 61 nuclei (range: 45-83) were counted with the five 
disector pairs per adrenal gland. The numerical density of epithelial cells in the zona 
fasciculata (NV(zona fasc. cells/zona fasc.)) was calculated by dividing the total number of 
cells counted in all disectors in an adrenal gland by the cumulative volume of the 
disectors (area of the unbiased counting frame × disector height × number of 
disectors) sampled in the adrenal gland. Assuming the same numerical density of 
epithelial cells in the zona fasciculata in both (right and left) adrenal glands and 
neglecting the small amount of tissue shrinkage when using Epon-embedding 282, the 
total number of zona fasciculata cells per adrenal gland (N(zona fasc. cells, adrenal gland)) was 
calculated as the product of the numerical density of epithelial cells in the zona 
fasciculata (NV(zona fasc. cells/zona fasc.)) and the volume of the zona fasciculata (V(zona fasc., 
adrenal gland)). 
The mean volume of zona fasciculata cells (v(zona fasc. cells)) was obtained by dividing 
the volume density (VV(zona fasc. cells/zona fasc.)) by the numerical density of the epithelial 
cells in the zona fasciculata (NV(zona fasc. cells/zona fasc.)). 
 
To control the nominal thickness of semi-thin sections (0.5 µm), a resectioning 
technique was used. Five semi-thin sections, which were not used for sampling, were 
selected from different section series and re-embedded in Epon (see under 3.6.3). 
Ultra-thin sections (approximately 70 nm) of the semi-thin sections were stained with 
uranyl acetate and lead citrate and examined with a Zeiss EM 10 electron micros-
cope (Zeiss, Germany). Electron micrographs (final magnification 10,500×) were 
taken from segments of the primary section, showing every evidence of having been 
re-sectioned normally to their surface. For calibration, a waffle grating replica with 
2,160 lines/mm (Plano, Germany) was used. The measured mean thickness of the 
semi-thin sections was 0.497±0.020 µm. Thus, the precision of the ultramicrotome 
was confirmed.  
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3.8 Stereological investigations of the kidneys 
 
Stereological analyses of the kidneys were carried out on male mice, chosen by 
random numbers from the different age and genetic groups. Detailed information on 
number, age, and genotype of the mice used for investigations of single stereological 
parameters is given in table 3.1. 
 
3.8.1 Determination of the zonal composition 
 
After weighing, the length of each kidney was determined. Then the kidneys were cut 
perpendicular to the longitudinal axis into parallel slices of approximately 1 mm 
thickness, with the first cut positioned randomly in a 1 mm interval from one of the 
poles. The total number of slices per kidney ranged from 7 to 14. Before further 
processing, specimens of the renal cortex were taken for Epon-embedding and 
subsequent stereological analysis of the mean volume and the total number of 
proximal tubular epithelium (PTE) cells (see 3.8.2). Cortex specimens were selected 
by systematic random sampling using a plastic transparency with regularly spaced  
(3 mm) test points that was superimposed on the kidney slices 287. The cortex 
specimens sized approximately 1 mm2 × 1 mm thickness of the kidney slice. 
 
Using PASM-PAS stained sections of plastic-embedded kidney slices, the 
quantitative stereological determination of the volume fractions of the individual renal 
zones was performed following the principle of Delesse 281. For this purpose, 
micrographs of the sections were produced using an Orthoplan photomicroscope 
(Leitz, Germany) at a final magnification of 30 ×, provided by a 2.5 × objective. An 
object micrometer was used for calibration, which was photographed and printed 
under the same conditions as the kidney sections. The distinct renal zones, as 
defined in the literature 288,289 - cortex, outer stripe of medulla (OSM), and inner stripe 
of medulla together with the inner zone of medulla (ISM/IZM) - were highlighted on 
the prints. Their cross-sectional areas were determined planimetrically on the 
photographs by circling the cut surface using a Videoplan® image analysis system 
(Zeiss-Kontron, Germany). 
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The volume fractions of the renal zones (VV(cortex/kidney), VV(OSM/kidney), and VV(ISM/IZM/ 
kidney)) were calculated separately in each kidney as the sum of cross-sectional areas 
of the individual zones, divided by the sum of cross-sectional areas of the whole 
kidney. The absolute volumes of the renal zones (V(cortex, kidney), V(OSM, kidney), and 
V(ISM/IZM, kidney)) were obtained as the product of the corresponding volume fractions 
and the volume of the kidney. The volume of the kidney was calculated by dividing 
the weight of the kidney by its specific weight, which is reported to correspond to 1.05 
mg/mm3 290. 
 
3.8.2 Determination of the volume of nephron segments 
 
The fractional volume of the proximal tubular epithelium (PTE) within cortex and 
OSM (VV(PTE/cortex&OSM)) was determined by point counting. Further, the fractional 
volumes of other nephron segments were obtained, like that of other tubular epithelia 
(OTE, VV(OTE/cortex&OSM)), and that of miscellaneous structures, like glomeruli, 
interstitium, and blood vessels (MIS, VV(MIS/cortex&OSM)). Sections of every third kidney 
slice were selected. Within one section, every 8th to 15th visual field (depending on 
the cross-sectional area of the kidneys) was evaluated. The visual fields were 
projected from a microscope on a monitor with a final magnification of 340 ×, 
provided by a 10 × objective. Per kidney, 90 to 138 points (six points per visual field) 
were counted. The point fraction of the individual nephron segments (e.g., for the 
PTE: PP(PTE/cortex&OSM)) of hitting points (for the PTE: P(PTE)) as a function of the total 
number of points (P(total)) is equivalent to the fractional volume of the individual 
nephron segments in the cortex and OSM (for the PTE: VV(PTE/cortex&OSM)) 282,291. The 
absolute volume of the individual nephron segments (for the PTE: V(PTE, cortex&OSM)) 
was obtained as the product of the corresponding volume fraction and the volume of 
the cortex and OSM. 
 
3.8.3 Determination of the mean volume and total number of PTE cells 
 
The mean volume and the total number of cortical PTE cells were determined 
applying the disector method in combination with systematic point counting, 
analogous to the stereological investigation of parameters of adrenal zona fasciculata 
cells (see 3.7.2).  
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Two specimens of the renal cortex were taken per kidney (four samples per animal) 
as described in 3.8.1, and embedded in Epon. At least 10 serial, toluidine blue and 
safranine stained semi-thin sections (0.5 µm) were obtained from each cortex 
specimen. One section out of the stack of serially cut semi-thin sections was drawn 
at random by means of a random number (R) between 2 and 10 as a reference 
section in a disector. The look-up section was sampled among no. 2-10 by means of 
R±3, destining a disector height of 1.5 µm. In this approach, two visual fields were 
systematically sampled at random in the renal cortex of the reference section and the 
corresponding fields were identified in the look-up section.  
Color prints of light microscopic images of the selected fields were prepared (1,450 × 
final magnification, provided by a 40 × objective) and were overlaid with a plastic 
transparency with equally spaced test points (n=70) and an unbiased counting frame, 
representing an area of 22,360 µm2.  
Profiles of PTE cell nuclei were sampled in the reference section and counted (Q-), if 
they were not present in the look-up section. The operation of counting of Q- (cell 
nuclei) was then repeated by interchanging the roles of the look-up section and the 
reference section. As documented in the literature 292 as well as confirmed in this 
study, PTE cells have one nucleus. Thus, no cell is counted twice with this method. 
To calculate the numerical density of PTE cells in the cortex (NV(PTE cells/cortex)), the 
total number of PTE cells counted per kidney (Q-=87 PTE cell nuclei/kidney on 
average, range: 60 - 102) was divided by the cumulative volume of the disectors per 
kidney. The total number of PTE cells in the cortex (N(PTE cells, cortex)) was calculated as 
the product of (NV(PTE cells/cortex) and the volume of the cortex (V(cortex, kidney)). 
The number of points hitting PTE cells (P(PTE cells)) was counted on the reference 
sections, as well as the points hitting the reference space, i.e., the renal cortex 
(P(cortex)). The volume density of PTE cells in the renal cortex (VV(PTE cells/cortex)) was 
estimated from the corresponding point fraction 282. The mean volume of PTE cells 
(v(PTE cells)) was obtained by dividing the volume density of PTE cells in the cortex 
(VV(PTE cells/cortex)) by the numerical density of PTE cells in the cortex (NV(PTE cells/cortex)). 
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3.8.4 Determination of the mean glomerular volume 
 
The mean glomerular volume (v(Glom)) was estimated following the method of Hirose 
et al. 293. In this model-based stereological approach, the glomeruli were considered 
as rotation ellipsoids. The mean glomerular area (a(glom)) was obtained from plani-
etric measurements of glomerular profile areas. In the calculation, a shape coefficient 
(β, =1.40) and a size distribution coefficient (κ , =1.04) were considered. The results 
were corrected for embedding shrinkage 293. The values for the shape and size 
distribution coefficient as well as for the shrinkage correction factor for plastic 
embedded murine renal tissue were taken from Wanke 229. The mean glomerular 
volume was calculated with the following equation 293: 
 
 
v (glom) = 1,5(glom)a⋅
κ
β  
 
 
v (glom) :  mean glomerular volume 
β :  shape coefficient 
κ :  size distribution coefficient 
 (glom)a :  mean area of glomerular profiles 
 
PASM-PAS stained sections of every third kidney slice were selected. Images of the 
sections were displayed on a color monitor using a Videoplan® image analysis 
system (Zeiss-Kontron, Germany). The final magnification on the monitor was 1380 × 
(40 × objective). An object micrometer (Zeiss) served for calibration. Within the 
section, these glomerular profiles were sampled, which appeared on the monitor 
while systematically meandering through the section. The lateral lines of a frame 
displayed on the monitor were used as “allowed and forbidden lines”, as meant by 
the unbiased counting rule 285,294. These glomerular profiles, which were between the 
lines, or which were touched or intersected by “allowed lines” were sampled, where-
as these, which were touched or intersected by “forbidden lines” were not sampled. 
The contours of the sampled glomerular profiles were circled with a cursor. Between 
114 and 316 glomerular profiles were evaluated per kidney (on average  
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165 glomerular profiles). The difference between right and left kidney of the same 
animal was seen as an internal quality control and ranged from 0.02 to 8.98%, and 
was on average 4.61 %. 
 
3.8.5 Determination of the nephron number 
 
For determination of the nephron number, the number of glomeruli per kidney (N(glom, 
kidney)) was estimated following the method of Weibel 282. The analysis was performed 
on images of PASM-PAS stained sections that were projected on a color monitor in 
combination with a Videoplan® image analysis system. An object micrometer served 
for calibration. A plastic transparency with a grid (four lines per mm) was super-
mposed on the sections to enable an area-based selection of the cortical areas to be 
evaluated. The selection of cortical areas was performed at a final magnification of 
25 × (2.5 × objective). By changing the objective, the selected cortical areas were 
investigated at a final magnification of 350 × (10 × objective). 
In a first step, the fractional area of glomerular profiles in the renal cortex 
(AA(glom/cortex)) was determined. This was achieved by planimetrically measuring the 
areas of glomerular profiles located completely or partially within a frame with known 
area that is displayed on the monitor. AA(glom/cortex) was determined in 24 to 55 test 
fields (average 40) per kidney representing 5.2 to 11.3 % (average 7.6%) of the total 
cortical area of the sections of the kidneys investigated.  
In a second step, the number of glomerular profiles per cortical area (QA(glom/cortex)) 
was counted using the identical fields as used for estimation of AA(glom/cortex). In those 
fields, the frame lines generated by the monitor were used according to the unbiased 
counting rule 285. Analogous to the determination of the mean glomerular volume 
(see 3.8.4), a shape coefficient and a size distribution coefficient were considered in 
the calculation, and the results were corrected for embedding shrinkage. The 
numerical volume density of glomeruli in the renal cortex was calculated by the 
following equation 282: 
 
    NV(glom/cortex) = 
tex)A(glom/cor
3
tex)A(glom/cor
A
Q
β
κ  
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NV(glom/cortex) :  numerical volume density of glomeruli in the renal cortex 
β : shape coefficient 
κ :  size distribution coefficient  
QA(glom/cortex):  number of glomerular profiles per unit of cortex area 
AA(glom/cortex):  fractional area of the glomerular profiles in the cortex 
 
The number of glomeruli per kidney was calculated from the product of the numerical 
volume density of glomeruli in the renal cortex (NV(glom/cortex)) and the volume of the 
renal cortexglomerular area fraction in the cortex (V (cortex, kidney)). 
 
 
3.9 Evaluation of the glomerulosclerosis index 
 
The degree of glomerular lesions was assessed semi-quantitatively on a scale of  
0 - 4 following the method of El Nahas et al. 295. The glomerular score was: Grade 0, 
glomeruli without light-microscopic structural changes; Grade 1, presence of 
mesangial expansion; Grade 2, segmental glomerular sclerosis/hyalinosis involving 
less than 50% of the glomerular tuft profile; Grade 3, glomerular sclerosis/hyalinosis 
involving more than 50% of the tuft profile; Grade 4, global glomerulosclerosis with 
total tuft obliteration. 
The glomerulosclerosis index was evaluated on images of PASM-PAS stained 
sections that were projected on a color monitor via a color video camera. The final 
magnification on the monitor was 1380 × (40 × objective). Two randomly selected 
sections of each kidney were investigated by systematically meandering through the 
section. The lateral lines of a frame generated by the monitor were used as “allowed 
and forbidden lines”. Glomerular profiles between the lines or touching the “allowed” 
line were sampled, and those touching the “forbidden” line were excluded, to give an 
unbiased sample 285. Between 107 and 164 glomerular profiles were evaluated per 
mouse (on average 143 glomerular profiles). The ultimate glomerular sclerosis index 
was obtained by averaging the scores of all glomerular profiles surveyed in each 
animal. 
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3.10 Detection of IGFBP-2 mRNA and protein in renal tissue 
 
Three mice per genetic group at 38 days of age were used for immunohistochemistry 
and in situ hybridization analysis of the kidneys. Animals were sacrificed under ether 
anesthesia. Subsequently, the left kidney of each mouse was removed, cut transver-
sally into four slices, shock frozen in liquid nitrogen, and stored at -80°C until used for 
Western ligand blot (WLB) analysis. The right kidney and the pancreas were immer-
sion fixed (see 3.5.2) and paraffin-embedded (see 3.6.1) for immunohistochemistry 
and in situ hybridization. The pancreata of B and GB mice were taken as positive 
control tissue for IGFBP-2 immunohistochemistry since the highest IGFBP-2 protein 
levels were found in pancreatic islets 152.  
 
3.10.1 Immunohistochemical detection of IGFBP-2 
 
The indirect immunoperoxidase technique 296 served to localize IGFBP-2 protein 
within the kidney. Approximately 5 µm thick paraffin sections were cut with a HM 315 
microtome and mounted on 3-aminopropyltriethoxy-silane-treated glass slides. The 
treatment of the sections was carried out at room temperature and all incubation 
steps were performed in a humidity chamber. Sections were deparaffinized in xylene, 
rehydrated in a descending ethanol series and washed in distilled water. Then, they 
were incubated in a preheated Target Retrieval Solution (Dako Diagnostika, Germa-
ny) for 10 min at 96°C and another 20 min in the down-cooling solution in order to 
improve the accessibility of the antibodies to target sites within the tissue. The slides 
were rinsed with distilled water and washed in PBS for 10 min. Next, tissue sections 
were treated with 1% hydrogen peroxide phosphate-buffered saline (PBS) for 10 min 
to block endogenous peroxidase activity, followed by a 10-min washing in PBS. 
Subsequently, the tissue sections were pre-incubated with 2% normal rabbit serum 
(Dako Diagnostika, Germany) PBS solution for 60 min to reduce non-specific binding. 
The pre-incubation serum was decanted before the slides were incubated with a goat 
anti-humanIGFBP-2 antibody (sc-6002, Santa Cruz Biotechnology Inc., Germany) for 
45 min that was diluted 1:100 in PBS solution containing 2% (vol/vol) normal rabbit 
serum. According to the manufacturers description, the epitopes the antibody 
recognizes are identical between human and murine IGFBP-2 and presents the 
identical amino acid sequence. After a 10-min washing in PBS, horseradish 
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peroxidase conjugated rabbit anti-goat IgG antibody (Dako Diagnostika, Germany), 
diluted 1:100 in PBS solution containing 5% (vol/vol) mouse serum was applied for 
45 min. Then slides were washed in PBS solution for 10 min and immunoreactivity 
was visualized using DAB tablets (3,3 diaminobenzidine; ENTEC Diagnostics, 
Denmark) tablets. The DAB tablet was dissolved in 10 ml distilled water containing 
10 µl 30% hydrogen peroxide, and the tissue sections were incubated with the 
solution for 5 min. Tissue sections were counterstained with Mayer`s hemalaun 
(AppliChem, Germany) solution, dehydrated in an ascending series of alcohols, 
cleared in xylene and mounted under glass coverslips (Menzel GmbH & Co KG, 
Germany) using Histofluid® (Superior, Germany). 
Specificity controls included substitution of the primary antibody with non-immune 
serum and omission of the secondary antibody. 
 
3.10.2 Detection of IGFBP-2 mRNA by in situ hybridization 
 
Approximately 5 µm thick paraffin sections were cut with a HM 315 microtome, 
mounted on SuperFrost®Plus (Menzel GmbH & Co KG, Germany) glass slides, and 
kept at 4°C until assayed. Serial sections from the identical paraffin blocks as used 
for immunohistochemistry allowed a direct comparison of IGFBP-2 mRNA expression 
and protein occurrence in individual kidney structures.  
Section pre-treatment included deparaffination and rehydration through successive 
graded alcohol solutions. Tissue sections were then postfixed in ice-cold 4% para-
formaldehyde-PBS solution, digested with Proteinase K (20 µg/ml; Roche, Germany), 
acetylated in acetic anhydride (0.25 %; Sigma, Germany) in triethanolamine (10 mM; 
Sigma, Germany), and equilibrated, due to a standard protocol. RNA riboprobes 
were generated by in vitro transcription. To this end, IGFBP-2 cDNA (kindly donated 
by Stenvert L. S. Drop, Department of Pediatrics, Division of Endocrinology, Sophia 
Children’s Hospital, Erasmus University, Rotterdam, The Netherlands) as well as the 
vector pGEM4Z were digested and the resulting fragments were ligated. The plasmid 
pGEM4Z-IGFBP2 was linearized with restriction enzymes and subsequently used as 
template for Digoxigenin (DIG)–UTP-labeled riboprobe synthesis. After transcription, 
the template cDNAs were digested by RNase-free DNase (Desoxyribonuclease; 
Invitrogen, Germany) and the riboprobes were precipitated. Concentration and length 
of the riboprobes were determinated by agarose gel electrophoresis. 
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For in situ hybridization, pre-treated tissue sections were prehybridized with hybridi-
zation solution (mRNA in situ hybridization Solution; Dako Diagnostika, Germany) at 
65°C. The probes were denatured for 5 min at 80°C and added to hybridization mix. 
The hybridization reaction was carried out at 65°C over-night in a closed sealed box 
in a water bath. Afterwards, the tissue sections were washed several times and 
RNase (RNaseA; Roche, Germany) treated. The slides were then blocked (DIG 
Wash and Block Buffer set; Roche, Germany) and subsequently labeled with alkaline 
phosphatase-coupled anti-digoxigenin antibody (DIG RNA Labeling Mix; Roche, 
Germany). Excess antibody was removed by several washes. Prior to the cytochemi-
cal detection of hybridized probe sections were equilibrated. Color development was 
performed under visual inspection with BM Purple (Roche, Germany), staining was 
stopped with distilled water. Sections were mounted with Vectashield® (Vector 
Laboratories, USA) mounting medium. 
In situ hybridization for detection of IGFBP-2 mRNA was kindly performed by Dagmar 
Kress, Institute of Molecular Animal Breeding and Biotechnology/Gene Center, 
University of Munich.  
 
3.10.3 Western Ligand Blot analysis 
 
In order to evaluate binding capacity of IGFBP-2 within the distinct renal zones, the 
right kidneys of three 38-day-old mice per genetic group were investigated by 
Western ligand blot (WLB) analysis 297. 
 
The kidney samples were thawed on a 4°C aluminum padding. Subsequently, three 
to four about 1 mm3-sized pieces were excised from the renal zones (cortex, OSM, 
and ISM/IZM) with a scalpel and were in part embedded in paraffin, sectioned, and 
stained with H&E, in order to control their purity. A microscopic evaluation of the 
control pieces confirmed that no neighbored renal zones were catched.  
The majority of renal zone samples were saved in 15 ml plastic tubes and 5 ml of 4°C 
tempered extraction buffer were added immediately. Then the samples were homo-
genized for about 1 min with a Polytron® PT-K 7 K1 homogenizer (ART, Germany). 
Next, the protein content of the extracts was standardized. For that purpose, the 
actual protein content was determined using the bicinchinoic acid (BCA) protein 
assay. A 96 well plate was prepared with 4 µl of bovine serum albumin dilutions as 
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standards as well as 4 µl of the extracts, before addition of 200 µl of BCA (Sigma, 
Germany) and CuSO4 (4%) (Sigma, Germany) in a 50:1 relation. The plate was 
incubated at 37°C for 30 min and evaluated by measuring the absorbance at 562 nm 
with a microplate reader. The results of the tissue extraction samples were in the 
linear range of the standard dilution curves. After determining the protein contents, 
the tissue extraction samples were standardized for constant protein content by 
dilution with adequate amounts of extraction buffer. 
 
Next, 20 µg of protein per tissue extraction sample was separated by SDS-PAGE, as 
described under 3.2.1. After electrophoresis, the separated proteins were transferred 
onto a polyvinylidene difluoride Q (PVDF) membrane (Millipore, Germany), using 
semi-dry electroblotting. Six layers of transfer buffer-moistened absorbent paper 
(Schleicher & Schüll, Germany) and a PVDF membrane were placed on the cathode 
of a semi-dry blotting chamber (Millipore, Germany). The PVDF membrane had been 
incubated in 100% methanol (AppliChem, Germany) for 10 min and subsequently 
washed in transfer buffer. Next, the SDS-PAGE gel was positioned on the PVDF 
membrane. The absorbent paper that was not covered by the PVDF membrane and 
the SDS-PAGE gel was enclosed with parafilm “M” (Am. National Can™, USA), in 
order to obtain an accurate currency through the gel. The SDS-PAGE gel was 
covered with six layers of absorbent paper and the anode. The transfer was run for 
90 min with an initial currency of 60 mA. A correct blotting was confirmed by staining 
the membrane with ponceau S red solution for 1 to 2 min and destaining until clear 
background with distilled water.  
 
For detection of the IGFBPs, the PVDF membrane was positioned in a 50 ml tube 
and incubated with different solutions. All incubations and washing steps were 
carried out at 4°C in a tube rotator (Bachhofer, Germany). First, a 3% NP-40 Tris-
Saline solution was added for 20 min, replaced by a blocking 1% fish gelatine Tris-
Saline solution for 60 min in order to avoid non-specific binding of the ligand to the 
membrane. Subsequently, the membrane was treated with a 0.1% Tween-20 Tris-
Saline solution for 15 min before over night incubation with the tracer containing  
106 cpm [125I]-IGF-II per blot. The following steps included two washings with  
0.1% Tween-20 Tris-Saline solution and three washings with Tris-Saline solution for 
30 min, respectively. Membrane bound [125I]-IGF-II was visualized using a Phospho-
 
-67- 
Research design and methods 
Imager Storm (Molecular Dynamics, Germany). The densitometric analysis of the 
IGFBP-2 bands was performed using the ImageQuantTM Software Package 
(Molecular Dynamics, USA). 
 
The following materials were used for Western Ligand blot analysis: 
 
Extraction buffer 388 mg Tris base (Roth, Germany) 
  3.2 ml Triton X-100, 2% (Sigma, Germany) 
  40 ml Laemmli buffer (5x) 
  ad 160 ml distilled water, adjust to pH 7.4 
 
 Laemmli buffer (5x) 
  7.5 g Tris base (Roth, Germany) 
  10 g SDS  
  50 g Glycerol (Merck, Germany) 
  1.0 ml EDTA, 1 mM (Sigma, Germany) 
  10 ml Bromphenol blue, 0.05% 
  ad 100 ml distilled water, adjust to pH 6.8 
 
Transfer buffer 3.03 g Tris base  
  14.4 g Glycerol 
  200 ml Methanol (Applichem, Germany) 
  800 ml distilled water 
 
Tris-Saline 1.21 g Tris base 
  8.765 g sodium chloride  
  ad 1000 ml distilled water, adjust to pH 7.4 
 
3% NP-40 Tris-Saline 
  485 ml Tris-Saline, pH 7.4 
  15 ml Nonidet P-40 (Fluka Chemie, Germany) 
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1% fish gelatine Tris-Saline 
  5.0 ml Tris-Saline, pH 7.4 
  50 µl fish gelatine (Amersham Pharmacia GmbH, Germany) 
 
0.1% Tween-20 Tris-Saline 
  500 ml Tris-Saline, pH 7.4 
  500 µl Tween 20 (Sigma, Germany) 
 
Tracer 5.0 ml 0.1% Tween-20 Tris-Saline, pH 7.4 
  50 µl fish gelatine 
  0.5 x 106 cpm/ml [125I]-IGF-II (Amersham Pharmacia GmbH, 
   Germany) 
 
3.11 Statistical Analysis and Data Presentation  
 
Data were analyzed by ANOVA taking the effect of genetic group into account. Means 
were compared by using LSD post-hoc tests (SPSS program package; SPSS, Inc., 
Chicago, IL, USA). P values < 0.05 were considered significant. Data are presented as 
means and standard deviations (SDs) throughout the study. 
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4 Results 
 
4.1 Body weight 
 
Body weight of male mice transgenic for mIGFBP-2 (B), bGH (G), or for both 
transgenes (GB), and of non-transgenic littermates (C) was recorded in 28 animals at 
38 days of age (n=7 per genetic group) and in 28 animals at 75 days of age (C: n=6; 
B: n=8; G: n=7; GB: n=7).  
 
In both 38- and 75-day-old B vs. C mice, the body weight was significantly decreased 
by 18% and 15%, respectively (Fig. 4.1). In contrast, the body weight of G mice was 
increased by 29% (p<0.001) at 38 days of age and by 76% (p<0.001) at 75 days of 
age, as compared to that of non-transgenic littermates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Body weights of mice of the four different  genetic groups. At both ages 
investigated, the body weight of G mice was markedly increased, compared to that of non-transgenic 
littermates. GB vs. G mice demonstrated a markedly reduced body weight, which in the 38-day-old 
group even was reduced as a tendency compared to C mice. (n/n): number of mice investigated at an 
age of 38 and 75 days, respectively. The data are shown as means and SDs. Significant differences 
(at least p<0.05) between the genetic groups are indicated by different superscripts (a, b, c, d). 
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In GB vs. G mice, the body weight was significantly decreased at both ages 
investigated. In the 38-day-old group, the body weight of GB mice was even slightly 
lower than that of non-transgenic controls. Thus, the body growth stimulation seen in 
G mice was completely abolished in 38-day-old GB mice. Regarded from the other 
side, as GB vs. B mice exhibited a significantly higher body weight, the growth 
inhibiting effect observed in B mice was reduced in 38-day-old GB mice. 
At 75 days of age, the body weight of GB mice ranged at an intermediate stage 
between those of G and C mice, being significantly different from both.  
 
In both age groups, GB vs. G mice demonstrated a more pronounced relative growth 
inhibiting effect than B vs. C mice (B vs. C mice: -18% (38 d), -13% (75 d);  
GB vs. G mice: -28% (38 d), -18% (75 d)). The absolute reduction of body weight 
between B and C mice and between GB and G mice was virtually constant at both 
ages investigated (B vs. C mice: -4.8 g (38 d), -4.3 g (75 d); GB vs. G mice:  
-9.8 g (38 d), -10.3 g (75 d)). 
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4.2 Serum IGFBP-2 and IGF-I concentrations  
 
Serum concentrations of IGFBP-2 and IGF-I were determined in 44 mice at 38 days 
of age (n=11 per genetic group) and in 44 mice at 75 days of age (C: n=10;  
B: n=128; G: n=11; GB: n=11).  
 
The serum IGFBP-2 levels of 38-day-old B and GB vs. C mice were about 2-fold 
increased (p<0.001; Fig. 4.2). In the 75-day-old group, the serum IGFBP-2 levels of  
B and GB mice displayed a 2.8-fold and 2.6-fold increase (p<0.001), respectively, 
compared to these of non-transgenic littermates. The findings demonstrate similarly 
elevated serum IGFBP-2 levels in both IGFBP-2 overexpressing groups.  
In G mice, the serum levels of endogenous IGFBP-2 were reduced to about one fifth 
in the 38-day-old group (p<0.001) and to about one third in the 75-day-old group 
(p<0.001), compared to these of littermate controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Serum IGFBP-2 levels of mice of the four genetic groups. At both ages 
investigated, B and GB mice exhibited similarly increased serum IGFBP-2 levels, whereas in G mice, 
the serum level of endogenous IGFBP-2 was significantly reduced, compared to non-transgenic 
littermate controls. (n/n): number of mice investigated at an age of 38 and 75 days, respectively. The 
data are shown as means and SDs. Significant differences (at least p<0.05) between the genetic 
groups are indicated by different superscripts (a, b, c).  
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The serum IGF-I levels in G and GB vs. C and B mice were significantly increased: 
38-day-old G and GB vs. C mice displayed an approximately 1.7-fold increase,  
75-day-old G and GB vs. C mice an approximately 2-fold increase in this parameter 
(Fig. 4.3). Between G and GB mice and between C and B mice, the circulating IGF-I 
levels were not significantly different at both ages investigated, demonstrating that 
IGFBP-2 overexpression had no effect on serum IGF-I levels. 
 
Within the four different genetic groups, no significant differences were detected in 
either serum IGFBP-2 or serum IGF-I levels between the 38- and 75-day-old group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Serum IGF-I levels of mice of the four genetic groups. In both G and GB vs. C 
mice, circulating IGF-I levels were elevated to a similar extend in the 38- and 75-day-old group. 
Between C and B mice, serum IGF-I levels were not significantly different. (n/n): number of mice 
investigated at an age of 38 and 75 days, respectively. The data are shown as means and SDs. 
Significant differences (at least p<0.05) between the genetic groups are indicated by different 
superscripts (a, b). 
0
250
500
750
1000
38 days 75 days
 C mice (11/10)
 B mice (11/12)
 G mice (11/11)
 GB mice (11/11)
aa
b b
a
a
b
b
se
ru
m
 IG
F-
I [
ng
/m
l]
//
 
-73- 
Results 
4.3 Clinical-chemical serum parameters 
 
Various clinical-chemical serum parameters were screened in 44 mice at the age of 
38 days (n=11 per genetic group) and in 44 mice at the age of 75 days (C: n=10;  
B: n=12; G: n=11; GB: n=11). The data are summarized in tables 4.1 and 4.2.  
 
The serum sodium concentrations did not significantly differ between the four genetic 
groups at both ages investigated. 
In both age groups, the serum chloride levels did not significantly differ between B 
and C mice, but were significantly reduced in G and GB vs. corresponding C mice. 
In the 38-day-old group, the serum potassium concentrations were slightly reduced in 
B and GB vs. C mice, and were significantly reduced in G vs. C mice (-38%). 
Contrary, at an age of 75 days, B and G vs. C mice showed slightly elevated serum 
potassium levels, and GB mice exhibited significantly increased serum potassium 
levels (by 36%), as compared to C mice. 
The serum calcium levels of both G and GB vs. C mice were equally increased by 
42% (p<0.001) at an age of 38 days, and by 39% (p<0.001) at an age of 75 days. 
Between B and C mice, this serum parameter did not significantly differ at both ages 
investigated.  
In the 38-day-old group, the serum phosphate concentrations did not significantly 
differ between mice of the four genetic groups. Contrary, in the 75-day-old group, the 
serum phosphate concentrations of B and G vs. C mice were slightly elevated, and 
these of GB vs. C mice were significantly elevated.  
The serum creatinine levels of C and B mice were comparable at both ages.  
G vs. C mice of both age groups exhibited significantly increased serum creatinine 
levels. In GB mice, this serum parameter ranged at an intermediate level between 
those of C and G mice, being not significantly different from both in the 38-day-old 
group. In the 75-day-old group, the serum creatinine levels of GB vs. C mice were 
significantly elevated, and were significantly reduced, compared to G mice.  
The serum urea concentrations did not differ between the four genetic groups at an 
age of 38 days. In the 75-day-old group, the serum urea concentrations of G and GB 
vs. C mice were reduced by 41 and 37% (p<0.001), respectively. The serum urea 
concentrations did not differ between 75-day-old C and B mice. 
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Table 4.1 
 
Parameter C mice B mice  G mice  GB mice 
    n=11    n=11    n=11      n=11 
 
Sodium [mmol/l] 157.2a  (4.3) 158.1a  (3.2) 155.7a  (4.8) 156.0a  (3.2) 
Chloride [mmol/l] 113.5a  (3.3) 114.5a  (2.0) 108.5b  (3.4) 109.8b  (3.2) 
Potassium [mmol/l]     7.8a  (2.0)     6.0ab (2.3)     4.8b  (0.7)     5.6ab (2.1) 
Calcium [mmol/l]     1.9a  (0.2)     2.1a  (0.3)     2.7b  (0.1)     2.7b  (0.1) 
Phosphate [mmol/l]     2.8a  (0.4)     2.7a  (0.3)     2.8a  (0,4)     3.0a  (0.3) 
Creatinine [mg/dl]   0.29a  (0.04)   0.31ab (0.03)   0.36c  (0.02)   0.34bc (0.04) 
Urea [mg/dl]   41.5a  (5.8)   45.6a  (12.2)   44.5a  (10.8)   46.9a  (8.9) 
Total protein [g/dl]     5.5a  (0.5)     5.6a  (0.3)     6.6b  (0.2)     7.0c  (0.3) 
Cholesterol [mg/dl] 111.7a  (16.0) 127.8a  (13.7) 181.2b  (21.8) 185.3b  (15.6) 
Triglyceride [mg/dl] 179.7a  (105.9) 176.0a  (71.3) 159.0a  (36.5) 206.3a  (75.4) 
 
Table 4.1 Clinical-chemical serum parameters of 38-day-old mice of the four different 
genetic groups. n: number of mice analyzed per genetic group. The data are shown as means and 
(SDs). Significant differences (at least p<0.05) between the genetic groups are indicated by different 
superscripts (a, b, c).  
 
 
The total serum protein concentrations were significantly elevated to a similar extend 
in both G and GB mice at 38 and 75 days of age, as compared to C mice, but were 
not different in B vs. C mice. 
Likewise, the serum cholesterol levels were similarly increased in 38- and 75-day-old 
G and GB vs. C mice (p<0.001). The serum cholesterol concentrations did not differ 
between C and B mice of both ages. 
The serum triglyceride concentrations of mice of the four genetic groups were not 
significantly different at the age of 38 days. In the 75-day-old group, the serum 
triglyceride levels of G vs. C mice were reduced (p<0.02), whereas these of B and 
GB mice were not significantly different from that of controls. 
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Table 4.2 
 
Parameter C mice B mice  G mice  GB mice 
    n=10    n=12    n=11      n=11 
 
Sodium [mmol/l] 161.0a  (1.9) 155.7a  (12.1) 156.9a  (5.4) 154.3a  (6.4) 
Chloride [mmol/l] 116.8a  (1.6) 114.1a  (7.0) 108.6b  (2.0) 109.5b  (3.8) 
Potassium [mmol/l]     6.9a  (2.2)     8.0ab (2.0)     8.0ab (1.9)     9.4b  (1.6) 
Calcium [mmol/l]     1.8a  (0.3)     1.9a  (0.3)     2.5b  (0.4)     2.5b  (0.4) 
Phosphate [mmol/l]     2.3a  (0.3)     2.6ab (0.4)     2.8ab (0,6)     3.0b  (0.6) 
Creatinine [mg/dl]   0.28ab (0.05)   0.25a  (0.08)   0.43c  (0.05)   0.34b  (0.07) 
Urea [mg/dl]   54.1a  (6.6)   48.9a  (9.4)   31.9b  (12.5)   34.2b  (6.1) 
Total protein [g/dl]     5.6a  (0.3)     5.9a  (0.7)     7.1b  (0.4)     6.7b  (0.4) 
Cholesterol [mg/dl] 112.0a  (22.4) 125.9a  (17.2) 168.5b  (28.2) 188.8b  (12.3) 
Triglyceride [mg/dl] 184.0a  (34.6) 165.6ab (35.4) 142.5b  (21.5) 178.5ab (42.3) 
 
 
Table 4.2 Clinical-chemical serum parameters of 75-day-old mice of the four different 
genetic groups. n: number of mice analyzed per genetic group. The data are shown as means and 
(SDs). Significant differences (at least p<0.05) between the genetic groups are indicated by different 
superscripts (a, b, c). 
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4.4 Data of the adrenal gland 
 
Parts of the findings of the adrenal gland have recently been published (Hoeflich, A., 
Weber, M. M., Fisch, T., Nedbal, S., Fottner, C., Elmlinger, M. W., Wanke, R. &  
Wolf, E. Insulin-like growth factor binding protein 2 (IGFBP-2) separates hypertrophic 
and hyperplastic effects of growth hormone (GH)/IGF-I excess on adrenocortical cells 
in vivo. FASEB J., 16, 1721-31 (2002)). 
The perfusion fixed adrenal glands of 12 mice (n=3 per genetic group) at 75 days of 
age were investigated.  
 
4.4.1 Weight of the adrenal gland 
 
G and GB mice exhibited a markedly increased adrenal gland weight (by 68% and 
32%, respectively; p<0.001), compared to non-transgenic controls (Fig. 4.3). In  
B vs. C mice, this parameter was only reduced as a tendency (by 15%, p=0.111), 
whereas in GB vs. G mice the adrenal gland weight was markedly reduced by 22% 
(p<0.001). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3 Adrenal gland weight from 75-day-old mice of the four different genetic 
groups. The demonstrated weight of the adrenal glands represents the sum of the weights of right 
and left adrenal gland per animal. n=3 mice were analyzed per geneic group. The data are shown as 
means and SDs. Significant differences (at least p<0.05) between the genetic groups are indicated by 
different superscripts (a, b, c). 
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The adrenal gland-to-body weight-ratio (relative adrenal gland weight) ranged 
between 1.13 ± 0.10 x 10-4 and 1.17 ± 0.09 x 10-4 and did not significantly differ 
between the genetic groups (data not shown). 
 
4.4.2 Volume fractions and volumes of the adrenal cortex and medulla 
 
The volume fractions of the adrenal cortex (VV(cortex/adrenal gland)) and medulla (VV(medulla/ 
adrenal gland)) ranged from 81% to 85% and from 19% to 15%, respectively, and did not 
differ significantly between the four genetic groups (data not shown).  
 
The volume of the adrenal cortex (V(cortex, adrenal gland)) of G and GB vs. C mice was  
2-fold and 1.7-fold (p<0.001) increased, respectively (Fig. 4.5 a). The adrenocortical 
volume of GB mice was significantly decreased (by 18%), compared to G mice, 
ranging at an intermediate level between those of G and C mice. Likewise, the 
adrenocortical volume was reduced by 25% in B vs. C mice (p<0.01).  
The volume of the adrenal medulla (V (medulla, adrenal gland)) of G mice was 1.7-fold 
(p<0.01) larger, as compared to that of C mice (Fig. 4.5 b). In GB mice, the 
adrenomedullary volume was significantly reduced (-26%), compared to G mice, 
reaching the level of non-transgenic controls. Between B and C mice, this parameter 
was not significantly different. 
 
The data show that GH excess stimulates growth of the adrenal cortex and medulla 
implicating that both contribute to adrenal enlargement in bGH transgenic mice. 
Similarly, both compartments are affected by IGFBP-2 overexpression. Representa-
tive sections of adrenal glands from the different groups are shown in figure 4.5 c. 
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Fig. 4.5 a      Fig. 4.5 b 
 
 
 
 
 
 
 
 
 
 
              C                      B                G                        GB 
Fig. 4.5 c 
 
Figure 4.5 Volumes of the adrenal cortex (a) and medulla (b). Both the adrenal cortex and 
medulla are enlarged by bGH expression and contribute to adrenal enlargement in bGH transgenic 
mice. Likewise, the volumes of both adrenocortex and -medulla are reduced by IGFBP-2 
overexpression. The left, perfusion fixed adrenal glands of n=3 mice per genetic group were 
investigated. The data are shown as means and SDs. Significant differences (at least p<0.05) 
between the genetic groups are indicated by different superscripts (a, b, c, d). 
(c) Representative histological sections of the adrenal gland from mice of the four 
different genetic groups. H&E stained paraffin sections; identical magnification;  
bar = 0.5 mm 
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4.4.3 Volume fractions and volumes of the zona fasciculata and zona glomerulosa 
 
The volume fractions of the zona fasciculata (VV(zona fasc./cortex)) and zona glomerulosa 
(VV(zona glom./cortex)) ranged from 70.4 to 71.4% and from 28.6 to 29.6%, respectively, 
and did not significantly differ between the four genetic groups (data not shown).  
 
The volume of the zona fasciculata (V(zona fasc., cortex)) was markedly increased in  
G vs. C mice (by 115%; p<0.001). V(zona fasc., cortex) was slightly reduced in B vs. C 
mice, whereas in GB vs. G mice, the volume of the zona fasciculata was significantly 
lowered by 24%, ranging at an intermediate level between that of G and C mice  
(Fig. 4.6 a). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.6 a      Fig. 4.6 b 
 
Figure 4.6 Volumes of the zona fasciculata (a) and zona glomerulosa (b). The volumes 
of both zona fasciculata and zona glomerulosa are markedly increased in G mice, and both 
parameters are decreased in GB vs. G mice and slightly decreased in B vs. C mice. The left, perfusion 
fixed adrenal glands of n=3 mice per genetic group were investigated. The data are shown as means 
and SDs. Significant differences (at least p<0.05) between the genetic groups are indicated by 
different superscripts (a, b, c). 
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The volume relations of the zona glomerulosa between the four genetic groups 
resembled those of the zona fasciculata (Fig. 4.6 b). In G and GB mice, the volume 
of the zona glomerulosa (V(zona glom., cortex)) was markedly increased, as compared to  
C and B mice. No significant difference in V(zona glom., cortex) was detectable between  
C and B mice, whereas the reduction in V(zona glom., cortex) of GB vs. G mice reached 
level of statistical significance. 
 
4.4.4 Mean volume and total number of zona fasciculata cells 
 
In G mice, the mean volume of zona fasciculata cells (Fig. 4.7 a) was enlarged by 
44% (p<0.005) and the total number of zona fasciculata cells (Fig. 4.7 b) was 
increased by 50% (p<0.005), as compared to non-transgenic controls. Strikingly, in 
GB mice, the mean zona fasciculata cell volume was similar to that of controls, i.e., 
the bGH-associated zona fasciculata cell hypertrophy was completely abolished, 
whereas the total number of zona fasciculata cells was elevated, comparable to that 
of G mice. Thus, a clear-cut effect of IGFBP-2, to inhibit hypertrophy, but not 
hyperplasia of zona fasciculata cells can be demonstrated in this model. In B vs. C 
mice, no significant difference in either mean volume or total number of zona 
fasciculata cells was found.  
Representative segments of the adrenal cortex from mice of the different genetic 
groups are shown in figure 4.7 c. 
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Fig. 4.7 a      Fig. 4.7 b 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.7 c 
 
Figure 4.7 Mean volume (a) and total number (b) of zona fasciculata cells. G mice 
exhibited hypertrophy and hyperplasia of zona fasciculata cells. In GB mice, hypertrophy was 
completely abolished, whereas the hyperplasia of zona fasciculata cells was not affected. The right, 
perfusion fixed adrenal glands of n=3 mice per genetic group were investigated. The data are shown 
as means and SDs. Significant differences (at least p<0.05) between the genetic groups are indicated 
by different superscripts (a, b). 
(c) Representative segments of the zona fasciculata from 75-day-old mice of the four 
different genetic groups. Semi-thin sections, toluidine blue and safranine stained; 
bar = 50 µm.  
GBC GB 
C B G GB
0
200
400
600
800
a
a
b
b
X
N (
zo
na
 fa
sc
. c
el
ls
, a
dr
en
al
 g
la
nd
)[
x1
03
]
C B G GB
0
400
800
1200
1600
2000
2400
a a
a
b
X
v (
zo
na
 fa
sc
. c
el
ls
)
[µ
m
³]
 
-82- 
Results 
4.4.5 Plasma corticosterone and ACTH levels 
 
Basal and ACTH-induced plasma corticosterone concentrations were measured in  
31 mice (C: n=8; B: n=7; G: n=8; GB: n=8) at four months of age. 
 
The basal plasma corticosterone level was more than three-fold increased (P<0.001) 
in G vs. C mice. In contrast, the plasma corticosterone concentration was elevated by 
only 40% (p=0.117) in GB vs. C mice, but was 47% (p<0.001) reduced in GB vs. G 
mice. In B vs. C mice, the basal plasma corticosterone level was slightly reduced (by 
26%), but the difference between these two groups did not reach level of statistic 
significance.  
The stimulation of corticosterone secretion by ACTH resulted in an approximately 
three-fold increase of plasma corticosterone levels in every genetic group. Compar-
able to not stimulated conditions, the stimulated plasma corticosterone level in G vs. 
C mice was three-fold increased (P<0.001), whereas it was significantly lowered in 
GB vs. G mice (by 40%) and slightly reduced in B vs. C mice. As described for not 
stimulated conditions, the stimulated plasma corticosterone concentration of GB mice 
did not significantly differ from that of controls. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Basal and ACTH-induced plasma corticosterone levels. (n/n): number of mice 
used for basal and ACTH-induced plasma corticosterone levels, respectively. The data are shown as 
means and SDs. Significant differences (at least p<0.05) between the genetic groups are indicated by 
different superscripts (a, b, c). 
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Plasma ACTH levels were determined in the morning in 26 mice (C: n=9; B: n=7;  
G: n=6; GB: n=4) and in the afternoon in 18 mice (C: n=6; B: n=4; G: n=4; GB: n=4) 
at four to seven months of age. Additionally, six MT-bGH transgenic mice and six 
non-transgenic littermate controls were investigated. 
 
The plasma ACTH concentrations were not significantly different between the genetic 
groups when investigated in the afternoon and were only slightly increased in G and 
GB vs. C and B mice when analyzed in the morning. Only differences between GB 
vs. C and B mice reached level of statistical significance (Fig. 4.9). Plasma ACTH 
levels of C and B mice were significantly higher in the afternoon than in the morning. 
This physiological diurnal variation of ACTH secretion was not seen in G and GB 
mice.  
According to the findings in PEPCK-bGH transgenic mice, morning plasma ACTH 
levels of MT-bGH transgenic mice (91.8 ± 29.0 pg/ml) were not significantly different 
from these of corresponding controls (74.4 ± 21.1 pg/ml), confirming that GH over-
expression does not significantly affect plasma ACTH concentrations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Morning and afternoon plasma ACTH levels from mice of the four genetic 
groups. (n/n): number of animals investigated in the morning and in the afternoon, respectively. The 
data are shown as means and SDs. Significant differences (at least p<0.05) between the genetic 
groups are indicated by different superscripts (a, b). Asterisks indicate significant (at least p<0.05) 
differences between morning and afternoon values within the genetic group.  
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4.5 Data of the kidneys 
 
4.5.1 Kidney weight 
 
The kidney weight was determined in 28 male mice at 38 days of age (n=7 per 
genetic group) and in 28 male mice at 75 days of age (C: n=6; B: n=8; G: n=7;  
GB: n=7) after perfusion fixation.  
The kidney weight was markedly increased in 38-day-old G mice (59%; p<0.001) and 
in 75-day-old G mice (89%; p<0.001), as compared to littermate controls (Fig. 4.10). 
In 38-day-old GB vs. G mice, the kidney weight was reduced to the level of controls 
(27%; p<0.05). In 75-day-old GB mice, the kidney weight was significantly lower vs. 
G mice, and was significantly higher vs. C mice, therefore ranging at an intermediate 
level between G and C mice.  
The kidney weight of B and C mice did not differ at both ages investigated, 
confirming an effect of IGFBP-2 overexpression on kidney growth in high but not in 
normal GH/IGF-I conditions.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 Kidney weight of 38- and 75-day-old mice. G vs. C mice showed a marked 
increase in kidney weight. This increase was significantly reduced in GB mice, which were not distin-
guishable from controls at an age of 38 days. The demonstrated weight of the kidneys represents the 
sum of the weights of right and left kidney per animal. (n/n): number of mice investigated at an age of 
38 and 75 days, respectively. The data are shown as means and SDs. Significant differences (at least 
p<0.05) between the genetic groups are indicated by different superscripts (a, b, c). 
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At the age of 38 days, the kidney weight-to-body weight-ratio (relative kidney weight) 
of the different transgenic mice vs. control mice was increased by 24% to 26%, with 
the differences between G and GB vs. C mice being statistically significant  
(Fig. 4.11). In the 75-day-old group, the relative kidney weight of B vs. C mice was 
significantly elevated (by 18%; p<0.05), but not that of G and GB mice. In 75- vs.  
38-day-old G and GB mice the relative kidney weight was significantly reduced by 
17% and 18%, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 Relative kidney weight of 38- and 75-day-old mice. (n/n): number of mice 
investigated at an age of 38 and 75 days, respectively. The data are shown as means and SDs. 
Significant differences (at least p<0.05) between the genetic groups are indicated by different 
superscripts (a, b). 
 
 
4.5.2 Number of nephrons 
 
The number of nephrons per kidney was determined by analyzing the number of 
glomeruli in 16 male mice (n=4 per genetic group) at an age of 38 days. 
The number of glomeruli in both kidneys per animal was 30.96 ± 6.09 x 103 in control 
mice and was not significantly different compared to that of B mice (33.96 ± 3.76  
x 103), G mice (34.56 ± 3.08 x 103), and GB mice (32.32 ± 5.80 x 103). This result 
excludes effects of expression of the bGH and/or the IGFBP-2 transgene on 
nephrogenesis. 
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4.5.3 Fractional volumes and volumes of the renal zones 
 
The fractional volumes and volumes of the renal zones - cortex, outer stripe of 
medulla (OSM), and inner stripe of medulla together with the inner zone of medulla 
(ISM/IZM) - were determined in 20 mice (n=5 per genetic group) at an age of 38 days 
and in 20 mice (n=5 per genetic group) at an age of 75 days. 
 
The volume fractions of the various renal zones did not significantly differ between 
38- and 75-day-old C mice (Tables 4.3, 4.4).  
In the 38-day-old group, the fractional cortex volume of B and GB vs. C and G mice 
was significantly reduced (Table 4.3). Contrary, the fractional volume of the OSM 
was slightly increased in B and GB vs. C and G mice; the differences between B vs. 
C and G mice reached level of statistical significance. G mice at 38 days of age 
exhibited no significant changes in the fractional volumes of the renal zones 
investigated, compared to C mice. No significant difference was detectable in the 
fractional volume of the ISM/IZM between controls and the different transgenic mice 
at an age of 38 days. 
 
Table 4.3 
 
genetic group     cortex      OSM    ISM/IZM 
       [%]        [%]         [%] 
 
C mice (n=5)  70.09a (1.89) 18.06a  (1.52) 11.85ab (0.65) 
B mice (n=5) 67.23b (1.80) 20.48bc (0.79) 12.29ab (1.34) 
G mice (n=5) 70.91a (1.09) 17.94a  (1.39) 11.15a  (0.41) 
GB mice (n=5) 67.90b (1.82) 19.32ac (0.80) 12.78b  (1.76) 
 
 
Table 4.3 Fractional volumes of the renal zones - cortex, outer stripe of medulla 
(OSM), and inner stripe of medulla together with inner zone of medulla (ISM/IZM) - of 
38-day-old mice. n=5 mice were analyzed per genetic group. The data were obtained from the 
average of both separately investigated kidneys per animal, and are shown as means and (SDs). 
Significant differences (at least p<0.05) between the genetic groups are indicated by different 
superscripts (a, b, c). 
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At an age of 75 days, controls and the various transgenic mice exhibited a similar 
fractional cortex volume (Table 4.4). The fractional volume of the OSM was slightly 
increased in 75-day-old transgenic mice vs. C mice; the differences between GB and 
C mice reached level of statistical significance. Contrary, the fractional volume of the 
ISM/IZM was significantly decreased in 75-day-old transgenic vs. control mice.  
 
 
Table 4.4 
 
group     cortex      OSM    ISM/IZM 
       [%]        [%]         [%] 
 
C mice (n=5) 69.76a (1.25) 19.06a  (0.99) 11.18a (1.28) 
B mice (n=5) 70.01a (0.74) 20.09ab (0.87)   9.90b (0.22) 
G mice (n=5) 70.57a (1.30) 20.32ab (1.70)   8.85b (0.92) 
GB mice (n=5) 69.57a (0.96) 21.12b  (0.85)   9.74b (0.74) 
 
 
Table 4.4 Fractional volumes of the renal zones cortex, outer stripe of medulla 
(OSM), and inner stripe of medulla together with inner zone of medulla (ISM/IZM) of 
75-day-old mice. n=5 mice were analyzed per genetic group. The data were obtained from the 
average of both separately investigated kidneys per animal, and are shown as means and (SDs). 
Significant differences (at least p<0.05) between the genetic groups are indicated by different 
superscripts (a, b, c). 
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The absolute volumes of the various renal zones were similar in 38- and 75-day-old  
C mice (Figs. 4.12, 4.13). The volumes of the various renal zones investigated were 
equal comparing B and C mice at both ages. 
 
In both age groups, G mice exhibited a marked increase in the volumes of all three 
renal zones investigated, compared to littermate controls. In G mice, the cortex and 
the OSM demonstrated the largest relative and absolute volume increase of the renal 
zones investigated. In 38-day-old G vs. C mice, the volumes of cortex and OSM were 
increased by 53% and 51% (p<0.01), respectively. In the 75-day-old group, the 
increase of cortex and OSM volume in G vs. C mice was 90% (p<0.001) and 101% 
(p<0.001), respectively. The ISM/IZM relatively and absolutely contributed the least 
to the renal enlargement of GH transgenic mice. 
 
In 38-day-old GB mice, the volumes of all renal zones investigated were on the level 
of non-transgenic controls, i.e., the growth stimulation observed in G mice was com-
pletely abolished in GB mice overexpressing both bGH and IGFBP-2. The reduction 
in cortex volume in 38-day-old GB vs. G mice was 31% (p<0.01) and in OSM volume 
was 22% (p<0.05). The reduction was lowest in the ISM/IZM volume (18%) and 
reached only borderline significance (p=0.055). 
In the 75- vs. 38-day-old group, the relative growth inhibition of the single renal zones 
in GB vs. G mice was reduced. The cortex was the most markedly reduced renal 
zone in 75-day-old GB vs. G mice (-18%; p<0.01), whereas the volumes of OSM and 
ISM/IZM were only slightly decreased.  
Interestingly, despite the less reduction of the relative volumes of every renal zone in 
75-day-old GB vs. G mice compared to 38-day-old GB vs. G mice, the volume 
reductions in absolute numbers remained virtually constant.  
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Figure 4.12 Volumes of renal the zones - cortex, outer stripe of medulla (OSM), and 
inner stripe of medulla together with inner zone of medulla (ISM/IZM) - of 38-day-old 
mice. (n): number of mice analyzed. The data are presented as the sum of both separately 
investigated kidneys per mouse, and are shown as means and SDs. Significant differences (at least 
p<0.05) between the genetic groups are indicated by different superscripts (a, b, c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 Volumes of renal the zones - cortex, outer stripe of medulla (OSM), and 
inner stripe of medulla together with inner zone of medulla (ISM/IZM) - of 75-day-old 
mice. (n): number of mice analyzed. The data are presented as the sum of both separately 
investigated kidneys per mouse, and are shown as means and SDs. Significant differences (at least 
p<0.05) between the genetic groups are indicated by different superscripts (a, b, c). 
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4.5.4 Volume fractions and volumes of nephron segments 
 
The fractional volumes and volumes of single nephron segments in the cortex and 
OSM were determined, namely that of the proximal tubular epithelium (PTE), that of 
all other tubular epithelia (OTE), and that of miscellaneous structures (MIS), like 
glomeruli, interstitium, and blood vessels. The kidneys from 20 mice (n=5 per genetic 
group) at an age of 38 days and 20 mice (n=5 per genetic group) at an age of  
75 days were analyzed. 
 
Between C and G mice of both age groups, the fractional volumes of the nephron 
segments investigated were not significantly different (Tables 4.5, 4.6). In the  
38-day-old group, the fractional volume of the PTE in the cortex and OSM (VV(PTE/ 
cortex&OSM)) in B and GB vs. C and G mice was reduced, whereas the fractional OTE 
volume (VV(OTE/cortex&OSM)) in B and GB vs. C and G mice was increased. However, 
only the differences in GB vs. C and G mice reached level of statistical significance.  
 
 
Table 4.5 
 
group VV(PTE/cortex, OSM) VV(OTE/cortex, OSM) VV(MIS/cortex, OSM) 
       [%]        [%]         [%] 
 
C mice (n=5) 68.5a  (3.0) 22.0ab (2.9)   9.5a (2.9) 
B mice (n=5) 66.3ab (3.5) 24.5ac (2.3)   9.2a (2.2) 
G mice (n=5) 68.6a  (1.9) 20.1b  (1.2) 11.3a (1.6) 
GB mice (n=5) 63.0b  (3.8) 25.6c  (3.7) 11.4a (3.0) 
 
 
Table 4.5 Fractional volume of nephron segments in the cortex and the outer stripe of 
medulla (OSM) of 38-day-old mice. PTE, proximal tubular epithelium; OTE, other tubular 
epithelia; MIS, miscellaneous structures, like glomeruli, interstitium, and blood vessels. n=5 mice were 
analyzed per genetic group. The data are presented as the average of both separately investigated 
kidneys per animal, and are shown as means and (SDs). Significant differences (at least p<0.05) 
between the genetic groups are indicated by different superscripts (a, b, c). 
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The results concerning VV(PTE/cortex&OSM) and VV(OTE/cortex&OSM) in 75-day-old mice 
resembled those in 38-day-old mice (Tab. 4.6). In the 75-day-group, VV(PTE/cortex&OSM) 
was significantly reduced in both B and GB vs. C and G mice, respectively. 
VV(OTE/cortex&OSM) in B and GB vs. C and G mice were increased, with the differences 
in B and GB vs. G mice being statistically significant. 
No significant differences were found in the fractional MIS volume (VV(MIS/cortex, OSM)) 
between the genetic groups at 38 and 75 days of age. 
 
 
Table 4.6 
 
group VV(PTE/cortex, OSM) VV(OTE/cortex, OSM) VV(MIS/cortex, OSM) 
       [%]        [%]         [%] 
 
C mice (n=5) 72.2a (2.8) 18.8ab (1.6)   9.1a (1.5) 
B mice (n=5) 67.6b (3.0) 21.3a  (2.7) 11.1a (1.8) 
G mice (n=5) 74.2a (3.6) 16.3b  (2.9)   9.5a (1.6) 
GB mice (n=5) 68.0b (2.9) 20.6a  (1.5) 11.4a (3.1) 
 
Table 4.6 Fractional volume of nephron segments in the cortex and the outer stripe of 
medulla (OSM) of 75-day-old mice. PTE, proximal tubular epithelium; OTE, other tubular 
epithelia; MIS, miscellaneous structures, like glomeruli, interstitium, and blood vessels. n=5 mice were 
analyzed per genetic group. The data are presented as the average of both separately investigated 
kidneys per animal, and are shown as means and (SDs). Significant differences (at least p<0.05) 
between the genetic groups are indicated by different superscripts (a, b). 
 
 
 
The absolute volume the various nephron segments investigated in the cortex and 
OSM, namely that of the PTE (V(PTE, cortex&OSM)), that of the OTE (V(OTE, cortex&OSM)), and 
that of the MIS (V(MIS, cortex&OSM)) was markedly enlarged in G vs. C mice of both age 
groups (Figs. 4.14, 4.15). In G vs. C mice, the PTE demonstrated the greatest 
relative and absolute volume increase of all nephron segments investigated: the 
relative increase in V(PTE, cortex&OSM) ranged from 41% (p<0.001) in the 38-day-group to 
102% (p<0.001) in the 75-day-group.  
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V(PTE, cortex&OSM) of GB mice at 38 days of age was equal to that of non-transgenic 
controls, i.e., the growth stimulatory effect on the PTE observed in G mice was 
completely abolished in GB mice overexpressing both bGH and IGFBP-2. The 
volumes of the OTE and MIS in the cortex and OSM in GB vs. G mice were also 
reduced to control levels, with the reduction in V(OTE, cortex & OSM) reaching not the level 
of statistical significance.  
In 75-day-old GB vs. G mice, the V(PTE, cortex&OSM) was potently reduced, however, 
V(PTE, cortex&OSM) of GB mice did not reach the level of controls. Interestingly, the 
degree of reduction of V(PTE, cortex&OSM) in GB vs. G mice in the 38-day-old group 
(30%; p<0.001) was identical to that in 75-day-old mice (30%; p<0.001). Contrary, 
V(OTE, cortex&OSM) and V(MIS, cortex&OSM) of 75-day-old GB vs. G mice were not significantly 
different.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 Volumes of nephron segments in the cortex and the outer stripe of 
medulla (OSM) of 38-day-old mice. PTE, proximal tubular epithelium; OTE, other tubular 
epithelia; MIS, miscellaneous structures, like glomeruli, interstitium, and blood vessels. (n): number of 
mice analyzed. The data are presented as the sum of both separately investigated kidneys per animal, 
and are shown as means and SDs. Significant differences (at least p<0.05) between the genetic 
groups are indicated by different superscripts (a, b, c). 
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These data demonstrate that the increase in V(PTE, cortex & OSM) in G vs. C mice 
contributes most to the enlargement of renal cortex and OSM, and thereby to the 
enlargement of the kidney of bGH transgenic mice. Further, as demonstrated in the 
75-day-old group, the growth inhibitory effect in the renal cortex and OSM in GB vs. 
G mice is referred exclusively to the proximal tubular epithelium but does not affect 
other tubular segments. 
 
V(PTE, cortex & OSM) of B vs. C mice were reduced as a tendency in both the 38- (-19%) 
and 75-day-group (-13%), whereas the volumes of the OTE and MIS in the renal 
cortex and OSM were virtually identical between B and C mice at both ages 
investigated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 Volumes of nephron segments in the cortex and the outer stripe of 
medulla (OSM) of 75-day-old mice. PTE, proximal tubular epithelium; OTE, other tubular 
epithelia; MIS, miscellaneous structures, like glomeruli, interstitium, and blood vessels. (n): number of 
mice analyzed. The data are presented as the sum of both separately investigated kidneys per animal, 
and are shown as means and SDs. Significant differences (at least p<0.05) between the genetic 
groups are indicated by different superscripts (a, b, c). 
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4.5.5 Mean volume and total number of PTE cells in the renal cortex 
 
The mean volume (v(PTE cells)) and the total number of PTE cells (N(PTE cells, cortex)) in the 
renal cortex was determined in 16 male mice (n=4 per genetic group) at an age of  
75 days. 
 
The mean volume of proximal tubular epithelial cells in the cortex did not differ 
between the four genetic groups (Fig. 4.16 a). 
In contrast, the total number of cortical PTE cells was nearly doubled (increased by 
90%, p<0.001) in G vs. C mice (Fig. 4.16 b) suggesting that the increase in V(PTE, 
cortex&OSM) of G mice was exclusively due to PTE cell hyperplasia, but not to PTE cell 
hypertrophy. In GB vs. G mice, the total cortical PTE cell number was markedly 
reduced by 18% (p<0.005), ranging at an intermediate level between those of G and 
C mice. The total PTE cell number in B vs. C mice was not different. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16 a     Figure 4.16 b 
 
Figure 4.16 Mean volume (a) and total number (b) of proximal tubular epithelial (PTE) 
cells. The mean volume of PTE cells did not differ between the four genetic groups. G mice displayed 
a significant increase in total PTE cell number, which was significantly reduced in GB vs. G mice. n=4 
animals were investigated per genetic group. The total PTE cell number is the sum of the PTE cell 
number of both separately investigated kidneys per animal. The data are shown as means and SDs. 
Significant differences (at least p<0.05) between the genetic groups are indicated by different 
superscripts (a, b, c, d). 
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4.5.6 Mean glomerular volume 
 
The mean glomerular volume (v(glom)) was determined in 20 mice at 38 days of age 
(n=5 per genetic group) and in 20 mice at 75 days of age (n=5 per genetic group).  
 
The mean glomerular volume in G and GB vs. C mice of both the 38-day-group and 
the 75-day-group was dramatically increased (Fig. 4.17). bGH transgenic mice 
exhibited an increase in v(glom) by 82% (p<0.001) at an age of 38 days and by 163% 
(p<0.001) at an age of 75 days, as compared to littermate controls.  
In GB vs. G mice, v(glom) was only slightly reduced by 11% (p<0.05) in the  
38-day-group and by 9% (p<0.05) in the 75-day-group. In both 38- and 75-day-old  
B mice, v(glom) did not and significantly differ from that of age-matched controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17 Mean glomerular volume of 38- and 75-day-old mice of the four genetic 
groups. In both age groups, G mice exhibited a dramatic glomerular enlargement, which in GB vs. G 
mice was only slightly reduced. (n/n): number of mice analyzed at an age of 38 days and 75 days, 
respectively. The data are shown as means and SDs. Significant differences (at least p<0.05) between 
the genetic groups are indicated by different superscripts (a, b, c). 
 
 
The comparison of the degree of increase of v(glom) of G and GB vs. C mice with the 
degree of increase of various other parameters, such as body and kidney weight, and 
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through GH overexpression. This discrepancy in glomerular growth and in the growth 
of other parameters, became even more evident, when relating v(glom) to these 
parameters (Tables 4.7, 4.8).  
The mean glomerular volume-to-body weight-ratio (v(glom)/body weight), the mean 
glomerular volume-to-kidney weight-ratio (v(glom)/kidney weight), and the mean 
glomerular volume-to-PTE volume-ratio (v(glom)/V(PTE)) were increased in G mice vs. 
littermate controls at both 38 and 75 days of age. This increase was most 
pronounced in v(glom)/body weight (46%, p<0.001) and v(glom)/V(PTE) (32%, p<0.001) of 
75-day-old G vs. C mice. These findings confirm an overproportional glomerular 
growth in G mice.  
In 38-day-old GB vs. G mice, every ratio investigated was significantly increased. 
Likewise, in the 75-day-group, every ratio calculated was elevated in GB vs. G mice, 
with v(Glom)/V(PTE) reaching level of statistical significance. In both 38- and 75-day-old 
GB vs. G mice, v(Glom)/V(PTE) displayed the greatest increase (approximately 26%, 
p<0.005; respectively). These findings illustrate that the stimulated glomerular growth 
of G mice was inhibited only by a minor degree in GB mice, as compared to the 
growth inhibition of various other parameters analysed in this study in GB vs. G mice. 
 
Table 4.7 
 
group v(glom)/body weight v(glom)/kidney weight   v(glom)/V(PTE) 
    (x 103 µm3/g)     (x 103 µm3/mg)       (x 10-6) 
 
C mice (n=5)    8.0a (0.53)   0.62a (0.07) 1.23a  (0.07) 
B mice (n=5)    9.7b (0.50)   0.65a (0.08) 1.41ab (0.02) 
G mice (n=5)  11.5c (1.31)   0.74a (0.16) 1.59b  (0.24) 
GB mice (n=5)  14.5d (2.34)   0.90b (0.13) 2.00c  (0.36) 
 
 
Table 4.7 Mean glomerular volume-to-body weight-ratio (v(glom)/body weight), mean 
glomerular volume-to-kidney weight-ratio (v(glom)/kidney weight), and mean glomerular 
volume-to-PTE volume-ratio (v(glom)/V(PTE)) of 38-day-old mice of the four genetic 
groups. The ratios were calculated from n=5 mice. The data are shown as means and (SDs). 
Significant differences (at least p<0.05) between the genetic groups are indicated by different 
superscripts (a, b, c, d). 
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Table 4.8 
 
group v(glom)/body weight v(glom)/kidney weight   v(glom)/V(PTE) 
    (x 103 µm3/g)     (x 103 µm3/mg)       (x 10-6) 
 
C mice (n=5)    8.3a (1.05)   0.69a (0.08) 1.24a (0.17) 
B mice (n=5)    8.6a (0.32)   0.60a (0.09) 1.30a (0.14) 
G mice (n=5)  12.1b (1.40)   0.96b (0.10) 1.64b (0.23) 
GB mice (n=5)  13.4b (1.20)   1.03b (0.08) 2.07c (0.07) 
 
 
Table 4.8 Mean glomerular volume-to-body weight-ratio (v(glom)/body weight), mean 
glomerular volume-to-kidney weight-ratio (v(glom)/kidney weight), and mean glomerular 
volume-to-PTE volume-ratio (v(glom)/V(PTE)) of 75-day-old mice of the four genetic 
groups. The ratios were calculated from n=5 mice. The data are shown as means and (SDs). 
Significant differences (at least p<0.05) between the genetic groups are indicated by different 
superscripts (a, b, c). 
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4.5.7 Glomerulosclerosis index  
 
The glomerulosclerosis index (scale 0 - 4) was determined in four mice per genetic 
group and per age group. 
 
Glomerular lesions were found in both G and GB mice, and were primarily 
characterized by mesangial expansion and matrix accumulation. No significant 
differences in the glomerulosclerosis index were found between G and GB mice at 
both ages investigated. This parameter was slightly increased in 75- vs. 38-day-old G 
and GB mice, however, the increase was not statistically significant (Fig. 4.18 a, b). 
Apart from a mild segmental mesangial expansion found in some glomeruli, no 
glomerular lesions were observed in C and B mice at both ages investigated. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 a           Figure 4.18 b 
 
Figure 4.18 a, b Glomerulosclerosis index of (a) 38- and (b) 75-day-old mice of the 
four genetic groups. The degree of glomerular lesions did not differ between G and GB mice. 
Glomerular changes were negligible in C and B mice. n=4 mice were analyzed per genetic group. The 
bar indicates the median of every genetic group. Significant differences (at least p<0.05) between the 
genetic groups are indicated by different superscripts (a, b). 
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4.5.8 Urine protein analysis 
 
4.5.8.1 Pattern of proteinuria 
 
The pattern of proteinuria was determined by SDS-PAGE analysis. Urine samples of 
44 mice at the age of 38 days (n=11 per genetic group) and 44 mice at the age of  
75 days (C: n=10 ;B: n=12; G: n=11; GB: n=11) were investigated. 
 
C and B mice exhibited identical patterns of proteins excreted in the urine at both 
ages investigated (Figs 4.19 a, b). Those mice exhibited a broad band in the region 
of approximately 18 kDa, which meets the size of major urinary proteins (MUPs) 
appearing in the urine under physiological conditions particularly in male mice.  
Both G and GB mice exhibited bands at approximately 64 kDa meeting the size of 
murine albumin. The staining intensity of the 64 kDa bands varied from delicate 
bands of urine samples of 38-day-old G and GB mice to very intensive stained, broad 
bands of urine samples of 75-day-old G and GB mice. In G and GB vs. age-matched 
C and B mice, the approximately 18 kDa bands were less intensive at both ages 
investigated. 
 
 
 
 
 
 
 
 
 
 
Figure 4.19 a            Figure 4.19 b 
 
Figure 4.19 SDS-PAGE of urine samples from (a) 38- and (b) 75-day-old mice of the 
four genetic groups. Alb, mouse albumin marker; M, Broad range molecular weight standards 
(Biorad, Ger.) with bands at 66, 45, 31, and 21.5 kDa. Mice of both bGH overexpressing groups exhi-
bited bands at approximately 64 kDa at various intensities, meeting the size of murine albumin and 
less intensive bands at approximately 18 kDa, meeting the size of major urinary proteins (MUPs). 
-66- 
Alb  M   C    C    C     B   B    B      G   G   G  GB GB GB M    C   C   C    B   B   B    G   G   G   GB GB GB 
-31-
-45- 
-21.5-
 
-100- 
Results 
4.5.8.2 Quantification of albuminuria 
 
The concentration of urinary albumin was measured by ELISA. Additionally, the 
urinary creatinine concentration was measured by autoanalyzer technique and 
albumin-creatinine-ratios were calculated. Urine samples of 44 mice (n=11 per 
genetic group) at the age of 38 days and 44 mice (C: n=10; B: n=12; G: n=11;  
GB: n=11) at the age of 75 days were analyzed.  
 
At an age of 38 days, G and GB vs. C mice exhibited 15- and 23-fold (p<0.001) 
increased urinary albumin concentrations (Fig. 4.20 a), and by 34% and 43% 
(p<0.005) reduced urinary creatinine concentrations (Table 4.9), respectively. Their 
albumin-creatinine-ratio was approximately 30-fold elevated (Fig. 4.20 b). 
In 75- vs. 38-day-old G and GB mice, the urinary albumin concentrations were  
4.7- and 6.1-fold increased (p<0.005) indicating a more severe albuminuria in the 
elder bGH overexpressing groups. 
In the 75-day-group, G and GB mice demonstrated a 94- and 184-fold (p<0.001) 
increased urinary albumin concentration (Fig. 4.21 a) compared to littermate controls. 
Within the elder age group, this parameter was significantly increased by 95% in  
GB vs. G mice. A significant increase of 112% was also detectable in the albumin-
creatinine-ratio of 75-day-old GB vs. G mice (Fig. 4.21 b) demonstrating a more 
severe albuminuria in 75-day-old GB mice than in G mice. 
In B vs. C mice of both age groups, the urinary albumin and creatinine concentration, 
and the albumin-creatinine-ratio did not significantly differ, with the exception of a 
reduced urinary creatinine concentration (by 36%, p<0.005) in 38-day-old B vs.  
C mice.  
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Figure 4.20 a       Figure 4.20 b 
 
Figure 4.20 Urinary albumin concentration (a) and albumin-creatinine-ratio (b) of  
38-day-old mice of the four genetic groups. G and GB mice exhibited severe albuminuria of a 
similar extend. (n): number of mice analyzed. The data are shown as means and SDs. Significant 
differences (at least p<0.05) between the genetic groups are indicated by different superscripts (a, b). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21 a     Figure 4.21 b 
 
Figure 4.21 Urinary albumin concentration (a) and albumin-creatinine-ratio (b) of  
75-day-old mice of the four genetic groups. G and GB mice exhibited severe albuminuria, 
which is significantly augmented in GB mice. (n): number of mice analyzed. The data are shown as 
means and SDs. Significant differences (at least p<0.05) between the genetic groups are indicated by 
different superscripts (a, b, c). 
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Table 4.9 
 
group                       urinary creatinine concentration [mg/dl] 
  38 days of age  75 days of age  
 
C mice (11/10)  37.9a (8.7) 50.4a (19.3) 
B mice (11/12) 24.3b (10.9) 43.5a (11.1) 
G mice (11/11) 21.5b (8.1) 28.3b (7.9) 
GB mice (11/11) 25.0b (8.5) 27.6b (8.2) 
 
 
Table 4.9 Urinary creatinine concentration of 38- and 75-day-old mice of the four 
genetic groups. G and GB vs. C mice demonstrated reduced urinary creatinine concentrations 
(n/n): number of mice analyzed at an age of 38 and 75 days, respectively. The data are shown as 
means and (SDs). Significant differences (at least p<0.05) between the genetic groups are indicated 
by different superscripts (a, b). 
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4.5.9 Western ligand blot analysis of renal IGFBP-2 
 
Western ligand blot (WLB) analysis was performed of protein extracts from the renal 
zones - cortex, OSM, and ISM/IZM. The right kidneys of three mice per genetic group 
at an age of 38 days were investigated.  
 
The apparent size of IGFBP-2 was 32 kDa (Fig. 4.22). The intensity of IGFBP-2 
bands was similar between samples of a particular renal zone from mice of the same 
genetic group. The intensity of the IGFBP-2 bands in both B and GB vs. C and G 
mice in every renal zone was enhanced to a comparable extent. In C and G mice, 
nearly no [I125]IGF-II binding activity was visible in the cortex, in contrast to the OSM 
and ISM/IZM, which exhibited endogenous IGFBP-2 abundance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22 Western ligand blot analysis of protein extracts of renal zones of kidneys 
from 38-day-old mice of the four genetic groups. OSM, outer stripe of medulla; ISM/IZM 
inner stripe of medulla together with inner zone of medulla. The apparent size of IGFBP-2 was 32 kDa. 
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The intensity of the fraction of bands between 29 kDa and 36 kDa shown in figure 
4.22 was densitometrically determined (Fig. 4.23).  
 
Non-transgenic control mice displayed less intensive IGFBP-2 bands in the cortex, 
and slightly more intensive IGFBP-2 bands in the OSM and ISM/IZM suggesting the  
presence of endogenous IGFBP-2 in the renal medulla. The intensity of IGFBP-2 
bands of single renal zones in G mice did not significantly differ from that of controls.  
 
Both B and GB vs. C mice demonstrated a markedly elevated intensity of IGFBP-2 
bands. In the cortex, the intensity of IGFBP-2 bands of B mice was 6.9-fold 
(p<0.001), and of GB mice was 4.4-fold (p<0.001) increased, compared to controls. 
In B and GB vs. C mice, the intensity of IGFBP-2 bands in the OSM was 2.4- and 
3.3-fold increased (p<0.01), and in the ISM/IZM was 2.4- and 2.3-fold increased 
(p<0.02), respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23 Densitometry of IGFBP-2 bands obtained by WLB analysis of different 
renal zones of mice of the four genetic groups. OSM, outer stripe of medulla; ISM/IZM, inner 
stripe of medulla together with inner zone of medulla. (n): number of mice analyzed. The data are 
shown as means and SDs. Significant differences (at least p<0.05) within the renal compartment 
between the genetic groups are indicated by different superscripts (a, b, c). (e) shows a significant 
difference between cortex and OSM, ISM/IZM of B mice. (f) shows a significant difference between 
cortex and ISM/IZM of G mice. 
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4.5.10 Detection IGFBP-2 mRNA and protein in the kidney 
 
Immunohistochemistry and in situ hybridization were used to localize IGFBP-2 or 
IGFBP-2 mRNA, respectively, in the kidneys. Investigations were carried out on 
subsequent sections of the left kidneys from mice (n=3 per genetic group; 38 days of 
age) examined by WLB analysis. 
 
Similar staining results were obtained from mice of the same genetic group. IGFBP-2 
and IGFBP-2 mRNA were detected by immunohistochemistry (IHC) and in situ 
hybridization (ISH) exclusively in B and GB mice. The staining patterns and 
intensities were comparable between B and GB mice. The highest staining intensity 
in both IHC and ISH was found in the renal cortex.  
Contrary, C and G mice as well as methodical negative controls did not display any 
immunohistochemical or in situ hybridization staining. (Figs. 24 a - d).  
 
Within the glomerulus, podocytes exhibited a strong IGFBP-2 immunostaining that 
could not be re-identified on subsequent sections that underwent ISH (Figs. 25 a, b). 
Other glomerular cells neither showed an IHC signal nor an ISH signal.  
A comparable divergence in IHC and ISH signals as seen in podocytes was found in 
epithelial cells of the parietal layer of the Bowman capsule and in epithelial cells of 
the pars convoluta of the proximal tubule (Figs. 25 a, b). These cells displayed an 
intracellular IGFBP-2 immunostaining that was of granular appearance and was 
located apically within the epithelial cells. Contrary, no equivalent positive signal on 
RNA levels was noticeable. The combination of IHC and ISH analysis suggests the 
cellular presence of IGFBP-2 protein but not its synthesis in podocytes and epithelial 
cells of the parietal layer of the Bowman capsule and of the pars convoluta of the 
proximal tubule. 
Epithelial cells of the thick ascending limb of Henle´s loop exhibited a slight IGFBP-2 
immunostaining located in the cytoplasm. The intensity of the immunostaining varied 
between single cells. A slight, positive signal with comparable localization was 
detectable by in situ hybridization (Figs. 27 a - d).  
The distal tubule epithelia showed the most intensive staining in both IHC and ISH, 
suggesting a strong expression of transgene encoded IGFBP-2 and local presence of 
IGFBP-2 protein within these structures (Figs. 26 a, b). 
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Fig. 4.24 a: Overview of the renal cortex Fig. 4.24 b: Overview of the renal cortex 
B mouse; H&E staining; original magnifica- B mouse; PAS staining; original magnification 
tion 125 x 125 x 
 
 
 
 
 
 
 
 
 
Fig. 4. 24 c: Overview of the renal cortex Fig. 4.24 d: Overview of the renal cortex 
B mouse; IHC IGFBP-2, counterstaining with B mouse; ISH IGFBP-2 mRNA; counterstaining 
hemalaun; original magnification 125 x with Nuclear fast red; original magnif. 125 x 
 
 
Figure 4.24 a - d: Overview of the renal cortex. Four subsequent sections of a kidney from a 
38-day-old IGFBP-2 transgenic (B) mouse were differentially stained. IGFBP-2 overexpression in B 
and GB mice do not reveal any morphological changes in the kidneys (a, b). Note the pronounced 
IGFBP-2 immunostaining (c) of tubular structures, which can be re-identified in the section analyzed 
by ISH (d). Further, a strong punctual signal is detectable in glomeruli of the IHC stained section, 
whereas no corresponding signal is noticeable on the ISH stained section.  
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Fig. 4.25 a: Glomerulus and beginning Fig. 4.25 b: Glomerulus and beginning  
pars convoluta of the proximal tubule  pars convoluta of the proximal tubule 
B mouse; IHC IGFBP-2; counterstaining with B mouse; ISH IGFBP-2 mRNA; counterstaining 
hemalaun; original magnification 400 x with Nuclear fast red; original magnif. 400 x 
 
 
Figure 4.25 a, b: Glomerulus and beginning pars convoluta of the proximal tubule. 
Two subsequent sections of the kidney from a 38-day-old IGFBP-2 transgenic (B) mouse are shown. 
Note the intensive IGFBP-2 immunostaining of podocytes, epithelial cells of the parietal layer of the 
Bowman capsule, and of the proximal tubule. The IHC staining of the epithelial cells of the parietal 
layer of the Bowman capsule and PTE cells is of granular appearance and intracellular located, with 
distinct apical distribution (a). No corresponding signal is noticeable by ISH (b). 
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Fig. 4.26 a: Distal tubules in the renal  Fig. 4.26 b: Distal tubules in the renal 
cortex cortex 
B mouse; IHC IGFBP-2; counterstaining with B mouse; ISH IGFBP-2 mRNA; counterstaining 
hemalaun; original magnification 400 x with Nuclear fast red; original magnif. 400 x 
 
 
Figure 4.26 a, b: Distal tubules in the renal cortex. Two subsequent sections of the kidney 
from a 38-day-old IGFBP-2 transgenic (B) mouse are shown. Distal tubules in the renal cortex exhibit 
both a strong IHC and ISH staining for IGFBP-2 and IGFBP-2 mRNA, respectively. Note the 
discrepancy in IHC and ISH staining of the proximal tubule in the top right-hand corner. 
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Fig. 4.27 a: Overview of borderline bet- Fig. 4.27 b: Overview of borderline bet- 
ween outer and inner stripe of medulla  ween outer and inner stripe of medulla 
B mouse; IHC IGFBP-2; counterstaining with B mouse; ISH IGFBP-2 mRNA; counterstaining 
hemalaun; original magnification 250 x with Nuclear fast red; original magnif. 250 x 
 
 
 
 
 
 
 
 
 
Fig. 4.27 c: Borderline between outer Fig. 4.27 d: Borderline between outer 
and inner stripe of medulla in detail  and inner stripe of medulla in detail 
B mouse; IHC IGFBP-2; counterstaining with B mouse; ISH IGFBP-2 mRNA; counterstaining 
hemalaun; original magnification 400 x with Nuclear fast red; original magnif. 400 x 
 
Figure 4.27 a - d: Borderline between outer and inner stripe of medulla in an 
overview (a, b) and in detail (c, d). Two subsequent sections of the kidney of a 38-day-old 
IGFBP-2 transgenic mouse are shown. Epithelial cells of the thick ascending limb of Henle´s loop 
exhibit a slight, diffuse intracellular distributed signal in both IHC and ISH analyses. Single cells 
display a more pronounced immuno- and ISH-staining.  
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5 Discussion 
 
5.1 General aspects 
 
The present study analyzed effects of IGFBP-2 overexpression on both normal and 
GH/IGF-I-stimulated growth and function of the adrenal glands and kidneys in 
transgenic mice. For that purpose, hemizygous PEPCK-bGH and hemizygous  
CMV-mIGFBP-2 transgenic mice were crossed and the resulting four different 
genetic groups of offspring (non-transgenic controls (C), mIGFBP-2 transgenic (B), 
bGH transgenic (G), and double transgenic (GB) mice) were examined at different 
ages. 
 
The overexpression of bGH in G mice caused a significant increase in body weight, 
whereas overexpression of IGFBP-2 led to decreased body weights in B vs. C and in 
GB vs. G mice of both age groups (38 and 75 days of age). The results of the 
present study concerning body weight and circulating levels of IGF-I and IGFBP-2 of 
mice of the four different genetic groups resembled those recently published by 
Hoeflich et al. 7. Confirming preceding data, the growth inhibitory effect of elevated 
IGFBP-2 was more pronounced under high than under normal GH/IGF-I conditions. 
In 38-day-old GB mice, the GH-induced body growth stimulation was abolished. 
Serum levels of bGH correspond to 2 µg/ml in both G and GB mice 7. Circulating 
endogenous IGF-I levels in both bGH overexpressing groups included in this study 
were found to be similarly elevated. This indicates that phenotypical differences 
between G and GB mice were not due to altered bGH expression or differences in 
systemic IGF-I levels by overexpression of IGFBP-2 in GB mice. Likewise, serum 
IGFBP-2 levels of both IGFBP-2 overexpressing groups were similarly elevated 
confirming previous data 7. Contrary, serum IGFBP-2 levels of G vs. C mice were 
significantly decreased in the present study, while they were found to be only slightly 
lowered in a previous experiment 7. In humans, GH treatment also leads to reduced 
IGFBP-2 serum levels, which are linked with a significant decrease in liver IGFBP-2 
mRNA levels 117. Thus, the reduced IGFBP-2 serum levels in bGH transgenic mice 
probably resulted from reduced hepatic endogenous IGFBP-2 expression. Further 
discussed regulators of IGFBP-2 are IGF-II and insulin. However, since serum 
IGFBP-2 levels are positively correlated with IGF-II levels 129,298, but IGF-II levels 
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were found to be slightly elevated in PEPCK-bGH transgenic mice 37, a regulatory 
effect of IGF-II on IGFBP-2 serum levels is not comprehensible in G mice. High 
insulin levels are known to be negatively correlated to serum IGFBP-2 levels 72,299. 
Since GH transgenic mice were reported to be hyperinsulinemic 14, reduced IGFBP-2 
levels of G mice might be secondary to bGH-induced elevation of insulin levels. 
 
5.2 Clinical-chemical findings 
 
GH is known to affect clinical-chemical serum parameters. However, the consequen-
ces of elevated IGFBP-2 levels on clinical-chemical serum parameters were unclear 
so far. 
Serum creatinine and urea represent kidney relevant serum parameters. Serum crea-
tinine levels of 38- and 75-day-old G vs. C mice were significantly elevated. This fin-
ding is in contrast to reports from 7- and 19-week-old MT-bGH and 7- and 14-week-
old PEPCK-bGH transgenic mice characterized by unchanged serum creatinine 
levels 85,229. Serum creatinine almost exclusively originates from muscle metabolism 
and its production has been shown to be proportional to muscle mass 300. Since  
G mice of the present study were of relatively young age, glomerular alterations 
correspond to initial stage changes of glomerulosclerosis. An increase in serum 
creatinine values due to impaired kidney function is observed after kidney function is 
reduced by more than 50% 79. Thus, elevation of serum creatinine in G mice of the 
present study probably resulted from increased muscle metabolism rather than from 
impaired renal excretion. However, serum creatinine is regarded as a quite 
insensitive parameter to characterize glomerular changes 301,302.  
Serum creatinine levels were not influenced by overexpression of IGFBP-2 in B vs. C 
and GB vs. G mice, with exception of a slight reduction of this serum parameter in 
75-day-old GB vs. G mice. This reduction possibly reflected reduced creatinine 
production in GB vs. G mice, due to their lowered muscle mass. 
Serum urea levels were unchanged in mice of the four genetic groups at an age of  
38 days, whereas this parameter was significantly decreased in G and GB vs. C and 
B mice in the elder (75-day-old) collective of the present study. Serum urea levels of 
G mice analyzed in this study are in line with findings from seven-week-old MT-bGH 
transgenic mice, which exhibited serum urea levels not different from those of 
controls, and from 14-week-old PEPCK-bGH transgenic mice, which displayed 
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reduced serum urea levels compared to those of control animals 229. The decrease of 
serum urea levels of GH transgenic mice is attributed to the anabolic effect of GH 303. 
However, a 2-fold increase of serum urea levels was found in MT-hGH transgenic 
mice at the end of their life-span, caused by marked catabolism and declining kidney 
function 79. Overexpression of IGFBP-2 in B vs. C and GB vs. G mice did not 
influence serum urea levels. 
Serum levels of phosphate are known to be linked to those of GH 304. Thus, in-
creased serum phosphate levels are found in growing children and in adults with 
active gigantism or acromegaly 305. GH-treated dogs also show increased serum 
phosphate levels 306. Likewise, 38- vs. 75-day-old C mice and 75-day-old G vs.  
C mice of the present study exhibited elevated serum phosphate levels. However, 
since serum GH levels were not determined in mice of this study, and age-related 
changes of serum GH levels in mice of the strain used are not known yet, a 
correlation between elevated serum phosphate levels and serum GH levels can only 
be speculated. Elevated serum phosphate levels in high GH states are - at least 
partially - due to reduced renal phosphate excretion. Since IGF-I, but not GH, has 
been shown to be able to specifically stimulate phosphate transport in isolated 
perfused rabbit proximal tubules, the GH-induced reduction in renal phosphate 
excretion is suggested to be IGF-I-mediated 210. Accordingly, IGF-I-treatment 
increases renal tubular phosphate reabsorption in humans and rats 307. In vitro, IGF-I 
stimulates phosphate absorption in murine PTE cells and this effect is not affected by 
IGFBP-2 308. Accordingly, IGFBP-2 overexpression in B vs. C and GB vs. G mice did 
not reduce serum phosphate levels in the 38-day-group. In the 75-day-group, serum 
phosphate levels of B and G mice were slightly, and of GB mice were significantly 
increased as compared to controls implicating an additional effect of both bGH and 
IGFBP-2 overexpression on serum phosphate levels. Since IGF-I also promotes the 
shift of phosphate from the serum mainly into muscle and bone tissue, possibly by 
stimulation of sodium-phosphate co-transport 304, the increased serum phosphate 
levels of 75-day-old B vs. C and GB vs. G mice might reflect an IGFBP-2-induced 
inhibition of this IGF-I effect. 
Serum calcium levels were elevated in mice of both bGH overexpressing groups. 
Similarly, hypercalcemia was found to be a frequent feature in acromegalic patients. 
After successful treatment, serum calcium values normalized in a number of those 
patients 305. In the rat, elevated GH levels also cause an increase of serum calcium 
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levels 309. Controversial reports exist about a linkage between GH excess and 
secondary hyperparathyroidism due to parathyroid hyperplasia 305,310.  
Serum sodium levels were not different between the four genetic groups. In contrast, 
serum chloride was slightly lowered (~5%) in G and GB vs. C and B mice of both age 
groups, probably due to altered renal excretion 311. A sodium as well as fluid retentive 
effect of high GH levels is well established in several GH transgenic mouse strains 
229,312, and in rats and humans 313. GH transgenic mice demonstrate increased 
plasma volumes, absolute and relative to body weight 314, and reduced hematocrit 
values 229,312. Thus, the sodium concentrations in the serum of G and eventually of 
GB mice in the present study likely remained unchanged because of secondary 
hypervolemia. As shown in PEPCK-bGH transgenic mice, serum and cardiac atria 
levels of the atrial natriuretic peptide (ANP), an endogenous regulator of volume 
homeostasis, are increased, compared to non-transgenic controls. The authors, 
therefore, suggest an influence of the ANP on the effect of GH in fluid retention 312. 
Further, in acromegalic patients, an increased renal tubular sodium-potassium-
ATPase activity has been found to be responsible for the anti-natriuretic effect of GH 
313. 
Serum potassium levels were inconsistently affected by bGH and/or IGFBP-2 over-
expression in the 38- and 75-day-old group implicating a certain influence of the age 
on this parameter. IGF-I has been demonstrated to decrease serum potassium levels 
315, most likely by promoting the cellular up-take of potassium 316,317. Thus, the 
slightly increased serum potassium levels in GB vs. G mice of both age groups might 
derive from an IGFBP-2-induced inhibition of that IGF-I effect.  
The serum concentrations of total proteins were elevated in bGH overexpressing 
mice of both age groups despite progressive renal protein loss. This result is in line 
with previous findings in several GH transgenic mouse strains and is regarded as a 
result of increased hepatic protein synthesis 79,229. Overexpression of IGFBP-2 in 
 B vs. C and GB vs. G mice had no significant influence on this parameter. 
The lipid status of mice of the four genetic groups was characterized by a significant 
elevation of serum cholesterol levels of G and GB vs. C and B mice. Serum triglyce-
ride levels in G mice were reduced, which is in line with previous findings in MT-hGH 
transgenic mice 79. Likewise, 7-week-old MT-bGH transgenic mice demonstrate 
increased serum cholesterol and reduced triglyceride levels 229. IGFBP-2 overexpres-
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sion in B vs. C and GB vs. G mice had no significant influence on serum cholesterol 
and triglyceride concentrations. 
 
5.3 Effects of bGH and/or IGFBP-2 transgene expression on the adrenal gland 
 
This study used the enlarged and corticosterone hypersecreting adrenal glands of 
PEPCK-bGH transgenic mice as a model to characterize components of growth in 
terms of hyperplasia and hypertrophy, and to evaluate potential modulatory effects of 
IGFBP-2 on growth characteristics and function of the adrenal cortex.  
PEPCK-bGH transgenic mice, an established model for studying long-term 
consequences of elevated GH, exhibited markedly increased adrenal weights, which 
is in line with previous findings 16. In contrast, the adrenal glands of GH-deficient 
Snell dwarf mice are several times smaller than those of normal mice 318. bGH 
transgenic mice display systemically elevated bGH and IGF-I levels. Since the 
adrenal gland expresses both the GHR 160,161 and IGF-IR 319, basically both bGH and 
IGF-I may be reasonable for effects on adrenal growth promotion in that model. 
However, several lines of evidence indicate that adrenocortical enlargement and 
increased corticosterone secretion in G mice were most likely caused by increased 
levels of IGF-I: 1) In cultured HAC, hGH does not stimulate basal or ACTH-stimulated 
cortisol secretion 162, whereas the IGFs show mitogenic and steroidogenic effects on 
fetal and adult adrenocortical cells. Moreover, IGF-I analogues with reduced affinity 
for IGFBPs even more potently stimulate steroidogenesis than normal IGF-I 163. 2) In 
vivo, infusion of IGF-I into guinea pigs increases the fractional weight of the adrenal 
glands, and again, this effect is more pronounced with long R3 IGF-I, an analogue 
with reduced affinity for IGFBPs 178. 3) Overexpression of IGF-II in transgenic mice 
causes adrenal enlargement and enhanced steroidogenesis 8. 4) Both adrenal IGF-I 
expression and circulating IGF-I levels were significantly elevated in bGH transgenic 
(G and GB) mice 159. 5) The elevation of plasma corticosterone levels in different GH 
transgenic mouse strains correlates largely with serum IGF-I levels rather than with 
circulating GH levels 16. 6) IGFBP-2, a presumed inhibitor of IGF actions in various 
human and rodent cell culture models and in vivo 7,72, strongly reduced adrenal 
growth and abolished corticosterone secretion in the context of high GH and IGF-I 
levels in GB mice. Contrary, in normal growth conditions, IGFBP-2 overexpression in 
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B vs. C mice reduced adrenal weight only as a tendency. Adrenal IGFBP-2 mRNA 
and protein levels were similarly elevated in B and GB mice 159. 
 
IGFBP-2 is assumed to inhibit IGF actions 7,72. Nevertheless, an influence of elevated 
IGFBP-2 on GH effects or a GH/IGF-I independent growth inhibitory effect of  
IGFBP-2 cannot be excluded 9. For instance, IGFBP-2 has been shown to increase 
GHR mRNA expression and binding of GH to its receptor in rat osteosarcoma cells 
320. In contrast, no significant differences in the levels of GHR mRNA and IGF-IR 
mRNA abundance in the adrenal glands of mice of the four genetic groups were 
observed 159. 
The extent of growth inhibition by IGFBP-2 excess in GB vs. G mice varies between 
different organs with the adrenal gland being overproportionally reduced in weight 7. 
The adrenal gland was the organ with the greatest relative weight reduction (-22%,  
-37%, respectively) in GB vs. G mice at an age of 75 days (present study) and of four 
months in a previous study. The fact that even the relative adrenal weight was as a 
tendency smaller in GB than in G mice at four months of age points to a specific 
effect of IGFBP-2 on adrenal growth especially in the context of GH excess 159.  
 
Using state-of-the-art stereological methods, the growth manipulating effects of bGH 
and/or IGFBP-2 overexpression on adrenal structures and cells was determined. The 
volume fractions of cortex and medulla, (VV(cortex/adrenal gland) and VV(medulla/adrenal gland)), 
were not different between the four genetic groups. This finding is consistent with the 
presence of IGF-IR in both zones 186,321. As a consequence, G mice exhibited 
increased absolute volumes of adrenal cortex and medulla. Contrary, IGFBP-2 
excess inhibited both adrenocortical and -medullary growth, and the degree of growth 
inhibition was greater in the context of GH/IGF-I excess than in animals with normal 
GH and IGF-I levels (C mice).  
The absolute volume of the zona fasciculata (V(zona fasc., cortex)) was markedly increa-
sed through GH overexpression in G mice, due to both hypertrophy (44% increase in 
mean cell volume) and hyperplasia (50% increase in cell number) of zona fasciculata 
cells. Contrary, overexpression of IGFBP-2 in GB mice significantly reduced  
V(zona fasc., cortex). Interestingly, on cellular level IGFBP-2 inhibited only the hypertrophic 
action of GH on zona fasciculata cells, whereas cellular hyperplasia was unaffected. 
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These data show for the first time that even with saturating amounts of GH and IGF-I, 
IGFBP-2 is capable of limiting cell growth and maximum cell size.  
 
The adrenocortical phenotype in GB mice resembles that in IGF-II transgenic mice. 
Like GB mice, IGF-II transgenic mice exhibit an increased volume of the adrenal 
cortex, which is exclusively due to hyperplasia (50% increase in cell number) of zona 
fasciculata cells, whereas the cell volume remains unchanged. Instead of increased 
IGF-I levels, IGF-II transgenic mice demonstrate two- to three-fold elevated serum 
IGF-II levels, adrenal IGF-II transgene expression, and increased IGFBP-2 serum 
levels 8,129. This comparison suggests that on the one hand, both IGFs act similarly in 
the context of high IGFBP-2 levels in regulating growth of zona fasciculata cells, 
implicating the activation of the same receptor, namely the IGF-IR 44,45. On the other 
hand, this comparison implicates that GH seems to have no direct effect on 
adrenocortical growth, which is also underlined by in vitro findings 162.  
 
The molecular mechanisms underlying the specific hypertrophy-inhibiting effect of 
IGFBP-2 on adrenocortical zona fasciculata cells remain unclear. If this effect were 
independent of GH or IGF-I, one would expect a decrease in cell volume also in B vs. 
C mice, which was not the case. On the other hand, IGFBP-2 could specifically block 
an increase in cell size rather than decrease normal-sized cells. If the effect of 
IGFBP-2 were GH/IGF-I dependent, it remains unclear why only the hypertrophic 
actions of GH/IGF-I excess were blocked. Since much evidence indicates that 
cellular size and proliferation is regulated by independent signaling pathways 
71,322,323, one can speculate, that IGFBP-2 specifically targets signal transduction 
pathways downstream of the IGF-I receptor. A possible candidate, involved in growth 
of zona fasciculata cells is the 3-phosphoinositide-dependent protein kinase-1 
(PDK1). PDK1 functions as a master kinase and plays a key role in regulating the 
activity of a group of insulin and IGF-stimulated protein kinases 324,325. Mice that 
possess PDK1 hypomorphic alleles and express only ~10% of the normal level of 
PDK1, exhibit reduced adrenal gland volumes. Morphometric analysis revealed that 
the volume of zona fasciculata cells of those mice was reduced by 45%, whereas the 
cell number was unchanged 326.  
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Analysis of plasma corticosterone levels in mice of the four genetic groups revealed 
that the changes in adrenal weight were paralleled by their capacity to secrete gluco-
corticoids. Both basal and ACTH-induced plasma corticosterone levels were marked-
ly increased in G mice, and this effect was significantly reduced by coexpression of 
IGFBP-2 in GB mice. Since the number of adrenocortical cells was not different 
between G and GB mice, corticosterone hypersecretion seems to depend on cell size 
rather than on cell number.  
Basal plasma corticosterone levels of C mice included in the present study were 
higher than those observed in an earlier experiment 8. In contrast to the previous 
experiment, blood samples of the present study were taken in the afternoon, the last 
third of the light period, where the highest levels of circulating corticosterone are 
measured in mice 327. The sampling time and/or different genetic backgrounds might 
be responsible for the differences in plasma corticosterone levels observed. 
 
Plasma ACTH levels of C and B mice were significantly higher in the afternoon than 
in the morning. This physiological diurnal variation of ACTH secretion was not seen 
in G and GB mice. In both G and GB mice, ACTH levels were normal or only slightly 
elevated. This finding is in contrast to a previous report, in which three-fold increased 
morning plasma ACTH levels were measured in male mice of one PEPCK-bGH 
transgenic strain 15. To further characterize effects of GH excess on plasma ACTH 
levels, MT-bGH transgenic mice were investigated in the present study. Their plasma 
ACTH levels also were not significantly different from these of non-transgenic litter-
mate controls. Furthermore, PEPCK-bGH transgenic mice maintained on an NMRI 
outbred background do not show significantly different morning plasma ACTH levels, 
if compared to non-transgenic controls 328. Therefore, it is unlikely that the trophic 
effects of GH on the adrenal gland are mediated via increased ACTH levels. 
Interestingly, plasma ACTH levels in GH transgenic mice were not reduced in spite of 
markedly increased plasma corticosterone concentrations suggesting a disturbed 
feedback regulation of ACTH secretion 329. 
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5.4 Effects of bGH and/or IGFBP-2 transgene expression on the kidney 
 
Stimulation of kidney growth through bGH overexpression in G mice is in line with 
previous findings 14. Coexpression of the CMV-IGFBP-2 transgene in GB mice 
markedly inhibited bGH-associated renal hypertrophy, while IGFBP-2 excess under 
normal growth conditions had no effect on renal growth. The results in the present 
study concerning renal growth modulation by IGFBP-2 overexpression are consistent 
with these of previous studies using the same collective of mice, and confirm the 
close involvement of the GH/IGF-axis in renal growth regulation 7.  
The renal enlargement observed in GH transgenic mice is likely to be mediated 
mainly by IGF-I rather than by GH for several reasons. 1) Both IGF-I transgenic mice, 
which are characterized by lowered serum GH levels, and GH transgenic mice 
exhibit elevated serum IGF-I levels and renal hypertrophy 85,86. 2) Similar renal 
growth effects can be achieved by administration of IGF-I or GH to normal 255,330 or 
GH deficient rats 237. 3) GH deficiency is linked to reduced circulating and renal IGF-I 
levels and reduced renal mass 200. 4) Markedly reduced serum IGF-I levels in mice, 
lacking hepatic Igf1 gene expression, are associated with reduced kidney growth in 
spite of elevated GH levels 41,42. 5) Overexpression of IGFBP-2, a presumed inhibitor 
of IGF-I action, causes a marked inhibition of renal growth in GB vs. G mice 7.  
 
The differences in renal weight of mice of the four genetic groups included in this 
study were not attributable to changed numbers of nephrons. Concerning G mice, 
this result was expected, as MT-bGH transgenic mice also do not exhibit changed 
nephron numbers 229, despite the earlier expression of the MT promoter (at 
embryonic day 13 331, whereas the PEPCK promoter is expressed from birth on-
wards 81). As perinatal commenced IGFBP-1 overexpression in mice is reported to be 
associated with reduced nephron numbers, this parameter needed to be assessed in 
the present study. Even normal (non-transgenic) mice born from IGFBP-1 transgenic 
mothers have reduced nephron numbers due to prenatally reduced IGF-I levels 243. 
In the present study, neither bGH nor IGFBP-2 transgene expression influenced the 
nephron numbers, and the nephron number in the kidneys of mice born from  
IGFBP-2 transgenic mothers was not different from those born from wild-type 
mothers in previous studies 229. 
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The present study analyzed the renal sites of action of bGH and IGFBP-2 excess on 
suborgan and cellular level using quantitative-stereological methods. The volume 
fractions of the renal zones did not or only slightly differ between the four genetic 
groups. Unchanged or slightly changed cortical and medullar volume fractions have 
also been observed in adult rats with renal hypertrophy due to STZ-induced diabetes 
mellitus, or due to unilateral nephrectomy 332. Renal hypertrophy in these models is 
known to be associated with elevated renal IGF-I immunoreactivity 194.  
The renal hypertrophy observed in G mice of the present study was due to an 
increase of the absolute volumes of all renal zones. However, the enlarged cortex 
and OSM relatively and absolutely contributed most to bGH-induced renal 
hypertrophy of G mice of both ages (38- and 75-day-old). The enlargement of the 
cortex and OSM was mainly due to an increase of the proximal tubular epithelium 
(PTE). As shown in 75-day-old G mice, the increase of the cortical PTE was 
exclusively caused by PTE cell hyperplasia (90% increase in total cell number), 
whereas the mean volume of PTE cells was not affected.  
As proximal tubular epithelia express both the GHR and IGF-IR, principally both 
direct and indirect - via IGF-I - effects of GH may be responsible for the increase in 
total PTE cell number. However, the PTE cell hyperplasia most likely reflects an IGF-I 
mediated effect of GH rather than a direct GH effect for several reasons. 1) In vivo, 
renal cellular hyperplasia in rats can be achieved by administration of both GH and 
IGF-I 255. 2) GH binding results in activation of phospholipase C in PTE cells, 
however, no direct growth promoting effect on PTE cells has been demonstrated for 
GH 18,333. 3) In vitro, IGF-I is a strong mitogen for PTE cells and promotes 
proliferation of PTE cells of various species 249-252 via activation of the IGF-I receptor 
250,253. 4) IGFBP-2, a presumed inhibitor of IGF actions markedly reduced the 
absolute volume of PTE in the cortex and OSM as well as the total number of PTE 
cells in the cortex in GH/IGF-I excess conditions (see below), but not in a normal 
GH/IGF-I background.  
 
IGFBP-2 transgene coexpression markedly inhibited the total volume of PTE in both 
38- and 75-day-old GB vs. G mice, further, in 75-day-old GB vs. G mice significantly 
reduced the total number of cortical PTE cells (18% decrease in total cell number), 
while the mean volume of cortical PTE cells was unaffected. This finding is in line 
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with a study demonstrating that IGFBP-2 together with IGFBP-4 and -5 is capable to 
inhibit the mitogenic activity of IGF-I in cultured rabbit PTE cells 252.  
The molecular pathways, by which IGF-I and IGFBP-2 act on hyperplasia of PTE 
cells remain speculative so far. As shown in rabbit PTE cells, IGF-I binding causes 
phosphorylation of the IGF-IR tyrosine kinase and a dose-dependent increase in PTE 
cell number 334. Several signal transduction pathways that promote cell growth and 
survival lay downstream of the IGF receptor tyrosine kinase 254. Protein synthesis 
represents a requirement for cellular growth. IGF-I induces protein synthesis in 
murine PTE cells, which is dependent on the activation of the PI (3) K/ Akt pathway 
and ERK1/2-type MAP kinase pathway 335. Furthermore, IGF-I has an anti-apoptotic 
effect on PTE cells, as shown in a rat cell culture study. This anti-apoptotic effect of 
IGF-I is mediated by PI (3) K/ Akt dependent BAD phosphorylation 254. The most 
likely mechanism, by which IGFPB-2 acts on GH-induced hyperplasia of PTE cells is 
by interfering with IGF-I, in that way sequestering IGF-I from the IGF-IR and thereby 
inhibiting its effects. Several in vitro studies support the concept of an IGF-dependent 
growth-inhibitory effect of IGFBP-2 9. Especially in PTE cells, IGFBP-2 together with 
IGFBP-4 and -5 inhibits IGF-I-induced cell proliferation 252.  
Remarkably, the renal zonal composition and the cellular growth investigated in this 
study were not different between B and C mice, indicating a modulatory effect of 
IGFBP-2 overexpression on the growth of renal structures only in stimulated growth 
conditions. Further investigations will be required in order to determine the molecular 
pathways of IGFBP-2 actions in PTE cells, and to address, whether IGFBP-2 affects 
IGF-I-induced proliferation or survival of PTE cells, or both. 
 
The effects of IGFBP-2 overexpression were in coincidence with a 4.4-fold increase 
of IGFBP-2 binding activity in the cortex in GB vs. C mice. Remarkably, IGFBP-2 
mRNA was not detected in PTE cells of GB mice, as demonstrated by in situ hybridi-
zation. Therefore, a systemic effect of high IGFBP-2 on growth of the PTE cells is 
assumed. Consistent with this assumption, PTE cells of B and GB mice showed a 
strong granular IGFBP-2 immunostaining using IHC, implicating tubular absorption 
and intracellular granular storage of ultrafiltrated IGFBP-2. No IGFBP-2 expression 
was detectable in PTE cells in C mice, which is in line with previous findings 212. 
However, Lindenbergh-Kortleve et al. 212 detected predominant IGFBP-2 expression 
in the thin limbs of Henle's Loop of the mature kidney using in situ hybridization, 
 
-121- 
Discussion 
which was not observed in this study. Conflicting data concerning renal IGFBP-2 
expression also derive from Northern blot analyses. IGFBP-2 mRNA was found in the 
kidneys of 28-day-old BALB/c mice 336, whereas no renal endogenous IGFBP-2 
expression was found by Northern blot hybridization in C mice in a previous study 152. 
The IGFBP expression pattern is known to be developmentally influenced 18,65. If 
there are also strain specific differences in IGFBP expression, which could explain 
the divergent findings, remain to be elucidated. 
 
In human patients and experimental animals with an increased permeability of the 
glomerular filtration barrier, e.g., in the nephrotic syndrome, ultrafiltration of the 
smaller (45 kDa) IGF-IGFBP complexes raises and a larger amount of IGF-I is 
excreted in the urine 337. This has led to the thesis that the increased tubular cell 
exposure to filtrated IGF-I may contribute to the tubulointerstitial disease that 
develops in most heavy proteinuric states 223. As intact IGFBP-3 levels are 
decreased in the serum of individuals suffering from chronic renal failure (CRF), but 
IGFBP-2 levels are elevated 74,266, due to an increased hepatic IGFBP-2 synthesis 
269, IGF-I shifts toward the smaller IGF-IGFBP-2 binary complex, which is more 
readily filtered than the larger ternary complex 337. In nephrotic rats, IGF-I is ultra-
filtrated predominantly in conjunction with IGFBP-2 and is present in proximal tubular 
fluid at 1.35 nM. The ultrafiltrated IGF-I has been shown to increase proliferation of 
cultured proximal tubular cells 220.  
Cystogenesis in humans and experimental animals is associated with hyperplasia of 
tubular epithelia 338. Acquired cystic kidney disease (ACKD) is the result of cyst 
formation in the failing kidney and displays a serious complication in longstanding 
CRF 338,339.  
The findings of the present study demonstrate that high IGFBP-2 levels in GB mice 
are capable of inhibiting proximal tubular epithelial growth. The tubulocystic 
alterations occurring in GH transgenic mice represent a model for human ACKD 17. In 
order to in depth characterize the relevance of elevated serum IGFBP-2 levels on 
renal tubular cyst formation, studies should address growth-modulating effects of 
IGFBP-2 on the proximal tubular epithelium in older GH transgenic mice.  
 
In humans with multicystic renal dysplasia, the kidneys are characterized by a strong 
IGFBP-2 mRNA expression and IGFBP-2 immunoreactivity, both limited exclusively 
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to cyst epithelia 13. Thus, the proposed growth promoting effect of IGFBP-2 in 
multicystic renal dysplasia seems to be in contrast to the anti-proliferative effect of 
high IGFBP-2 levels on PTE cells observed in this study. However, the effects of 
IGFBP-2 overexpression of both studies cannot be directly compared, as in the 
human study, fetal and early postnatal organs were analyzed, whereas in this study, 
juvenile-adult and adult kidneys were examined. Thus, potential development-
specific effects of components of the GH/IGF-axis cannot be excluded and might be 
responsible for the different outcome of high IGFBP-2 levels in proximal tubules 18,65. 
Further, in human multicystic renal dysplasia, the cyst epithelia were demonstrated to 
be dedifferentiated and may be better suited to proliferation 13. Contrary, in mice of 
this study, no signs of dedifferentiation of PTE cells were observed. 
 
GH overexpression in mice is known to be associated with the development of pro-
gressive glomerular hypertrophy, which is overproportional as a function of either 
body or kidney weight, and associated with the development of glomerulosclerosis 
79,85,229. The present findings concerning glomerular alterations in G mice are 
consistent with those of previous studies. In contrast to its substantial growth 
inhibitory potency concerning the proximal tubular epithelium, IGFBP-2 
overexpression in both 38- and 75-day-old GB vs. G mice reduced GH-induced 
glomerular enlargement only to a minor degree (~10%). The failure of IGFBP-2 in 
limiting glomerular growth became even more evident, when the glomerular volume 
was related to either body- or kidney weight, or total PTE volume. Thus, IGFBP-2 
excess dissociates the effects of high GH/IGF-I levels on growth of renal structures, 
namely on that of the PTE and of glomeruli. Contrary, under normal growth 
conditions, IGFBP-2 overexpression had no significant effect on glomerular 
parameters investigated in this study.  
Manifest glomerulosclerosis including hyalinosis, capillary obliteration and synechia 
formation was rarely observed in the GH overexpressing animals of this study, due to 
the young age of the mice investigated. Thus, the increase in the glomerulosclerosis-
index of G as well as of GB mice was above all due to mesangial matrix 
accumulation. An accumulation of mesangial matrix was also confirmed by 
immunohistochemistry, which demonstrated mesangial accumulation of type IV 
collagen, laminin, and fibronectin of similar extend in both G and GB mice of the 
present study (Fisch, T. M., Wolf, E., Wanke, R., unpublished data). The 
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glomerulosclerosis-index of G and GB mice was not significantly different. This 
finding was not unexpected, since glomerular hypertrophy, as a key event in 
formation of progressive glomerulosclerosis 227,229, was not severely affected by 
IGFBP-2 coexpression in GB vs. G mice. 
Interestingly, the degree of inhibition of GH/IGF-I-induced glomerular hypertrophy in 
GB vs. G mice (~10%) through overexpression of IGFBP-2, a presumed inhibitor of 
IGF-I actions, ranges in the same magnitude as the degree of stimulation of 
glomerular growth (~30%) through IGF-I overexpression in seven-week-old MT-IGF-I 
transgenic mice 85. This implies that elevated levels of IGF-I would only marginally 
contribute to glomerular hypertrophy. However, a true statement about the 
contributions of GH and IGF-I to glomerular hypertrophy (and subsequent sclerosis) 
from a comparison of these models is not allowed for several reasons, such as 
different patterns of transgene-derived and/or endogenous IGF-I and/or GH 
expression in IGF-I vs. GH transgenic mice, or various side effects of the expression 
of the transgenes that cannot be assessed completely 72. For example, IGF-I 
overexpression in transgenic mice is associated with an inhibited expression of 
endogenous GH and IGF-I 126. In vitro studies show that high IGF-I levels stimulate 
IGFBP-2 secretion by murine mesangial cells, maybe to protect themselves from 
excessive IGF-I stimulation 12, which may also occur in vivo. IGF-I is known to 
stimulate mesangial cell proliferation and matrix production 340,341, which are 
characteristics of GH-induced glomerular hypertrophy and sclerosis 229. Contrary, 
high GH levels are known to reduce endogenous IGFBP-2 levels 117,118, thereby 
probably exposing mesangial cells to disproportionate stimulation through IGF-I. 
Such an effect was demonstrated in vitro for high levels of glucose, which reduced 
IGFBP-2 synthesis of mesangial cells, in the presence or absence of elevated IGF-I 
levels 12. In the present study, no IGFBP-2 mRNA or IGFBP-2 could be detected by 
in situ hybridization or by immunohistochemy, respectively, within mesangial cells of 
mice of the four genetic groups investigated. Within the glomerulus, IGFBP-2 
immunoreactivity was found only in podocytes of B and GB mice and was most likely 
attributable to absorption of filtrated IGFBP-2.  
 
The results of urine protein analysis were in line with the alterations of glomerular 
morphology. Both G and GB mice displayed selective glomerular proteinuria.  
IGFBP-2 overexpression in B vs. C and GB vs. G mice did not alter the pattern of 
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proteinuria. Severe albuminuria in GH transgenic mice is attributed to glomerular 
changes leading to an increased glomerular filtration of albumin 85,229. The age-
related increase in urinary albumin excretion in G and GB mice reflects the pro-
gression of glomerular lesions. In 75-day-old GB mice, the urinary albumin concen-
tration and urinary albumin/creatinine-ratio was significantly elevated when compared 
to G mice. This fact may be explained by a lowered capacity of tubular protein reab-
sorption due to the markedly reduced total volume of the proximal tubular epithelia in 
GB vs. G mice. C and B mice displayed a physiologic microalbuminuria.  
Urine of bGH overexpressing mice displayed reduced concentrations of major urinary 
proteins (MUPs), which is a characteristic finding in GH transgenic mice 229. Normal 
MUP synthesis requires a pulsatile GH secretion, whereas constant high GH levels 
cause a reduction in hepatic synthesis of MUPs 342,343. MUPs are liver synthesized 
pheromone-binding proteins, which are physiologically excreted and play complex 
roles in chemosensory signaling among rodents 344. 
 
In conclusion, the collective of mice used in this study represents a valuable model 
for unraveling the roles of components of the GH/IGF-axis in growth regulation in 
vivo. The findings of the present study demonstrate that excess of GH/IGF-I results in 
renal and adrenal enlargement via cellular hyperplasia or cellular hyperplasia linked 
to hypertrophy indicating a cell type-dependent growth response. Likewise, high 
IGFBP-2 levels modulate cellular growth in a cell type-specific fashion. 
Demonstrating a clear-cut effect, IGFBP-2 exclusively inhibited GH/IGF-I-induced 
hypertrophy but not hyperplasia of adrenal zona fasciculata cells. In contrast, high 
IGFBP-2 levels inhibited GH/IGF-I-induced hyperplasia of PTE cells without affecting 
PTE cell size. This selective modulation of cellular growth parameters represents an 
important new facet in the spectrum of IGFBP-2 actions.  
 
As shown in this study, transgenic overexpression strategies can be elegantly used 
to characterize the potential of individual genes involved in the regulation of growth. 
Nevertheless, the current IGFBP overexpression models are limited, as they have 
been established on different genetic backgrounds, with different expression vectors 
and copy numbers that have been integrated randomly into the genome. Thus, it 
cannot be excluded that some of the observed phenotypic alterations are related to 
strain-specific factors. Strategies for future studies should aim to target the respective 
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transgene to a specific locus in the genome, avoiding position effects that may 
markedly influence the activity of a transgene 5. Furthermore, the analysis of 
polygenic models resulting from phenotypic selection may be interesting for 
understanding the physiology of IGFBPs and their interactions with other biological 
systems involved in growth regulation. 
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6 Summary 
Effects of insulin-like growth factor-binding protein-2 (IGFBP-2) 
overexpression on adrenal and renal growth processes and 
functions: findings in transgenic mouse models 
 
The growth hormone (GH)/insulin-like growth factor- (IGF-) axis plays a crucial role in 
adrenal and renal growth and function and is intimately involved in the pathogenesis 
of various diseases of the adrenal gland and kidney. The functions of IGF binding 
proteins (IGFBPs) have been studied extensively in vitro, revealing IGF-dependent 
and also IGF-independent effects on cell growth, differentiation, and survival. In 
contrast, the biological relevance of IGFBPs in vivo is only partially understood. 
IGFBP-2 is the second most abundant IGFBP in the circulation and acts as a growth 
inhibitor in vivo in mice.  
This study investigates the effects of IGFBP-2 on growth and function of the adrenal 
gland and the kidney under normal and GH/IGF-I stimulated growth conditions. For 
that purpose, hemizygous cytomegalovirus (CMV)-promoter murine (m) IGFBP-2 
transgenic mice were crossed with hemizygous phosphoenolpyruvate carboxykinase 
(PEPCK)-promoter bovine (b) GH transgenic mice, generating four genetic groups of 
offsping: mice carrying both transgenes (GB), a single mIGFBP-2 (B) or bGH 
transgene (G), and non-transgenic controls (C). The kidneys and adrenal glands of 
male individuals at the age of 38 and 75 days were analyzed, using qualitative 
morphological and quantitative-stereological methods. In addition, in situ 
hybridization, immunohistochemistry and Western ligand blot analysis of the kidney 
were performed. The investigations further included the measurement of various 
serum and urine parameters.  
The absolute weight of the adrenal glands was significantly increased in 75-day-old 
G vs. C and B mice. This adrenal enlargement was found to involve both hypertrophy 
(44% increase in mean cell volume) and hyperplasia (50% increase in cell number) 
of zona fasciculata cells. IGFBP-2 overexpression in GB mice significantly reduced 
bGH-induced adrenal enlargement. bGH-induced hypertrophy of zona fasciculata 
cells was completely abolished in GB mice, whereas hyperplasia was not affected. 
Basal and ACTH-induced plasma corticosterone levels of four-month-old G mice, but 
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not of GB mice, were 2- to 3-fold increased as compared to C mice. Plasma ACTH 
levels were similar in all groups.  
The absolute kidney weight was significantly increased in 38- and 75-day-old G vs. C 
and B mice. This renal enlargement was found to be mainly due to stimulated growth 
of the cortex and the outer stripe of the medulla. The increased volume of these two 
renal zones was primarily the consequence of an increased volume of the proximal 
tubular epithelium (PTE). Determination of the mean volume and total number of 
cortical PTE cells in 75-day-old G mice revealed that this increase was exclusively 
due to PTE cell hyperplasia (90% increase in cell number), whereas the mean PTE 
cell volume was unaffected. Comparing the findings of GB mice with those of G mice 
revealed that overexpression of IGFBP-2 significantly reduced renal enlargement and 
total PTE volume in both age groups. bGH-induced hyperplasia of PTE cells was 
selectively inhibited in 75-day-old GB mice without affecting cell size. Glomerular 
hypertrophy observed in G mice was only slightly reduced by coexpression of 
IGFBP-2 in GB mice and glomerular damage was not affected. 
 
The results of the present study demonstrate that overexpression of IGFBP-2 
modulates cellular growth in a cell type-specific fashion in vivo. The findings 
represent an important new facet in the spectrum of IGFBP-2 actions. Therefore the 
transgenic mice included in this study are considered as valuable models for 
unraveling the mechanisms involved in regulation of cell size and cell number. 
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7 Zusammenfassung 
Effekte einer Überexpression des insulin-like growth factor 
Bindungsproteins-2 (IGFBP-2) auf adrenale und renale Wachstums-
prozesse und Funktionen: An transgenen Mausmodellen erhobene 
Befunde 
 
Das Wachstumshormon (growth hormone; GH)/insulin-like growth factor- (IGF-) 
System ist maßgeblich an der Regulation adrenaler und renaler Wachstumsprozesse 
beteiligt und spielt eine wesentliche Rolle in der Pathogenese verschiedener 
Erkrankungen der Nebenniere und Niere. Die Funktion der IGF Bindungsproteine 
(IGFBPs) wurde intensiv in vitro untersucht. Dabei zeigten sich sowohl IGF-
abhängige als auch IGF-unabhängige Effekte auf das Wachstum, die Differenzierung 
und das Überleben von Zellen. Die biologische Relevanz der IGFBPs in vivo ist 
dagegen bislang weitgehend ungeklärt. IGFBP-2 ist das in der Zirkulation am zweit-
häufigsten vorkommende IGFBP und erwies sich in Untersuchungen an Mäusen als 
Wachstumsinhibitor.  
Ziel dieser Studie war es, die Effekte von IGFBP-2 auf das Wachstum und die 
Funktion der Nebenniere und der Niere unter normalen und GH/IGF-I stimulierten 
Wachstumsbedingungen zu untersuchen. Zu diesem Zweck wurden Mäuse, die 
murines (m) IGFBP-2 unter der Kontrolle des Cytomegalievirus (CMV)-Promotors 
exprimieren, mit Mäusen gekreuzt, die bovines (b) GH unter der Kontrolle des 
Phosphoenolpyruvatkarboxykinase (PEPCK)-Promotors exprimieren. Aus dieser 
Anpaarung resultierende Nachkommen gehörten vier genetischen Gruppen an: 
doppelt transgene Mäuse (GB), einfach mIGFBP-2 (B) oder bGH transgene (G) 
Mäuse, und nicht-transgene Kontrolltiere (C). Die Nieren und Nebennieren wurden 
mittels qualitativer morphologischer und quantitativ-stereologischer Methoden 
untersucht. Die Nieren wurden zusätzlich mittels in situ Hybridisierung, Immun-
histochemie und Western Ligandenblot analysiert. Weiterhin wurden verschiedene 
Serum- und Urinparameter bestimmt.  
Das absolute Gewicht der Nebennieren von 75 Tage alten G Mäusen war im 
Vergleich zu C und B Mäusen signifikant erhöht. Das erhöhte Nebennierenvolumen 
beinhaltete sowohl eine Hypertrophie (44% Zunahme der Zellzahl) als auch eine 
Hyperplasie (50% Zunahme des mittleren Zellvolumens) von Zona fasciculata Zellen. 
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Die Überexpression von IGFBP-2 führte bei GB Mäusen im Vergleich zu G Mäusen 
zu einer signifikanten Reduktion des Nebennierenvolumens. Die GH-induzierte 
Hypertrophie der Zona fasciculata Zellen wurde vollständig gehemmt, wohingegen 
die Hyperplasie nicht beeinflusst war. Basale und ACTH-induzierte 
Plasmakortikosteronspiegel von vier Monate alten G Mäusen, nicht jedoch die von 
GB Mäusen, waren im Vergleich zu C Mäusen 2- bis 3-fach erhöht. Die Plasma 
ACTH Spiegel der vier genetischen Gruppen waren nicht signifikant verschieden. 
Das Nierengewicht war bei 38 und 75 Tage alten G Mäusen im Vergleich zu C und B 
Mäusen signifikant erhöht. Diese Erhöhung des Nierengewichts resultierte 
überwiegend aus einer Stimulation des Wachstums des Kortex und des 
Außenstreifens der Medulla. Die Vergrößerung dieser beiden Zonen beruhte 
vornehmlich auf der Zunahme des Volumens des proximalen Tubulusepithels (PTE). 
Die Bestimmung des mittleren Volumens und der absoluten Anzahl von PTE-Zellen 
ergab, dass der Anstieg des Volumens des PTE in G versus C Mäusen 
ausschließlich durch eine Hyperplasie der PTE Zellen verursacht war (90% Anstieg 
der Zellzahl), während das mittlere PTE-Zellvolumen nicht beeinflusst war. Ein 
Vergleich der an GB und G Mäusen erhobenen Befunde zeigte, dass die 
Überexpression von IGFBP-2 in beiden Altersgruppen zu einer signifikanten 
Reduktion des Nierengewichts und des Volumens des PTE führte. Die bGH-
induzierte Hyperplasie der PTE Zellen 75 Tage alter G Mäuse war durch IGFBP-2 
Überexpression in GB Tieren selektiv gehemmt, wohingegen das mittlere Volumen 
der PTE Zellen unbeeinflusst blieb. Die bei G Mäusen beobachtete glomeruläre 
Hypertrophie wurde durch die Koexpression von IGFBP-2 nur geringgradig reduziert 
und der glomeruläre Schädigungsgrad wurde nicht beeinflußt.  
 
Die Befunde der vorliegenden Studie demonstrieren eine durch Überexpression von 
IGFBP-2 bedingte Zelltyp-spezifische Modulation von zellulärem Wachstum. Die 
Ergebnisse stellen einen wesentlichen, neuen Aspekt in der Wirkungsweise von 
IGFBP-2 dar. Die in dieser Studie verwendeten transgenen Mäuse werden daher als 
wertvolle Modelle angesehen, um die an der Regulation von Zellgröße und -zahl 
beteiligten Mechanismen zu entschlüsseln.  
 
 
-130- 
References 
8 References 
 
1. Le Roith, D., Bondy, C., Yakar, S., Liu, J. L. & Butler, A. The somatomedin 
hypothesis: 2001. Endocr Rev 22, 53-74. (2001). 
2. Jones, J. I. & Clemmons, D. R. Insulin-like growth factors and their binding 
proteins: biological actions. Endocr Rev 16, 3-34. (1995). 
3. Rosenzweig, S. A. What's new in the IGF-binding proteins? Growth Horm IGF 
Res 14, 329-36 (2004). 
4. Rajaram, S., Baylink, D. J. & Mohan, S. Insulin-like growth factor-binding 
proteins in serum and other biological fluids: regulation and functions. Endocr 
Rev 18, 801-31. (1997). 
5. Wolf, E., Schneider, M. R., Zhou, R., Fisch, T. M., Herbach, N., Dahlhoff, M., 
Wanke, R., Hoeflich, A. Functional consequences of IGFBP excess - lessons 
from transgenic mice. Pediatr Nephrol (in press). 
6. Hoeflich, A. Funktionelle Analyse von IGFBP-2 in vitro und in vivo. 
Habilitationsschrift. University of Munich (2001). 
7. Hoeflich, A., Nedbal, S., Blum, W. F., Erhard, M., Lahm, H., Brem, G., Kolb, H. 
J., Wanke, R. & Wolf, E. Growth inhibition in giant growth hormone transgenic 
mice by overexpression of insulin-like growth factor-binding protein-2. 
Endocrinology 142, 1889-98. (2001). 
8. Weber, M. M., Fottner, C., Schmidt, P., Brodowski, K. M., Gittner, K., Lahm, 
H., Engelhardt, D. & Wolf, E. Postnatal overexpression of insulin-like growth 
factor II in transgenic mice is associated with adrenocortical hyperplasia and 
enhanced steroidogenesis. Endocrinology 140, 1537-43. (1999). 
9. Hoeflich, A., Reisinger, R., Lahm, H., Kiess, W., Blum, W. F., Kolb, H. J., 
Weber, M. M. & Wolf, E. Insulin-like growth factor-binding protein 2 in 
tumorigenesis: protector or promoter? Cancer Res 61, 8601-10. (2001). 
10. Hoeflich, A., Fettscher, O., Lahm, H., Blum, W. F., Kolb, H. J., Engelhardt, D., 
Wolf, E. & Weber, M. M. Overexpression of insulin-like growth factor-binding 
protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor 
cells. Cancer Res 60, 834-8. (2000). 
11. Tonshoff, B., Blum, W. F., Wingen, A. M. & Mehls, O. Serum insulin-like 
growth factors (IGFs) and IGF binding proteins 1, 2, and 3 in children with 
chronic renal failure: relationship to height and glomerular filtration rate. The 
European Study Group for Nutritional Treatment of Chronic Renal Failure in 
Childhood. J Clin Endocrinol Metab 80, 2684-91. (1995). 
12. Horney, M. J., Shirley, D. W., Kurtz, D. T. & Rosenzweig, S. A. Elevated 
glucose increases mesangial cell sensitivity to insulin-like growth factor I. Am J 
Physiol 274, F1045-53. (1998). 
13. Matsell, D. G., Bennett, T., Goodyer, P., Goodyer, C. & Han, V. K. The 
pathogenesis of multicystic dysplastic kidney disease: insights from the study 
of fetal kidneys. Lab Invest 74, 883-93 (1996). 
14. Wanke, R., Wolf, E., Brem, G., Hermanns, W. Physiology and pathology of 
growth - studies in GH transgenic mice. J Anim Breed Genet 113, 445-456 
(1996). 
15. Cecim, M., Alvarez-Sanz, M., Van de Kar, L., Milton, S. & Bartke, A. Increased 
plasma corticosterone levels in bovine growth hormone (bGH) transgenic 
mice: effects of ACTH, GH and IGF-I on in vitro adrenal corticosterone 
production. Transgenic Res 5, 187-92. (1996). 
 
-131- 
References 
16. Cecim, M., Ghosh, P. K., Esquifino, A. I., Began, T., Wagner, T. E., Yun, J. S. 
& Bartke, A. Elevated corticosterone levels in transgenic mice expressing 
human or bovine growth hormone genes. Neuroendocrinology 53, 313-6. 
(1991). 
17. Wolf, E. W., R. Growth hormone overproduction in transgenic mice: 
Phenotypic alterations and deduced animal models. In: Welfare aspects of 
transgenic animals (van Zutphen, L. F. M., van der Meer, M., edts.) Springer 
Verlag, Berlin. (1997). 
18. Feld, S. & Hirschberg, R. Growth hormone, the insulin-like growth factor 
system, and the kidney. Endocr Rev 17, 423-80. (1996). 
19. Kopchick, J. J. & Andry, J. M. Growth hormone (GH), GH receptor, and signal 
transduction. Mol Genet Metab 71, 293-314 (2000). 
20. Robinson, I. C. The growth hormone secretory pattern: a response to 
neuroendocrine signals. Acta Paediatr Scand Suppl 372, 70-8; discussion 79-
80 (1991). 
21. Clark, R. G., Carlsson, L. M. & Robinson, I. C. Growth hormone secretory 
profiles in conscious female rats. J Endocrinol 114, 399-407 (1987). 
22. Chene, N., Martal, J., de la Llosa, P. & Charrier, J. Growth hormones. II. 
Structure-function relationships. Reprod Nutr Dev 29, 1-25 (1989). 
23. Muller, E. E., Locatelli, V. & Cocchi, D. Neuroendocrine control of growth 
hormone secretion. Physiol Rev 79, 511-607 (1999). 
24. Tuggle, C. K. & Trenkle, A. Control of growth hormone synthesis. Domest 
Anim Endocrinol 13, 1-33 (1996). 
25. Scacchi, M., Ida Pincelli, A. & Cavagnini, F. Nutritional status in the 
neuroendocrine control of growth hormone secretion: the model of anorexia 
nervosa. Front Neuroendocrinol 24, 200-24 (2003). 
26. Bermann, M., Jaffe, C. A., Tsai, W., DeMott-Friberg, R. & Barkan, A. L. 
Negative feedback regulation of pulsatile growth hormone secretion by insulin-
like growth factor I. Involvement of hypothalamic somatostatin. J Clin Invest 
94, 138-45 (1994). 
27. Zhang, Y., Jiang, J., Kopchick, J. J. & Frank, S. J. Disulfide linkage of growth 
hormone (GH) receptors (GHR) reflects GH-induced GHR dimerization. 
Association of JAK2 with the GHR is enhanced by receptor dimerization. J Biol 
Chem 274, 33072-84 (1999). 
28. Martinez, V., Balbin, M., Ordonez, F. A., Rodriguez, J., Garcia, E., Medina, A. 
& Santos, F. Hepatic expression of growth hormone receptor/binding protein 
and insulin-like growth factor I genes in uremic rats. Influence of nutritional 
deficit. Growth Horm IGF Res 9, 61-8 (1999). 
29. Shuto, Y., Nakano, T., Sanno, N., Domoto, H., Sugihara, H. & Wakabayashi, I. 
Reduced growth hormone receptor messenger ribonucleic acid in an aged 
man with chronic malnutrition and growth hormone resistance. J Clin 
Endocrinol Metab 84, 2320-3 (1999). 
30. Bennett, P. A., Levy, A., Carmignac, D. F., Robinson, I. C. & Lightman, S. L. 
Differential regulation of the growth hormone receptor gene: effects of 
dexamethasone and estradiol. Endocrinology 137, 3891-6 (1996). 
31. Meinhardt, U., Eble, A., Besson, A., Strasburger, C. J., Sraer, J. D. & Mullis, P. 
E. Regulation of growth-hormone-receptor gene expression by growth 
hormone and pegvisomant in human mesangial cells. Kidney Int 64, 421-30 
(2003). 
 
-132- 
References 
32. Dastot, F., Duquesnoy, P., Sobrier, M. L., Goossens, M. & Amselem, S. 
Evolutionary divergence of the truncated growth hormone receptor isoform in 
its ability to generate a soluble growth hormone binding protein. Mol Cell 
Endocrinol 137, 79-84 (1998). 
33. Baumann, G., Amburn, K. & Shaw, M. A. The circulating growth hormone 
(GH)-binding protein complex: a major constituent of plasma GH in man. 
Endocrinology 122, 976-84 (1988). 
34. Hokken-Koelega, A. C., Hackeng, W. H., Stijnen, T., Wit, J. M., de Muinck 
Keizer-Schrama, S. M. & Drop, S. L. Twenty-four-hour plasma growth 
hormone (GH) profiles, urinary GH excretion, and plasma insulin-like growth 
factor-I and -II levels in prepubertal children with chronic renal insufficiency 
and severe growth retardation. J Clin Endocrinol Metab 71, 688-95 (1990). 
35. Iida, K., Del Rincon, J. P., Kim, D. S., Itoh, E., Nass, R., Coschigano, K. T., 
Kopchick, J. J. & Thorner, M. O. Tissue-specific regulation of growth hormone 
(GH) receptor and insulin-like growth factor-I gene expression in the pituitary 
and liver of GH deficient (lit/lit) mice and transgenic mice that overexpress 
bGH or a bGH antagonist. Endocrinology (2004). 
36. Chen, N. Y., Chen, W. Y. & Kopchick, J. J. Liver and kidney growth hormone 
(GH) receptors are regulated differently in diabetic GH and GH antagonist 
transgenic mice. Endocrinology 138, 1988-94 (1997). 
37. Nedbal, S. Effects and interactions of growth hormone (GH) and insulin-like 
growth factor-binding protein-2 (IGFBP-2) in transgenic mice. Thesis, 
University of Munich. (2001). 
38. Blundell, T. L. & Humbel, R. E. Hormone families: pancreatic hormones and 
homologous growth factors. Nature 287, 781-7 (1980). 
39. Ohlsson, C., Sjogren, K., Jansson, J. O. & Isaksson, O. G. The relative 
importance of endocrine versus autocrine/paracrine insulin- like growth factor-I 
in the regulation of body growth. Pediatr Nephrol 14, 541-3. (2000). 
40. Dupont, J. & Holzenberger, M. Biology of insulin-like growth factors in 
development. Birth Defects Res Part C Embryo Today 69, 257-71 (2003). 
41. Yakar, S., Liu, J. L., Stannard, B., Butler, A., Accili, D., Sauer, B. & LeRoith, D. 
Normal growth and development in the absence of hepatic insulin-like growth 
factor I. Proc Natl Acad Sci U S A 96, 7324-9. (1999). 
42. Sjogren, K., Liu, J. L., Blad, K., Skrtic, S., Vidal, O., Wallenius, V., LeRoith, D., 
Tornell, J., Isaksson, O. G., Jansson, J. O. & Ohlsson, C. Liver-derived insulin-
like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not 
required for postnatal body growth in mice. Proc Natl Acad Sci U S A 96, 
7088-92. (1999). 
43. Daughaday, W. H. Growth hormone axis overview--somatomedin hypothesis. 
Pediatr Nephrol 14, 537-40. (2000). 
44. Baxter, R. C. Insulin-like growth factor (IGF)-binding proteins: interactions with 
IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab 278, E967-76 
(2000). 
45. Pantaleon, M., Jericho, H., Rabnott, G. & Kaye, P. L. The role of insulin-like 
growth factor II and its receptor in mouse preimplantation development. 
Reprod Fertil Dev 15, 37-45 (2003). 
46. DaCosta, S. A., Schumaker, L. M. & Ellis, M. J. Mannose 6-phosphate/insulin-
like growth factor 2 receptor, a bona fide tumor suppressor gene or just a 
promising candidate? J Mammary Gland Biol Neoplasia 5, 85-94 (2000). 
 
-133- 
References 
47. LeRoith, D., Werner, H., Beitner-Johnson, D. & Roberts, C. T., Jr. Molecular 
and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16, 
143-63 (1995). 
48. De Meyts, P., Wallach, B., Christoffersen, C. T., Urso, B., Gronskov, K., Latus, 
L. J., Yakushiji, F., Ilondo, M. M. & Shymko, R. M. The insulin-like growth 
factor-I receptor. Structure, ligand-binding mechanism and signal transduction. 
Horm Res 42, 152-69 (1994). 
49. Czech, M. P. Signal transmission by the insulin-like growth factors. Cell 59, 
235-8 (1989). 
50. Tollefsen, S. E., Stoszek, R. M. & Thompson, K. Interaction of the alpha beta 
dimers of the insulin-like growth factor I receptor is required for receptor 
autophosphorylation. Biochemistry 30, 48-54 (1991). 
51. Mulroney, S. E., Haramati, A., Werner, H., Bondy, C., Roberts, C. T., Jr. & 
LeRoith, D. Altered expression of insulin-like growth factor-I (IGF-I) and IGF 
receptor genes after unilateral nephrectomy in immature rats. Endocrinology 
130, 249-56 (1992). 
52. Werner, H., Shen-Orr, Z., Stannard, B., Burguera, B., Roberts, C. T., Jr. & 
LeRoith, D. Experimental diabetes increases insulinlike growth factor I and II 
receptor concentration and gene expression in kidney. Diabetes 39, 1490-7 
(1990). 
53. Ludwig, T., Eggenschwiler, J., Fisher, P., D'Ercole, A. J., Davenport, M. L. & 
Efstratiadis, A. Mouse mutants lacking the type 2 IGF receptor (IGF2R) are 
rescued from perinatal lethality in Igf2 and Igf1r null backgrounds. Dev Biol 
177, 517-35 (1996). 
54. Nissley, S. P., Kiess, W., Sklar, M., M. The insulin-like growth factor 
II/mannose-6-phosphate receptor: In: LeRoith, D. (eds.) Insulin-like growth 
factors: Cellular and Molecular Aspects. CRC Press, Boca Raton. 111-150 
(1991). 
55. Funk, B., Kessler, U., Eisenmenger, W., Hansmann, A., Kolb, H. J. & Kiess, 
W. Expression of the insulin-like growth factor-II/mannose-6-phosphate 
receptor in multiple human tissues during fetal life and early infancy. J Clin 
Endocrinol Metab 75, 424-31 (1992). 
56. Pfuender, M., Sauerwein, H., Funk, B., Kessler, U., Barenton, B., Schwarz, H. 
P., Hoeflich, A. & Kiess, W. The insulin-like growth factor-II/mannose-6-
phosphate receptor is present in fetal bovine tissues throughout gestation. 
Domest Anim Endocrinol 12, 317-24 (1995). 
57. Sklar, M. M., Thomas, C. L., Municchi, G., Roberts, C. T., Jr., LeRoith, D., 
Kiess, W. & Nissley, P. Developmental expression of rat insulin-like growth 
factor-II/mannose 6-phosphate receptor messenger ribonucleic acid. 
Endocrinology 130, 3484-91 (1992). 
58. Kim, H. S., Nagalla, S. R., Oh, Y., Wilson, E., Roberts, C. T., Jr. & Rosenfeld, 
R. G. Identification of a family of low-affinity insulin-like growth factor binding 
proteins (IGFBPs): characterization of connective tissue growth factor as a 
member of the IGFBP superfamily. Proc Natl Acad Sci U S A 94, 12981-6. 
(1997). 
59. Hwa, V., Oh, Y. & Rosenfeld, R. G. The insulin-like growth factor-binding 
protein (IGFBP) superfamily. Endocr Rev 20, 761-87. (1999). 
60. Rosenfeld, R. G., Hwa, V., Wilson, L., Lopez-Bermejo, A., Buckway, C., 
Burren, C., Choi, W. K., Devi, G., Ingermann, A., Graham, D., Minniti, G., 
 
-134- 
References 
Spagnoli, A. & Oh, Y. The insulin-like growth factor binding protein 
superfamily: new perspectives. Pediatrics 104, 1018-21. (1999). 
61. Baxter, R. C., Binoux, M., Clemmons, D. R., Conover, C., Drop, S. L., Holly, J. 
M., Mohan, S., Oh, Y. & Rosenfeld, R. G. Recommendations for nomenclature 
of the insulin-like growth factor binding protein (IGFBP) superfamily. Growth 
Horm IGF Res 8, 273-4 (1998). 
62. Ferry, R. J., Jr., Cerri, R. W. & Cohen, P. Insulin-like growth factor binding 
proteins: new proteins, new functions. Horm Res 51, 53-67 (1999). 
63. Boisclair, Y. R., Rhoads, R. P., Ueki, I., Wang, J. & Ooi, G. T. The acid-labile 
subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but 
forgotten component of the circulating IGF system. J Endocrinol 170, 63-70. 
(2001). 
64. Twigg, S. M. & Baxter, R. C. Insulin-like growth factor (IGF)-binding protein 5 
forms an alternative ternary complex with IGFs and the acid-labile subunit. J 
Biol Chem 273, 6074-9 (1998). 
65. Firth, S. M. & Baxter, R. C. Cellular actions of the insulin-like growth factor 
binding proteins. Endocr Rev 23, 824-54 (2002). 
66. Guler, H. P., Zapf, J., Schmid, C. & Froesch, E. R. Insulin-like growth factors I 
and II in healthy man. Estimations of half-lives and production rates. Acta 
Endocrinol (Copenh) 121, 753-8 (1989). 
67. Hodgkinson, S. C., Davis, S. R., Moore, L. G., Henderson, H. V. & Gluckman, 
P. D. Metabolic clearance of insulin-like growth factor-II in sheep. J Endocrinol 
123, 461-8 (1989). 
68. Hoeflich, A., Reisinger, R., Schuett, B. S., Elmlinger, M. W., Russo, V. C., 
Vargas, G. A., Jehle, P. M., Lahm, H., Renner-Muller, I. & Wolf, E. Peri/nuclear 
localization of intact insulin-like growth factor binding protein-2 and a distinct 
carboxyl-terminal IGFBP-2 fragment in vivo. Biochem Biophys Res Commun 
324, 705-10 (2004). 
69. Clemmons, D. R. Role of insulin-like growth factor binding proteins in 
controlling IGF actions. Mol Cell Endocrinol 140, 19-24. (1998). 
70. Rajah, R., Katz, L., Nunn, S., Solberg, P., Beers, T., Cohen, P. Insulin-like 
growth factor binding protein proteases: Functional regulators of cell growth. 
Prog Growth Factor Res 6, 273-284 (1996). 
71. Conlon, I. & Raff, M. Size control in animal development. Cell 96, 235-44. 
(1999). 
72. Wolf, E., Lahm, H., Wu, M., Wanke, R. & Hoeflich, A. Effects of IGFBP-2 
overexpression in vitro and in vivo. Pediatr Nephrol 14, 572-8. (2000). 
73. Weber, M. M., Fottner, C. & Wolf, E. The role of the insulin-like growth factor 
system in adrenocortical tumourigenesis. Eur J Clin Invest 30 Suppl 3, 69-75. 
(2000). 
74. Tonshoff, B., Blum, W. F. & Mehls, O. Serum insulin-like growth factors and 
their binding proteins in children with end-stage renal disease. Pediatr Nephrol 
10, 269-74. (1996). 
75. Lupu, F., Terwilliger, J. D., Lee, K., Segre, G. V. & Efstratiadis, A. Roles of 
growth hormone and insulin-like growth factor 1 in mouse postnatal growth. 
Dev Biol 229, 141-62 (2001). 
76. Schneider, M. R., Lahm, H., Wu, M., Hoeflich, A. & Wolf, E. Transgenic mouse 
models for studying the functions of insulin-like growth factor-binding proteins. 
Faseb J 14, 629-40. (2000). 
 
-135- 
References 
77. Murphy, L. J. & Silha, J. V. Unexpected and unexplained phenotypes in 
transgenic models. Growth Horm IGF Res 10, 233-5 (2000). 
78. Palmiter, R. D., Brinster, R. L., Hammer, R. E., Trumbauer, M. E., Rosenfeld, 
M. G., Birnberg, N. C. & Evans, R. M. Dramatic growth of mice that develop 
from eggs microinjected with metallothionein-growth hormone fusion genes. 
Nature 300, 611-5. (1982). 
79. Brem, G., Wanke, R., Wolf, E., Buchmuller, T., Muller, M., Brenig, B. & 
Hermanns, W. Multiple consequences of human growth hormone expression 
in transgenic mice. Mol Biol Med 6, 531-47. (1989). 
80. Palmiter, R. D., Norstedt, G., Gelinas, R. E., Hammer, R. E. & Brinster, R. L. 
Metallothionein-human GH fusion genes stimulate growth of mice. Science 
222, 809-14 (1983). 
81. McGrane, M. M., de Vente, J., Yun, J., Bloom, J., Park, E., Wynshaw-Boris, 
A., Wagner, T., Rottman, F. M. & Hanson, R. W. Tissue-specific expression 
and dietary regulation of a chimeric phosphoenolpyruvate 
carboxykinase/bovine growth hormone gene in transgenic mice. J Biol Chem 
263, 11443-51. (1988). 
82. Wanke, R., Hermanns, W., Folger, S., Wolf, E. & Brem, G. Accelerated growth 
and visceral lesions in transgenic mice expressing foreign genes of the growth 
hormone family: an overview. Pediatr Nephrol 5, 513-21. (1991). 
83. Kopchick, J. J., Bellush, L. L. & Coschigano, K. T. Transgenic models of 
growth hormone action. Annu Rev Nutr 19, 437-61 (1999). 
84. Quaife, C. J., Mathews, L. S., Pinkert, C. A., Hammer, R. E., Brinster, R. L. & 
Palmiter, R. D. Histopathology associated with elevated levels of growth 
hormone and insulin-like growth factor I in transgenic mice. Endocrinology 
124, 40-8. (1989). 
85. Doi, T., Striker, L. J., Gibson, C. C., Agodoa, L. Y., Brinster, R. L. & Striker, G. 
E. Glomerular lesions in mice transgenic for growth hormone and insulinlike 
growth factor-I. I. Relationship between increased glomerular size and 
mesangial sclerosis. Am J Pathol 137, 541-52. (1990). 
86. Wanke, R., Wolf, E., Hermanns, W., Folger, S., Buchmuller, T. & Brem, G. The 
GH-transgenic mouse as an experimental model for growth research: clinical 
and pathological studies. Horm Res 37, 74-87. (1992). 
87. Wanke, R., Hermanns, W., Wolf, E. & Brem, G. Wachstum und 
Organpathologie bei exzessiver Wachstumshormonproduktion am Beispiel der 
mMT I-hGH-transgenen Maus. Verh Dtsch Ges Pathol 74, 510 (1990). 
88. Wolf, E., Rapp, K. & Brem, G. Expression of metallothionein-human growth 
hormone fusion genes in transgenic mice results in disproportionate skeletal 
gigantism. Growth Dev Aging 55, 117-27. (1991). 
89. Shea, B. T., Hammer, R. E. & Brinster, R. L. Growth allometry of the organs in 
giant transgenic mice. Endocrinology 121, 1924-30. (1987). 
90. Wanke, R., Folger, S., Hermanns, W., Wolf, E., Schams, D. & Brem, G. 
Induktion neoplastischer und nicht-neoplastischer Leberveränderungen durch 
Wachstumshormon-Überproduktion bei bGH-transgenen Mäusen. Verh Dtsch 
Ges Pathol 75, 312 (1991). 
91. Wanke, R., Milz, S., Rieger, N., Ogiolda, L., Renner-Muller, I., Brem, G., 
Hermanns, W. & Wolf, E. Overgrowth of skin in growth hormone transgenic 
mice depends on the presence of male gonads. J Invest Dermatol 113, 967-
71. (1999). 
 
-136- 
References 
92. Wolf, E., Kahnt, E., Ehrlein, J., Hermanns, W., Brem, G. & Wanke, R. Effects 
of long-term elevated serum levels of growth hormone on life expectancy of 
mice: lessons from transgenic animal models. Mech Ageing Dev 68, 71-87. 
(1993). 
93. Bartke, A., Brown-Borg, H., Mattison, J., Kinney, B., Hauck, S. & Wright, C. 
Prolonged longevity of hypopituitary dwarf mice. Exp Gerontol 36, 21-8 (2001). 
94. Longo, V. D. & Finch, C. E. Evolutionary medicine: from dwarf model systems 
to healthy centenarians? Science 299, 1342-6 (2003). 
95. Snell, G. D. Dwarf, a new Mendelian recessive character of the house mouse. 
Proc Natl Acad Sci U S A 15, 733-734 (1929). 
96. Li, S., Crenshaw, E. B., 3rd, Rawson, E. J., Simmons, D. M., Swanson, L. W. 
& Rosenfeld, M. G. Dwarf locus mutants lacking three pituitary cell types result 
from mutations in the POU-domain gene pit-1. Nature 347, 528-33 (1990). 
97. Sornson, M. W., Wu, W., Dasen, J. S., Flynn, S. E., Norman, D. J., O'Connell, 
S. M., Gukovsky, I., Carriere, C., Ryan, A. K., Miller, A. P., Zuo, L., 
Gleiberman, A. S., Andersen, B., Beamer, W. G. & Rosenfeld, M. G. Pituitary 
lineage determination by the Prophet of Pit-1 homeodomain factor defective in 
Ames dwarfism. Nature 384, 327-33 (1996). 
98. Eicher, E. M. & Beamer, W. G. Inherited ateliotic dwarfism in mice. 
Characteristics of the mutation, little, on chromosome 6. J Hered 67, 87-91 
(1976). 
99. Zhou, Y., Xu, B. C., Maheshwari, H. G., He, L., Reed, M., Lozykowski, M., 
Okada, S., Cataldo, L., Coschigamo, K., Wagner, T. E., Baumann, G. & 
Kopchick, J. J. A mammalian model for Laron syndrome produced by targeted 
disruption of the mouse growth hormone receptor/binding protein gene (the 
Laron mouse). Proc Natl Acad Sci U S A 94, 13215-20 (1997). 
100. Fowden, A. L. Endocrine regulation of fetal growth. Reprod Fertil Dev 7, 351-
63 (1995). 
101. Garcia-Aragon, J., Lobie, P. E., Muscat, G. E., Gobius, K. S., Norstedt, G. & 
Waters, M. J. Prenatal expression of the growth hormone (GH) 
receptor/binding protein in the rat: a role for GH in embryonic and fetal 
development? Development 114, 869-76 (1992). 
102. Pantaleon, M., Whiteside, E. J., Harvey, M. B., Barnard, R. T., Waters, M. J. & 
Kaye, P. L. Functional growth hormone (GH) receptors and GH are expressed 
by preimplantation mouse embryos: a role for GH in early embryogenesis? 
Proc Natl Acad Sci U S A 94, 5125-30 (1997). 
103. Salmon, W. D., Jr. & Daughaday, W. H. A hormonally controlled serum factor 
which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 49, 
825-36 (1957). 
104. Mathews, L. S., Norstedt, G. & Palmiter, R. D. Regulation of insulin-like growth 
factor I gene expression by growth hormone. Proc Natl Acad Sci U S A 83, 
9343-7 (1986). 
105. Newman, C. B. Medical therapy for acromegaly. Endocrinol Metab Clin North 
Am 28, 171-90 (1999). 
106. Colao, A., Ferone, D., Marzullo, P. & Lombardi, G. Systemic complications of 
acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25, 
102-52 (2004). 
107. Toogood, A. A. Growth hormone (GH) status and body composition in normal 
ageing and in elderly adults with GH deficiency. Horm Res 60, 105-11 (2003). 
 
-137- 
References 
108. Okada, S. & Kopchick, J. J. Biological effects of growth hormone and its 
antagonist. Trends Mol Med 7, 126-32 (2001). 
109. Yoshizato, H., Fujikawa, T., Soya, H., Tanaka, M. & Nakashima, K. The 
growth hormone (GH) gene is expressed in the lateral hypothalamus: 
enhancement by GH-releasing hormone and repression by restraint stress. 
Endocrinology 139, 2545-51 (1998). 
110. Sonksen, P. H., Salomon, F. & Cuneo, R. Metabolic effects of hypopituitarism 
and acromegaly. Horm Res 36 Suppl 1, 27-31 (1991). 
111. Ganda, O. P. S., D. C. Growth hormone, acromegaly, and diabetes. Diabetes 
Rev 1, 286-300 (1993). 
112. Valera, A., Rodriguez-Gil, J. E., Yun, J. S., McGrane, M. M., Hanson, R. W. & 
Bosch, F. Glucose metabolism in transgenic mice containing a chimeric P-
enolpyruvate carboxykinase/bovine growth hormone gene. Faseb J 7, 791-
800 (1993). 
113. Costa, C., Solanes, G., Visa, J. & Bosch, F. Transgenic rabbits 
overexpressing growth hormone develop acromegaly and diabetes mellitus. 
Faseb J 12, 1455-60 (1998). 
114. Lee, P. D., Durham, S. K., Martinez, V., Vasconez, O., Powell, D. R. & 
Guevara-Aguirre, J. Kinetics of insulin-like growth factor (IGF) and IGF-binding 
protein responses to a single dose of growth hormone. J Clin Endocrinol 
Metab 82, 2266-74 (1997). 
115. Scanes, C. G. D., W. H. Growth hormone action: Growth. In "Growth 
Hormone" (S. Harvey, C. G. Scanes, and W. H. Daughaday, eds.). CRC 
Press, Boca Raton, FL., 351-370 (1995). 
116. Olivecrona, H., Hilding, A., Ekstrom, C., Barle, H., Nyberg, B., Moller, C., 
Delhanty, P. J., Baxter, R. C., Angelin, B., Ekstrom, T. J. & Tally, M. Acute and 
short-term effects of growth hormone on insulin-like growth factors and their 
binding proteins: serum levels and hepatic messenger ribonucleic acid 
responses in humans. J Clin Endocrinol Metab 84, 553-60 (1999). 
117. Olivecrona, H., Hilding, A., Ekstrom, C., Barle, H., Nyberg, B., Moller, C., 
Delhanty, P. J., Baxter, R. C., Angelin, B., Ekstrom, T. J. & Tally, M. Acute and 
short-term effects of growth hormone on insulin-like growth factors and their 
binding proteins: serum levels and hepatic messenger ribonucleic acid 
responses in humans. J Clin Endocrinol Metab 84, 553-60. (1999). 
118. Donahue, L. R. & Beamer, W. G. Growth hormone deficiency in 'little' mice 
results in aberrant body composition, reduced insulin-like growth factor-I and 
insulin-like growth factor-binding protein-3 (IGFBP-3), but does not affect 
IGFBP-2, -1 or -4. J Endocrinol 136, 91-104. (1993). 
119. Camacho-Hubner, C., Clemmons, D. R. & D'Ercole, A. J. Regulation of insulin-
like growth factor (IGF) binding proteins in transgenic mice with altered 
expression of growth hormone and IGF-I. Endocrinology 129, 1201-6. (1991). 
120. Lemmey, A. B., Glassford, J., Flick-Smith, H. C., Holly, J. M. & Pell, J. M. 
Differential regulation of tissue insulin-like growth factor-binding protein 
(IGFBP)-3, IGF-I and IGF type 1 receptor mRNA levels, and serum IGF-I and 
IGFBP concentrations by growth hormone and IGF-I. J Endocrinol 154, 319-
28 (1997). 
121. Lewitt, M. S., Saunders, H., Phuyal, J. L. & Baxter, R. C. Complex formation 
by human insulin-like growth factor-binding protein-3 and human acid-labile 
subunit in growth hormone-deficient rats. Endocrinology 134, 2404-9 (1994). 
 
-138- 
References 
122. Rosenfeld, R. G., Rosenbloom, A. L. & Guevara-Aguirre, J. Growth hormone 
(GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 15, 369-
90 (1994). 
123. List, E. O., Coschigano, K. T. & Kopchick, J. J. Growth hormone 
receptor/binding protein (GHR/BP) knockout mice: a 3-year update. Mol Genet 
Metab 73, 1-10 (2001). 
124. Kopchick, J. J. & Laron, Z. Is the Laron mouse an accurate model of Laron 
syndrome? Mol Genet Metab 68, 232-6 (1999). 
125. Laron, Z., Avitur, Y., Klinger, B. Insulin resistance in Laron syndrome (primary 
insulin-like growth factor-I [IGF-I] deficiency) and effect of IGF-I replacement 
therapy. J Pediatr Endocrinol Metab 10, 105-115 (1997). 
126. Mathews, L. S., Hammer, R. E., Behringer, R. R., D'Ercole, A. J., Bell, G. I., 
Brinster, R. L. & Palmiter, R. D. Growth enhancement of transgenic mice 
expressing human insulin-like growth factor I. Endocrinology 123, 2827-33 
(1988). 
127. Doi, T., Striker, L. J., Quaife, C., Conti, F. G., Palmiter, R., Behringer, R., 
Brinster, R. & Striker, G. E. Progressive glomerulosclerosis develops in 
transgenic mice chronically expressing growth hormone and growth hormone 
releasing factor but not in those expressing insulinlike growth factor-1. Am J 
Pathol 131, 398-403. (1988). 
128. Wolf, E., Hoeflich, A. & Lahm, H. What is the function of IGF-II in postnatal 
life? Answers from transgenic mouse models. Growth Horm IGF Res 8, 185-
93. (1998). 
129. Wolf, E., Kramer, R., Blum, W. F., Foll, J. & Brem, G. Consequences of 
postnatally elevated insulin-like growth factor-II in transgenic mice: endocrine 
changes and effects on body and organ growth. Endocrinology 135, 1877-86. 
(1994). 
130. Wilson, D. M., Thomas, J. A., Hamm, T. E., Jr., Wyche, J., Hintz, R. L. & 
Rosenfeld, R. G. Transplantation of insulin-like growth factor-II-secreting 
tumors into nude rodents. Endocrinology 120, 1896-901 (1987). 
131. Koea, J. B., Breier, B. H., Shaw, J. H. & Gluckman, P. D. A possible role for 
IGE-II: evidence in sheep for in vivo regulation of IGF-I mediated protein 
anabolism. Endocrinology 130, 2423-5 (1992). 
132. Baker, J., Liu, J. P., Robertson, E. J. & Efstratiadis, A. Role of insulin-like 
growth factors in embryonic and postnatal growth. Cell 75, 73-82 (1993). 
133. DeChiara, T. M., Efstratiadis, A. & Robertson, E. J. A growth-deficiency 
phenotype in heterozygous mice carrying an insulin-like growth factor II gene 
disrupted by targeting. Nature 345, 78-80 (1990). 
134. Powell-Braxton, L., Hollingshead, P., Warburton, C., Dowd, M., Pitts-Meek, S., 
Dalton, D., Gillett, N. & Stewart, T. A. IGF-I is required for normal embryonic 
growth in mice. Genes Dev 7, 2609-17 (1993). 
135. Liu, J. P., Baker, J., Perkins, A. S., Robertson, E. J. & Efstratiadis, A. Mice 
carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) 
and type 1 IGF receptor (Igf1r). Cell 75, 59-72 (1993). 
136. Woods, K. A., Camacho-Hubner, C., Savage, M. O. & Clark, A. J. Intrauterine 
growth retardation and postnatal growth failure associated with deletion of the 
insulin-like growth factor I gene. N Engl J Med 335, 1363-7 (1996). 
137. Efstratiadis, A. Genetics of mouse growth. Int J Dev Biol 42, 955-76 (1998). 
138. Sauer, B. Inducible gene targeting in mice using the Cre/lox system. Methods 
14, 381-92 (1998). 
 
-139- 
References 
139. Yakar, S., Liu, J. L., Fernandez, A. M., Wu, Y., Schally, A. V., Frystyk, J., 
Chernausek, S. D., Mejia, W. & Le Roith, D. Liver-specific igf-1 gene deletion 
leads to muscle insulin insensitivity. Diabetes 50, 1110-8 (2001). 
140. Yakar, S., Setser, J., Zhao, H., Stannard, B., Haluzik, M., Glatt, V., Bouxsein, 
M. L., Kopchick, J. J. & LeRoith, D. Inhibition of growth hormone action 
improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest 113, 96-
105 (2004). 
141. Holzenberger, M., Leneuve, P., Hamard, G., Ducos, B., Perin, L., Binoux, M. & 
Le Bouc, Y. A targeted partial invalidation of the insulin-like growth factor I 
receptor gene in mice causes a postnatal growth deficit. Endocrinology 141, 
2557-66 (2000). 
142. Holzenberger, M., Dupont, J., Ducos, B., Leneuve, P., Geloen, A., Even, P. C., 
Cervera, P. & Le Bouc, Y. IGF-1 receptor regulates lifespan and resistance to 
oxidative stress in mice. Nature 421, 182-7 (2003). 
143. Lau, M. M., Stewart, C. E., Liu, Z., Bhatt, H., Rotwein, P. & Stewart, C. L. Loss 
of the imprinted IGF2/cation-independent mannose 6-phosphate receptor 
results in fetal overgrowth and perinatal lethality. Genes Dev 8, 2953-63 
(1994). 
144. Wang, Z. Q., Fung, M. R., Barlow, D. P. & Wagner, E. F. Regulation of 
embryonic growth and lysosomal targeting by the imprinted Igf2/Mpr gene. 
Nature 372, 464-7 (1994). 
145. Pintar, J. E., Cerro, J. A. & Wood, T. L. Genetic approaches to the function of 
insulin-like growth factor- binding proteins during rodent development. Horm 
Res 45, 172-7 (1996). 
146. Pintar, J., Schuller, A., Bradshaw, S., Cerro, J., and Grewal, A. Genetic 
disruption of IGF binding proteins. In Molecular Mechanisms to Regulate the 
Activities of Insulin-like Growth Factors (Takano, K., Hizuka, N., and 
Takahashi, S.-I., eds.) Elsevier Science, Amsterdam, The Netherlands. 65-70 
(1998). 
147. Zhou, R., Flaswinkel, H., Schneider, M. R., Lahm, H., Hoeflich, A., Wanke, R. 
& Wolf, E. Insulin-like growth factor-binding protein-4 inhibits growth of the 
thymus in transgenic mice. J Mol Endocrinol 32, 349-64 (2004). 
148. Mazerbourg, S., Callebaut, I., Zapf, J., Mohan, S., Overgaard, M. & Monget, P. 
Up date on IGFBP-4: regulation of IGFBP-4 levels and functions, in vitro and 
in vivo. Growth Horm IGF Res 14, 71-84 (2004). 
149. Devlin, R. D., Du, Z., Buccilli, V., Jorgetti, V. & Canalis, E. Transgenic mice 
overexpressing insulin-like growth factor binding protein-5 display transiently 
decreased osteoblastic function and osteopenia. Endocrinology 143, 3955-62 
(2002). 
150. Tonner, E., Barber, M. C., Allan, G. J., Beattie, J., Webster, J., Whitelaw, C. B. 
& Flint, D. J. Insulin-like growth factor binding protein-5 (IGFBP-5) induces 
premature cell death in the mammary glands of transgenic mice. Development 
129, 4547-57 (2002). 
151. Bienvenu, G., Seurin, D., Grellier, P., Froment, P., Baudrimont, M., Monget, 
P., Le Bouc, Y. & Babajko, S. Insulin-like growth factor binding protein-6 
transgenic mice: postnatal growth, brain development, and reproduction 
abnormalities. Endocrinology 145, 2412-20 (2004). 
152. Hoeflich, A., Wu, M., Mohan, S., Foll, J., Wanke, R., Froehlich, T., Arnold, G. 
J., Lahm, H., Kolb, H. J. & Wolf, E. Overexpression of insulin-like growth 
 
-140- 
References 
factor-binding protein-2 in transgenic mice reduces postnatal body weight 
gain. Endocrinology 140, 5488-96. (1999). 
153. Hoeflich, A., Schmidt, P., Foll, J., Rottmann, O., Weber, M. M., Kolb, H. J., 
Pirchner, F. & Wolf, E. Altered growth of mice divergently selected for body 
weight is associated with complex changes in the growth hormone/insulin-like 
growth factor system. Growth Horm IGF Res 8, 113-23 (1998). 
154. Mesiano, S. & Jaffe, R. B. Developmental and functional biology of the primate 
fetal adrenal cortex. Endocr Rev 18, 378-403 (1997). 
155. Sillence, M. N. & Etherton, T. D. Chronic effects of recombinant porcine 
growth hormone on adrenal weight and activity in pigs. J Anim Sci 67, 1740-3 
(1989). 
156. Coyne, M. D., Alpert, L. C., Harter, K. C. & Nunez, A. Effect of the growth 
hormone-secreting tumor StW5 on pituitary and adrenal gland function in rats. 
Horm Res 14, 36-46 (1981). 
157. Lewinski, A., Bartke, A., Esquifino, A., Sewerynek, E. & Steger, R. W. Adrenal 
catecholamine content: effects of congenital GH, PRL and TSH deficiency and 
of hormone replacement therapy in the male mouse. Exp Clin Endocrinol 87, 
176-82 (1986). 
158. Merola, B., Rossi, E., Colao, A., Cataldi, M., Longobardi, S., Schettini, G. & 
Lombardi, G. Effect of a short-term treatment with recombinant growth 
hormone (GH) on adrenal responsiveness to corticotrophin stimulation in 
children affected by isolated GH deficiency. J Clin Endocrinol Metab 74, 1210-
4 (1992). 
159. Hoeflich, A., Weber, M. M., Fisch, T., Nedbal, S., Fottner, C., Elmlinger, M. W., 
Wanke, R. & Wolf, E. Insulin-like growth factor binding protein 2 (IGFBP-2) 
separates hypertrophic and hyperplastic effects of growth hormone (GH)/IGF-I 
excess on adrenocortical cells in vivo. Faseb J 16, 1721-31. (2002). 
160. Tiong, T. S. & Herington, A. C. Tissue distribution, characterization, and 
regulation of messenger ribonucleic acid for growth hormone receptor and 
serum binding protein in the rat. Endocrinology 129, 1628-34 (1991). 
161. Mercado, M., DaVila, N., McLeod, J. F. & Baumann, G. Distribution of growth 
hormone receptor messenger ribonucleic acid containing and lacking exon 3 
in human tissues. J Clin Endocrinol Metab 78, 731-5 (1994). 
162. Michl, P., Engelhardt, D., Oberneder, R. & Weber, M. M. Growth hormone has 
no direct effect on human adrenal steroid and insulin-like growth factor-binding 
protein secretion. Endocr Res 25, 281-93 (1999). 
163. l'Allemand, D., Penhoat, A., Lebrethon, M. C., Ardevol, R., Baehr, V., Oelkers, 
W. & Saez, J. M. Insulin-like growth factors enhance steroidogenic enzyme 
and corticotropin receptor messenger ribonucleic acid levels and corticotropin 
steroidogenic responsiveness in cultured human adrenocortical cells. J Clin 
Endocrinol Metab 81, 3892-7 (1996). 
164. l'Allemand, D., Penhoat, A., Blum, W. & Saez, J. M. Is there a local IGF-
system in human adrenocortical cells? Mol Cell Endocrinol 140, 169-73 
(1998). 
165. Ilvesmaki, V., Blum, W. F. & Voutilainen, R. Insulin-like growth factor-II in 
human fetal adrenals: regulation by ACTH, protein kinase C and growth 
factors. J Endocrinol 137, 533-42 (1993). 
166. Coulter, C. L., Goldsmith, P. C., Mesiano, S., Voytek, C. C., Martin, M. C., 
Han, V. K. & Jaffe, R. B. Functional maturation of the primate fetal adrenal in 
 
-141- 
References 
vivo: I. Role of insulin-like growth factors (IGFs), IGF-I receptor, and IGF 
binding proteins in growth regulation. Endocrinology 137, 4487-98 (1996). 
167. Han, V. K., Lu, F., Bassett, N., Yang, K. P., Delhanty, P. J. & Challis, J. R. 
Insulin-like growth factor-II (IGF-II) messenger ribonucleic acid is expressed in 
steroidogenic cells of the developing ovine adrenal gland: evidence of an 
autocrine/paracrine role for IGF-II. Endocrinology 131, 3100-9 (1992). 
168. Rotwein, P., Pollock, K. M., Watson, M. & Milbrandt, J. D. Insulin-like growth 
factor gene expression during rat embryonic development. Endocrinology 121, 
2141-4 (1987). 
169. Mesiano, S., Mellon, S. H. & Jaffe, R. B. Mitogenic action, regulation, and 
localization of insulin-like growth factors in the human fetal adrenal gland. J 
Clin Endocrinol Metab 76, 968-76 (1993). 
170. McNulty, W. P., Novy, M. J. & Walsh, S. W. Fetal and postnatal development 
of the adrenal glands in Macaca mulatta. Biol Reprod 25, 1079-89 (1981). 
171. van Dijk, J. P., Tanswell, A. K. & Challis, J. R. Insulin-like growth factor (IGF)-II 
and insulin, but not IGF-I, are mitogenic for fetal rat adrenal cells in vitro. J 
Endocrinol 119, 509-16 (1988). 
172. Mesiano, S., Katz, S. L., Lee, J. Y. & Jaffe, R. B. Insulin-like growth factors 
augment steroid production and expression of steroidogenic enzymes in 
human fetal adrenal cortical cells: implications for adrenal androgen 
regulation. J Clin Endocrinol Metab 82, 1390-6 (1997). 
173. Mesiano, S. & Jaffe, R. B. Interaction of insulin-like growth factor-II and 
estradiol directs steroidogenesis in the human fetal adrenal toward 
dehydroepiandrosterone sulfate production. J Clin Endocrinol Metab 77, 754-8 
(1993). 
174. Fottner, C., Engelhardt, D. & Weber, M. M. Regulation of steroidogenesis by 
insulin-like growth factors (IGFs) in adult human adrenocortical cells: IGF-I 
and, more potently, IGF-II preferentially enhance androgen biosynthesis 
through interaction with the IGF-I receptor and IGF-binding proteins. J 
Endocrinol 158, 409-17. (1998). 
175. Ilvesmaki, V., Blum, W. F. & Voutilainen, R. Insulin-like growth factor binding 
proteins in the human adrenal gland. Mol Cell Endocrinol 97, 71-9 (1993). 
176. l'Allemand, D., Penhoat, A., Blum, W. & Saez, J. M. Is there a local IGF-
system in human adrenocortical cells? Mol Cell Endocrinol 140, 169-73. 
(1998). 
177. Penhoat, A., Leduque, P., Jaillard, C., Chatelain, P. G., Dubois, P. M. & Saez, 
J. M. ACTH and angiotensin II regulation of insulin-like growth factor-I and its 
binding proteins in cultured bovine adrenal cells. J Mol Endocrinol 7, 223-32. 
(1991). 
178. Conlon, M. A., Tomas, F. M., Owens, P. C., Wallace, J. C., Howarth, G. S. & 
Ballard, F. J. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates 
organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein 
concentrations in the guinea pig. J Endocrinol 146, 247-53. (1995). 
179. Le Roy, C., Li, J. Y., Stocco, D. M., Langlois, D. & Saez, J. M. Regulation by 
adrenocorticotropin (ACTH), angiotensin II, transforming growth factor-beta, 
and insulin-like growth factor I of bovine adrenal cell steroidogenic capacity 
and expression of ACTH receptor, steroidogenic acute regulatory protein, 
cytochrome P450c17, and 3beta-hydroxysteroid dehydrogenase. 
Endocrinology 141, 1599-607 (2000). 
 
-142- 
References 
180. Weber, M. M., Simmler, P., Fottner, C. & Engelhardt, D. Insulin-like growth 
factor II (IGF-II) is more potent than IGF-I in stimulating cortisol secretion from 
cultured bovine adrenocortical cells: interaction with the IGF-I receptor and 
IGF-binding proteins. Endocrinology 136, 3714-20. (1995). 
181. Stocco, D. M. & Clark, B. J. Role of the steroidogenic acute regulatory protein 
(StAR) in steroidogenesis. Biochem Pharmacol 51, 197-205 (1996). 
182. Nicol, M. R., Wang, H., Ivell, R., Morley, S. D., Walker, S. W. & Mason, J. I. 
The expression of steroidogenic acute regulatory protein (StAR) in bovine 
adrenocortical cells. Endocr Res 24, 565-9 (1998). 
183. Fujii, H., Iida, S., Tsugawa, M., Gomi, M., Moriwaki, K. & Tarui, S. Inhibitory 
effect of somatomedin C/insulin-like growth factor I on adrenocorticotropin- or 
forskolin-induced steroidogenesis in isolated rat adrenocortical cells. 
Endocrinology 126, 26-30 (1990). 
184. Leboulleux, S., Gaston, V., Boulle, N., Le Bouc, Y. & Gicquel, C. Loss of 
heterozygosity at the mannose 6-phosphate/insulin-like growth factor 2 
receptor locus: a frequent but late event in adrenocortical tumorigenesis. Eur J 
Endocrinol 144, 163-8 (2001). 
185. Penhoat, A., Rainey, W. E., Viard, I. & Saez, J. M. Regulation of adrenal cell-
differentiated functions by growth factors. Horm Res 42, 39-43 (1994). 
186. Weber, M. M., Auernhammer, C. J., Kiess, W. & Engelhardt, D. Insulin-like 
growth factor receptors in normal and tumorous adult human adrenocortical 
glands. Eur J Endocrinol 136, 296-303 (1997). 
187. Penhoat, A., Naville, D., Jaillard, C., Chatelain, P. G. & Saez, J. M. Hormonal 
regulation of insulin-like growth factor I secretion by bovine adrenal cells. J 
Biol Chem 264, 6858-62 (1989). 
188. Fottner, C., Engelhardt, D., Elmlinger, M. W. & Weber, M. M. Identification and 
characterization of insulin-like growth factor (IGF)- binding protein expression 
and secretion by adult human adrenocortical cells: differential regulation by 
IGFs and adrenocorticotropin. J Endocrinol 168, 465-74. (2001). 
189. Fottner, C., Engelhardt, D. & Weber, M. M. Characterization of insulin-like 
growth factor binding proteins (IGFBPs) secreted by bovine adrenocortical 
cells in primary culture: regulation by insulin-like growth factors (IGFs) and 
adrenocorticotropin (ACTH). Horm Metab Res 31, 203-8 (1999). 
190. Fottner, C., Spöttl, G., Engelhardt, D., Weber, M. M. The divergent effect of 
insulin-like growth factor binding protein (IGFBP)-1 on the steroidogenic effect 
of IGF-I and IGF-II in bovine adrenocortical cells is not due to its 
phosphorylation status. Growth Horm IGF Res 13, 219 (2003). 
191. Boulle, N., Logie, A., Gicquel, C., Perin, L. & Le Bouc, Y. Increased levels of 
insulin-like growth factor II (IGF-II) and IGF- binding protein-2 are associated 
with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 
83, 1713-20. (1998). 
192. Boulle, N., Baudin, E., Gicquel, C., Logie, A., Bertherat, J., Penfornis, A., 
Bertagna, X., Luton, J. P., Schlumberger, M. & Le Bouc, Y. Evaluation of 
plasma insulin-like growth factor binding protein-2 as a marker for 
adrenocortical tumors. Eur J Endocrinol 144, 29-36 (2001). 
193. Zumkeller, W. & Schofield, P. N. The role of insulin-like growth factors and 
IGF-binding proteins in the physiological and pathological processes of the 
kidney. Virchows Arch B Cell Pathol Incl Mol Pathol 62, 207-20 (1992). 
 
-143- 
References 
194. Hirschberg, R. & Adler, S. Insulin-like growth factor system and the kidney: 
physiology, pathophysiology, and therapeutic implications. Am J Kidney Dis 
31, 901-19. (1998). 
195. Chin, E. & Bondy, C. Insulin-like growth factor system gene expression in the 
human kidney. J Clin Endocrinol Metab 75, 962-8 (1992). 
196. Chin, E., Zhou, J. & Bondy, C. A. Renal growth hormone receptor gene 
expression: relationship to renal insulin-like growth factor system. 
Endocrinology 131, 3061-6 (1992). 
197. Rogers, S. A., Karl, I. E. & Hammerman, M. R. Growth hormone directly 
stimulates gluconeogenesis in canine renal proximal tubule. Am J Physiol 257, 
E751-6 (1989). 
198. Chin, E., Zhou, J., Dai, J., Baxter, R. C. & Bondy, C. A. Cellular localization 
and regulation of gene expression for components of the insulin-like growth 
factor ternary binding protein complex. Endocrinology 134, 2498-504 (1994). 
199. Esposito, C., Liu, Z. H., Striker, G. E., Phillips, C., Chen, N. Y., Chen, W. Y., 
Kopchick, J. J. & Striker, L. J. Inhibition of diabetic nephropathy by a GH 
antagonist: a molecular analysis. Kidney Int 50, 506-14. (1996). 
200. Chin, E., Zhou, J. & Bondy, C. Anatomical relationships in the patterns of 
insulin-like growth factor (IGF)-I, IGF binding protein-1, and IGF-I receptor 
gene expression in the rat kidney. Endocrinology 130, 3237-45 (1992). 
201. Abboud, H. E. Growth factors and the mesangium. J Am Soc Nephrol 2, S185-
9 (1992). 
202. Conti, F. G., Striker, L. J., Elliot, S. J., Andreani, D. & Striker, G. E. Synthesis 
and release of insulinlike growth factor I by mesangial cells in culture. Am J 
Physiol 255, F1214-9 (1988). 
203. Matejka, G. L., Eriksson, P. S., Carlsson, B. & Jennische, E. Distribution of 
IGF-I mRNA and IGF-I binding sites in the rat kidney. Histochemistry 97, 173-
80 (1992). 
204. Kobayashi, S., Clemmons, D. R. & Venkatachalam, M. A. Colocalization of 
insulin-like growth factor-binding protein with insulin-like growth factor I. Am J 
Physiol 261, F22-8 (1991). 
205. Chin, E., Michels, K. & Bondy, C. A. Partition of insulin-like growth factor 
(IGF)-binding sites between the IGF-I and IGF-II receptors and IGF-binding 
proteins in the human kidney. J Clin Endocrinol Metab 78, 156-64 (1994). 
206. Evan, A. P., Henry, D. P., Connors, B. A., Summerlin, P. & Lee, W. H. 
Analysis of insulin-like growth factors (IGF)-I, and -II, type II IGF receptor and 
IGF-binding protein-2 mRNA and peptide levels in normal and nephrectomized 
rat kidney. Kidney Int 48, 1517-29 (1995). 
207. Valentino, K. L., Pham, H., Ocrant, I. & Rosenfeld, R. G. Distribution of insulin-
like growth factor II receptor immunoreactivity in rat tissues. Endocrinology 
122, 2753-63 (1988). 
208. Cui, S., Flyvbjerg, A., Nielsen, S., Kiess, W. & Christensen, E. I. IGF-II/Man-6-
P receptors in rat kidney: apical localization in proximal tubule cells. Kidney Int 
43, 796-807 (1993). 
209. Flyvbjerg, A., Nielsen, S., Sheikh, M. I., Jacobsen, C., Orskov, H. & 
Christensen, E. I. Luminal and basolateral uptake and receptor binding of IGF-
I in rabbit renal proximal tubules. Am J Physiol 265, F624-33 (1993). 
210. Quigley, R. & Baum, M. Effects of growth hormone and insulin-like growth 
factor I on rabbit proximal convoluted tubule transport. J Clin Invest 88, 368-74 
(1991). 
 
-144- 
References 
211. Price, G. J., Berka, J. L., Edmondson, S. R., Werther, G. A. & Bach, L. A. 
Localization of mRNAs for insulin-like growth factor binding proteins 1 to 6 in 
rat kidney. Kidney Int 48, 402-11. (1995). 
212. Lindenbergh-Kortleve, D. J., Rosato, R. R., van Neck, J. W., Nauta, J., van 
Kleffens, M., Groffen, C., Zwarthoff, E. C. & Drop, S. L. Gene expression of 
the insulin-like growth factor system during mouse kidney development. Mol 
Cell Endocrinol 132, 81-91. (1997). 
213. Rabkin, R., Brody, M., Lu, L. H., Chan, C., Shaheen, A. M. & Gillett, N. 
Expression of the genes encoding the rat renal insulin-like growth factor-I 
system. J Am Soc Nephrol 6, 1511-8 (1995). 
214. Hise, M. K., Mantzouris, N. M., Lahn, J. S., Sheikh, M. S., Shao, Z. M. & 
Fontana, J. A. IGF binding protein 5 and IGF-I receptor regulation in 
hypophysectomized rat kidneys. Am J Physiol 266, F147-54 (1994). 
215. Albini, C. H., Quattrin, T., Vandlen, R. L. & MacGillivray, M. H. Quantitation of 
urinary growth hormone in children with normal and abnormal growth. Pediatr 
Res 23, 89-92 (1988). 
216. Maack, T. & Park, C. H. Endocytosis and lysosomal hydrolysis of proteins in 
proximal tubules. Methods Enzymol 191, 340-54 (1990). 
217. Haffner, D., Schaefer, F., Girard, J., Ritz, E. & Mehls, O. Metabolic clearance 
of recombinant human growth hormone in health and chronic renal failure. J 
Clin Invest 93, 1163-71 (1994). 
218. Johnson, V. & Maack, T. Renal extraction, filtration, absorption, and 
catabolism of growth hormone. Am J Physiol 233, F185-96 (1977). 
219. Johannsson, G. & Ahlmen, J. End-stage renal disease: endocrine aspects of 
treatment. Growth Horm IGF Res 13 Suppl A, S94-S101 (2003). 
220. Hirschberg, R. Bioactivity of glomerular ultrafiltrate during heavy proteinuria 
may contribute to renal tubulo-interstitial lesions: evidence for a role for 
insulin-like growth factor I. J Clin Invest 98, 116-24 (1996). 
221. Rabkin, R., Fervenza, F., Maidment, H., Ike, J., Jamison, R., Hintz, R., Bukar, 
J., Arcila, P., Gesundheit, N. IGF-I pharmacokinetics in chronic renal failure. J 
Am Soc Nephrol 5, 340 (1994). 
222. Frystyk, J., Ivarsen, P., Skjaerbaek, C., Flyvbjerg, A., Pedersen, E. B. & 
Orskov, H. Serum-free insulin-like growth factor I correlates with clearance in 
patients with chronic renal failure. Kidney Int 56, 2076-84. (1999). 
223. Wang, S. N., LaPage, J. & Hirschberg, R. Role of glomerular ultrafiltration of 
growth factors in progressive interstitial fibrosis in diabetic nephropathy. 
Kidney Int 57, 1002-14 (2000). 
224. Tang, S., Lai, K. N., Chan, T. M., Lan, H. Y., Ho, S. K. & Sacks, S. H. 
Transferrin but not albumin mediates stimulation of complement C3 
biosynthesis in human proximal tubular epithelial cells. Am J Kidney Dis 37, 
94-103 (2001). 
225. Burton, C. J., Bevington, A., Harris, K. P. & Walls, J. Growth of proximal 
tubular cells in the presence of albumin and proteinuric urine. Exp Nephrol 2, 
345-50 (1994). 
226. Jacot, T. A., Striker, G. E., Stetler-Stevenson, M. & Striker, L. J. Mesangial 
cells from transgenic mice with progressive glomerulosclerosis exhibit stable, 
phenotypic changes including undetectable MMP-9 and increased type IV 
collagen. Lab Invest 75, 791-9 (1996). 
227. Wanke, R., Wolf, E., Brem, G. & Hermanns, W. Role of podocyte damage in 
the pathogenesis of glomerulosclerosis and tubulointerstitial lesions: findings 
 
-145- 
References 
in the growth hormone transgenic mouse model of progressive nephropathy. 
Verh Dtsch Ges Pathol 85, 250-6 (2001). 
228. Rastaldi, M. P., Armelloni, S., Berra, S., Li, M., Pesaresi, M., Poczewski, H., 
Langer, B., Kerjaschki, D., Henger, A., Blattner, S. M., Kretzler, M., Wanke, R. 
& D'Amico, G. Glomerular podocytes possess the synaptic vesicle molecule 
Rab3A and its specific effector rabphilin-3a. Am J Pathol 163, 889-99 (2003). 
229. Wanke, R. Zur Morpho- und Pathogenese der progressiven 
Glomerulosklerose. Habilitationsschrift, University of Munich. (1996). 
230. Marshall, S. M., Flyvbjerg, A., Jorgensen, K. D., Weeke, J. & Orskov, H. 
Effects of growth hormone and thyroxine on kidney insulin-like growth factor-I 
and renal growth in hypophysectomized rats. J Endocrinol 136, 399-406 
(1993). 
231. Kawaguchi, H., Itoh, K., Mori, H., Hayashi, Y. & Makino, S. Renal pathology in 
rats bearing tumour-secreting growth hormone. Pediatr Nephrol 5, 533-8 
(1991). 
232. Molon-Noblot, S., Laroque, P., Prahalada, S., Stabinski, L. G., Peter, C. P., 
Duprat, P. & van Zwieten, M. J. Morphological changes in the kidney of dogs 
chronically exposed to exogenous growth hormone. Toxicol Pathol 28, 510-7 
(2000). 
233. Dullaart, R. P., Meijer, S., Marbach, P. & Sluiter, W. J. Effect of a somatostatin 
analogue, octreotide, on renal haemodynamics and albuminuria in 
acromegalic patients. Eur J Clin Invest 22, 494-502 (1992). 
234. Ogle, G. D., Rosenberg, A. R. & Kainer, G. Renal effects of growth hormone. 
I. Renal function and kidney growth. Pediatr Nephrol 6, 394-8 (1992). 
235. Gershberg, H., Heinemann, H. O. & Stumpf, H. H. Renal function studies and 
autopsy report in a patient with gigantism and acromegaly. J Clin Endocrinol 
Metab 17, 377-85 (1957). 
236. Takai, M., Izumino, K., Oda, Y., Terada, Y., Inoue, H. & Takata, M. Focal 
segmental glomerulosclerosis associated with acromegaly. Clin Nephrol 56, 
75-7 (2001). 
237. Hirschberg, R. Effects of growth hormone and IGF-I on glomerular 
ultrafiltration in growth hormone-deficient rats. Regul Pept 48, 241-50 (1993). 
238. Goya, R. G., Castelletto, L. & Sosa, Y. E. Plasma levels of growth hormone 
correlate with the severity of pathologic changes in the renal structure of aging 
rats. Lab Invest 64, 29-34 (1991). 
239. Yoshida, H., Mitarai, T., Kitamura, M., Suzuki, T., Ishikawa, H., Fogo, A. & 
Sakai, O. The effect of selective growth hormone defect in the progression of 
glomerulosclerosis. Am J Kidney Dis 23, 302-12 (1994). 
240. Flyvbjerg, A., Frystyk, J., Thorlacius-Ussing, O. & Orskov, H. Somatostatin 
analogue administration prevents increase in kidney somatomedin C and 
initial renal growth in diabetic and uninephrectomized rats. Diabetologia 32, 
261-5 (1989). 
241. Flyvbjerg, A., Bennett, W. F., Rasch, R., van Neck, J. W., Groffen, C. A., 
Kopchick, J. J. & Scarlett, J. A. Compensatory renal growth in 
uninephrectomized adult mice is growth hormone dependent. Kidney Int 56, 
2048-54. (1999). 
242. Liu, Z. Z., Kumar, A., Wallner, E. I., Wada, J., Carone, F. A. & Kanwar, Y. S. 
Trophic effect of insulin-like growth factor-I on metanephric development: 
relationship to proteoglycans. Eur J Cell Biol 65, 378-91 (1994). 
 
-146- 
References 
243. Doublier, S., Amri, K., Seurin, D., Moreau, E., Merlet-Benichou, C., Striker, G. 
E. & Gilbert, T. Overexpression of human insulin-like growth factor binding 
protein-1 in the mouse leads to nephron deficit. Pediatr Res 49, 660-6. (2001). 
244. Rogers, S. A., Powell-Braxton, L. & Hammerman, M. R. Insulin-like growth 
factor I regulates renal development in rodents. Dev Genet 24, 293-8 (1999). 
245. Baud, L., Fouqueray, B., Bellocq, A., Doublier, S. & Dumoulin, A. Growth 
hormone and somatostatin in glomerular injury. J Nephrol 12, 18-23. (1999). 
246. Johnson, D. W., Saunders, H. J., Brew, B. K., Ganesan, A., Baxter, R. C., 
Poronnik, P., Cook, D. I., Gyory, A. Z., Field, M. J. & Pollock, C. A. Human 
renal fibroblasts modulate proximal tubule cell growth and transport via the 
IGF-I axis. Kidney Int 52, 1486-96 (1997). 
247. O'Shea, M., Miller, S. B. & Hammerman, M. R. Insulin-like growth factor I and 
the kidney. Semin Nephrol 13, 96-108 (1993). 
248. Norman, J. T., Fine, L. G. Renal Growth and Hypertrophy in: Textbook of 
Nephrology. S. G. Massry & R. J. Glassock (Eds.), Baltimore; 
Williams&Wilkins. 146-158 (1995). 
249. Cheung, C. W., Vesey, D. A., Nicol, D. L. & Johnson, D. W. The roles of IGF-I 
and IGFBP-3 in the regulation of proximal tubule, and renal cell carcinoma cell 
proliferation. Kidney Int 65, 1272-9 (2004). 
250. Blazer-Yost, B. L., Watanabe, M., Haverty, T. P. & Ziyadeh, F. N. Role of 
insulin and IGF1 receptors in proliferation of cultured renal proximal tubule 
cells. Biochim Biophys Acta 1133, 329-35 (1992). 
251. Zhang, G. H., Ichimura, T., Wallin, A., Kan, M. & Stevens, J. L. Regulation of 
rat proximal tubule epithelial cell growth by fibroblast growth factors, insulin-
like growth factor-1 and transforming growth factor-beta, and analysis of 
fibroblast growth factors in rat kidney. J Cell Physiol 148, 295-305 (1991). 
252. Yap, J., Tsao, T., Fawcett, J., Fielder, P. J., Keller, G. A. & Rabkin, R. Effect of 
insulin-like growth factor binding proteins on the response of proximal tubular 
cells to insulin-like growth factor-I. Kidney Int 52, 1216-23. (1997). 
253. Gansler, T., Hsu, W. C., Gramling, T. S., Robinson, K. A., Buse, M. G., 
Blocker, N., Roy, L., Green, S., Garvin, A. J. & Sens, D. A. Growth factor 
binding and bioactivity in human kidney epithelial cell cultures. In Vitro Cell 
Dev Biol 26, 285-90 (1990). 
254. Kiley, S. C., Thornhill, B. A., Tang, S. S., Ingelfinger, J. R. & Chevalier, R. L. 
Growth factor-mediated phosphorylation of proapoptotic BAD reduces tubule 
cell death in vitro and in vivo. Kidney Int 63, 33-42 (2003). 
255. Mehls, O., Irzynjec, T., Ritz, E., Eden, S., Kovacs, G., Klaus, G., Floege, J. & 
Mall, G. Effects of rhGH and rhIGF-1 on renal growth and morphology. Kidney 
Int 44, 1251-8 (1993). 
256. Wolf, G. & Neilson, E. G. Cellular biology of tubulointerstitial growth. Curr Top 
Pathol 88, 69-97 (1995). 
257. Liu, B. & Preisig, P. A. Compensatory renal hypertrophy is mediated by a cell 
cycle-dependent mechanism. Kidney Int 62, 1650-8 (2002). 
258. Preisig, P. What makes cells grow larger and how do they do it? Renal 
hypertrophy revisited. Exp Nephrol 7, 273-83 (1999). 
259. Doi, T., Striker, L. J., Elliot, S. J., Conti, F. G. & Striker, G. E. Insulinlike growth 
factor-1 is a progression factor for human mesangial cells. Am J Pathol 134, 
395-404. (1989). 
 
-147- 
References 
260. Feld, S. M., Hirschberg, R., Artishevsky, A., Nast, C. & Adler, S. G. Insulin-like 
growth factor I induces mesangial proliferation and increases mRNA and 
secretion of collagen. Kidney Int 48, 45-51 (1995). 
261. Mooney, A., Jobson, T., Bacon, R., Kitamura, M. & Savill, J. Cytokines 
promote glomerular mesangial cell survival in vitro by stimulus-dependent 
inhibition of apoptosis. J Immunol 159, 3949-60 (1997). 
262. Conti, F. G., Striker, L. J., Lesniak, M. A., MacKay, K., Roth, J. & Striker, G. E. 
Studies on binding and mitogenic effect of insulin and insulin-like growth factor 
I in glomerular mesangial cells. Endocrinology 122, 2788-95. (1988). 
263. Gooch, J. L., Tang, Y., Ricono, J. M. & Abboud, H. E. Insulin-like growth 
factor-I induces renal cell hypertrophy via a calcineurin-dependent 
mechanism. J Biol Chem 276, 42492-500. (2001). 
264. Doublier, S., Seurin, D., Fouqueray, B., Verpont, M. C., Callard, P., Striker, L. 
J., Striker, G. E., Binoux, M. & Baud, L. Glomerulosclerosis in mice transgenic 
for human insulin-like growth factor-binding protein-1. Kidney Int 57, 2299-307. 
(2000). 
265. Gay, E., Seurin, D., Babajko, S., Doublier, S., Cazillis, M. & Binoux, M. Liver-
specific expression of human insulin-like growth factor binding protein-1 in 
transgenic mice: repercussions on reproduction, ante- and perinatal mortality 
and postnatal growth. Endocrinology 138, 2937-47. (1997). 
266. Houang, M., Cabrol, S., Perin, L., Ducos, B., Bensman, A. & Le Bouc, Y. 
Insulin-like growth factor-I (IGF-I), insulin-like growth factor binding proteins 
(IGFBP) and insulin-like growth factor type I receptor in children with various 
status of chronic renal failure. Growth Horm IGF Res 10, 332-41. (2000). 
267. Powell, D. R., Liu, F., Baker, B. K., Hinzt, R. L., Kale, A., Suwanichkul, A. & 
Durham, S. K. Effect of chronic renal failure and growth hormone therapy on 
the insulin-like growth factors and their binding proteins. Pediatr Nephrol 14, 
579-83. (2000). 
268. Hirschberg, R. & Kaysen, G. A. Insulin-like growth factor I and its binding 
proteins in the experimental nephrotic syndrome. Endocrinology 136, 1565-71. 
(1995). 
269. Tonshoff, B., Powell, D. R., Zhao, D., Durham, S. K., Coleman, M. E., 
Domene, H. M., Blum, W. F., Baxter, R. C., Moore, L. C. & Kaskel, F. J. 
Decreased hepatic insulin-like growth factor (IGF)-I and increased IGF binding 
protein-1 and -2 gene expression in experimental uremia. Endocrinology 138, 
938-46. (1997). 
270. Ulinski, T., Mohan, S., Kiepe, D., Blum, W. F., Wingen, A. M., Mehls, O. & 
Tonshoff, B. Serum insulin-like growth factor binding protein (IGFBP)-4 and 
IGFBP-5 in children with chronic renal failure: relationship to growth and 
glomerular filtration rate. The European Study Group for Nutritional Treatment 
of Chronic Renal Failure in Childhood. German Study Group for Growth 
Hormone Treatment in Chronic Renal Failure. Pediatr Nephrol 14, 589-97. 
(2000). 
271. Tonshoff, B., Veldhuis, J. D., Heinrich, U. & Mehls, O. Deconvolution analysis 
of spontaneous nocturnal growth hormone secretion in prepubertal children 
with preterminal chronic renal failure and with end-stage renal disease. Pediatr 
Res 37, 86-93. (1995). 
272. Kapila, P., Jones, J. & Rees, L. Effect of chronic renal failure and prednisolone 
on the growth hormone-insulin-like growth factor axis. Pediatr Nephrol 16, 
1099-104 (2001). 
 
-148- 
References 
273. Fukuda, I., Hizuka, N., Okubo, Y., Takano, K., Asakawa-Yasumoto, K., 
Shizume, K., Demura, H., Kimata, N., Ishikawa, N. & Toma, H. Changes in 
serum insulin-like growth factor binding protein-2, -3, and - 6 levels in patients 
with chronic renal failure following renal transplantation. Growth Horm IGF 
Res 8, 481-6. (1998). 
274. Bernstein, J., Gilbert-Barness, E. Congenital malformations of the kidney. In: 
Renal Pathology (edt. Tisher, C. C., Brenner, B. M), JB Lippincott Company, 
Philadelphia. 1278-1308 (1989). 
275. Bang, P. Valid measurements of total IGF concentrations in biological fluids: 
recommendations from the 3rd International Symposium on Insulin-like 
Growth Factors. Eur J Endocrinol 132, 338-9 (1995). 
276. Blum, W. F. & Breier, B. H. Radioimmunoassays for IGFs and IGFBPs. 
Growth Regul 4 Suppl 1, 11-9 (1994). 
277. Blum, W. F., Horn, N., Kratzsch, J., Jorgensen, J. O., Juul, A., Teale, D., 
Mohnike, K. & Ranke, M. B. Clinical studies of IGFBP-2 by radioimmunoassay. 
Growth Regul 3, 100-4 (1993). 
278. Hermanns, W., Liebig, K. & Schulz, L. C. Postembedding 
immunohistochemical demonstration of antigen in experimental polyarthritis 
using plastic embedded whole joints. Histochemistry 73, 439-46 (1981). 
279. Caulfield, J. B. Effects of varying the vehicle for OsO4 in tissue fixation. J 
Biophys Biochem Cytol 3, 827-30 (1957). 
280. Frith, C. H. Histology, adrenal gland, mouse. In Monographs of Pathologyof 
Laboratory Animals. Endocrine System (Jones, T. C., Mohr, U., and Hunt, R. 
D., eds). pp. 8 - 12 (1983). 
281. Delesse, M. A. Procede mecanique pour determiner la composition des 
roches. C. R. Acad. Sci. (Paris). 25, 544-545 (1847). 
282. Weibel, E. R. Stereological Methods. I. Practical Methods for Biological 
Morphometry. Academic Press, London. (1979). 
283. Swinyard, C. A. Methods for volumetric determination of fresh endocrine 
glands. Anatomical Records 74, 71 - 78 (1939). 
284. Sterio, D. C. The unbiased estimation of number and sizes of arbitrary 
particles using the disector. J Microsc 134, 127-36. (1984). 
285. Gundersen, H. J. G. Notes on the estimation of the numerical density of 
arbitrary profiles: The edge effect. J. Microsc. 111, 219-223 (1977). 
286. Gundersen, H. J. Stereology of arbitrary particles. A review of unbiased 
number and size estimators and the presentation of some new ones, in 
memory of William R. Thompson. J Microsc 143 ( Pt 1), 3-45 (1986). 
287. Nyengaard, J. R. Stereologic methods and their application in kidney 
research. J Am Soc Nephrol 10, 1100-23. (1999). 
288. Kriz, W. & Koepsell, H. The structural organization of the mouse kidney. Z. 
Anat. Entwickl.-Gesch. 144, 137-163 (1974). 
289. Kriz, W. & Bankir, L. A standard nomenclature for structures of the kidney. The 
Renal Commission of the International Union of Physiological Sciences 
(IUPS). Kidney Int 33, 1-7. (1988). 
290. Herbach, N. Clinical and pathological characterization of a novel transgenic 
mouse model of diabetes mellitus expressing a dominant negative glucose-
dependent insulinotropic polypeptide receptor (GIPRdn). Thesis, University of 
Munich. (2002). 
291. Glagolev. On the geometrical methods of quantitative mineralogic analysis of 
rocks. Trans. Inst. Econ. Min. 53 (1933). 
 
-149- 
References 
292. Bachmann, S., Sakai, T., Kriz, W. Nephron and collecting duct structure in the 
kidney. In: Monographs on Pathology of Laboratory Animals (Jones, T. C., 
Mohr, U., Hunt, R. D. (eds.) Springer Verlang Berlin Heidelberg New York 
London Paris Tokyo. (1986). 
293. Hirose, K., Osterby, R., Nozawa, M. & Gundersen, H. J. Development of 
glomerular lesions in experimental long-term diabetes in the rat. Kidney Int 21, 
889-95 (1982). 
294. Gundersen, H. J. Estimators of the number of objects per area unbiased by 
edge effects. Microsc Acta 81, 107-17 (1978). 
295. el Nahas, A. M. The role of growth hormone and insulin-like growth factor-I in 
experimental renal growth and scarring. Am J Kidney Dis 17, 677-9. (1991). 
296. Nakane, P. K. & Pierce, G. B., Jr. Enzyme-labeled antibodies for the light and 
electron microscopic localization of tissue antigens. J Cell Biol 33, 307-18 
(1967). 
297. Hossenlopp, P., Seurin, D., Segovia-Quinson, B., Hardouin, S. & Binoux, M. 
Analysis of serum insulin-like growth factor binding proteins using western 
blotting: use of the method for titration of the binding proteins and competitive 
binding studies. Anal Biochem 154, 138-43 (1986). 
298. Fukuda, I., Hizuka, N., Takano, K., Asakawa-Yasumoto, K., Shizume, K. & 
Demura, H. Characterization of insulin-like growth factor II (IGF-II) and IGF 
binding proteins in patients with non-islet-cell tumor hypoglycemia. Endocr J 
40, 111-9 (1993). 
299. Ketelslegers, J. M., Maiter, D., Maes, M., Underwood, L. E. & Thissen, J. P. 
Nutritional regulation of the growth hormone and insulin-like growth factor-
binding proteins. Horm Res 45, 252-7 (1996). 
300. Kasiske, B., L., Keane, W., F. Laboratory assessment of renal disease: 
clearence, urinanalysis, and renal biopsy. In: The Kidney, 5th ed. (Brenner B., 
M., edt), W. B. Saunders Company, Philadelphia. 1137-1174 (1996). 
301. Bohle, A., Mackensen-Haen, S., von Gise, H., Grund, K. E., Wehrmann, M., 
Batz, C., Bogenschutz, O., Schmitt, H., Nagy, J., Muller, C. & et al. The 
consequences of tubulo-interstitial changes for renal function in 
glomerulopathies. A morphometric and cytological analysis. Pathol Res Pract 
186, 135-44 (1990). 
302. Levey, A. S., Perrone, R. D. & Madias, N. E. Serum creatinine and renal 
function. Annu Rev Med 39, 465-90 (1988). 
303. Salomon, F., Cuneo, R. & Sonksen, P. H. Growth hormone and protein 
metabolism. Horm Res 36 Suppl 1, 41-3 (1991). 
304. Knochel, J., P., Agarwal, R. Hypophosphatemia and hyperphosphatemia. In: 
The Kidney, 5th ed. (Brenner B., M., edt), W. B. Saunders Company, 
Philadelphia. 1086-1136 (1996). 
305. Halse, J. & Haugen, H. N. Calcium and phosphate metabolism in acromegaly. 
Acta Endocrinol (Copenh) 94, 459-67 (1980). 
306. Corvilain, J. & Abramow, M. Effect of Growth Hormone on Tubular Transport 
of Phosphate in Normal and Parathyroidectomized Dogs. J Clin Invest 43, 
1608-12 (1964). 
307. Hirschberg, R., Brunori, G., Kopple, J. D. & Guler, H. P. Effects of insulin-like 
growth factor I on renal function in normal men. Kidney Int 43, 387-97 (1993). 
308. Hirschberg, R., Ding, H. & Wanner, C. Effects of insulin-like growth factor I on 
phosphate transport in cultured proximal tubule cells. J Lab Clin Med 126, 
428-34. (1995). 
 
-150- 
References 
309. Sutton, R., A., L., Dirks, J., H. Disturbances of calcium and magnesium 
metabolism. In: The Kidney, 5th ed. (Brenner B., M., edt), W. B. Saunders 
Company, Philadelphia. (1996). 
310. Aloia, J., Powell, D., Mendizibal, E. & Roginsky, M. Parathyroid function in 
acromegaly. Horm Res 6, 145-9 (1975). 
311. Berry, C. A., Ives, H. E., Floyd, C. R., Jr. Renal transport of glucose, amino 
acids, sodium, chloride, and water. In: The Kidney, 5th ed. (Brenner B., M., 
edt), W. B. Saunders Company, Philadelphia. 334-370 (1996). 
312. Dirsch, V. M., Wolf, E., Wanke, R., Schulz, R., Hermanns, W. & Vollmar, A. M. 
Effect of chronic GH overproduction on cardiac ANP expression and 
circulating ANP levels. Mol Cell Endocrinol 144, 109-18 (1998). 
313. Bengtsson, B. A., Brummer, R. J. & Bosaeus, I. Growth hormone and body 
composition. Horm Res 33, 19-24. (1990). 
314. Cecim, M., Bartke, A., Yun, J. G., Wagner, T. E. Growth allometry of 
transgenic mice expressing the mouse metallothionein/bovine growth 
hormone gene. Transgene 1, 125-132 (1993). 
315. Usala, A. L., Madigan, T., Burguera, B., Sinha, M. K., Caro, J. F., 
Cunningham, P., Powell, J. G. & Butler, P. C. Brief report: treatment of insulin-
resistant diabetic ketoacidosis with insulin-like growth factor I in an adolescent 
with insulin-dependent diabetes. N Engl J Med 327, 853-7 (1992). 
316. Zierler, K. L. & Rabinowitz, D. Effect of Very Small Concentrations of Insulin 
on Forearm Metabolism. Persistence of Its Action on Potassium and Free 
Fatty Acids without Its Effect on Glucose. J Clin Invest 43, 950-62 (1964). 
317. Kamel, K., S., Halperin, M., L., Faber, M., D., Steigerwalt, S., P., Heilig, C., W., 
Narins, R., G. Disorders of potassium balance. In: The Kidney, 5th ed. 
(Brenner B., M., edt), W. B. Saunders Company, Philadelphia. (1996). 
318. Lewinski, A., Bartke, A., Esquifino, A., Sewerynek, E. & Steger, R. W. Adrenal 
catecholamine content: effects of congenital GH, PRL and TSH deficiency and 
of hormone replacement therapy in the male mouse. Exp Clin Endocrinol 87, 
176-82. (1986). 
319. Fottner, C., Hoeflich, A., Wolf, E. & Weber, M. M. Role of the insulin-like 
growth factor system in adrenocortical growth control and carcinogenesis. 
Horm Metab Res 36, 397-405 (2004). 
320. Slootweg, M. C., Ohlsson, C., Salles, J. P., de Vries, C. P. & Netelenbos, J. C. 
Insulin-like growth factor binding proteins-2 and -3 stimulate growth hormone 
receptor binding and mitogenesis in rat osteosarcoma cells. Endocrinology 
136, 4210-7 (1995). 
321. Weber, M. M., Kiess, W., Beikler, T., Simmler, P., Reichel, M., Adelmann, B., 
Kessler, U. & Engelhardt, D. Identification and characterization of insulin-like 
growth factor I (IGF-I) and IGF-II/mannose-6-phosphate (IGF-II/M6P) 
receptors in bovine adrenal cells. Eur J Endocrinol 130, 265-70 (1994). 
322. Conlon, I. J., Dunn, G. A., Mudge, A. W. & Raff, M. C. Extracellular control of 
cell size. Nat Cell Biol 3, 918-21. (2001). 
323. Coelho, C. M. & Leevers, S. J. Do growth and cell division rates determine cell 
size in multicellular organisms? J Cell Sci 113 ( Pt 17), 2927-34 (2000). 
324. Alessi, D. R. Discovery of PDK1, one of the missing links in insulin signal 
transduction. Colworth Medal Lecture. Biochem Soc Trans 29, 1-14 (2001). 
325. Toker, A. & Newton, A. C. Cellular signaling: pivoting around PDK-1. Cell 103, 
185-8 (2000). 
 
-151- 
References 
326. Lawlor, M. A., Mora, A., Ashby, P. R., Williams, M. R., Murray-Tait, V., Malone, 
L., Prescott, A. R., Lucocq, J. M. & Alessi, D. R. Essential role of PDK1 in 
regulating cell size and development in mice. Embo J 21, 3728-38. (2002). 
327. Ottenweller, J. E., Meier, A. H., Russo, A. C. & Frenzke, M. E. Circadian 
rhythms of plasma corticosterone binding activity in the rat and the mouse. 
Acta Endocrinol (Copenh) 91, 150-7 (1979). 
328. Henkel, H. M. Hypophysial and adrenal changes in growth hormone trangenic 
mice: an investigation by immumohistochemistry, morphometry and 
radioimmunoassay. Thesis, University of Munich. (1995). 
329. Weidenfeld, J. & Feldman, S. Glucocorticoid feedback regulation of 
adrenocortical responses to neural stimuli: role of CRF-41 and corticosteroid 
type I and type II receptors. Neuroendocrinology 58, 49-56 (1993). 
330. Guler, H. P., Zapf, J., Scheiwiller, E. & Froesch, E. R. Recombinant human 
insulin-like growth factor I stimulates growth and has distinct effects on organ 
size in hypophysectomized rats. Proc Natl Acad Sci U S A 85, 4889-93 (1988). 
331. Shea, B. T., Hammer, R. E. & Brinster, R. L. Growth allometry of the organs in 
giant transgenic mice. Endocrinology 121, 1924-30 (1987). 
332. Seyer-Hansen, K., Hansen, J. & Gundersen, H. J. Renal hypertrophy in 
experimental diabetes. A morphometric study. Diabetologia 18, 501-5 (1980). 
333. Hammerman, M. R. & Miller, S. B. Renal cellular biology of growth hormone 
and insulin-like growth factor I. Pediatr Nephrol 5, 505-8 (1991). 
334. Ernst, F., Hetzel, S., Stracke, S., Czock, D., Vargas, G., Lutz, M. P., Keller, F. 
& Jehle, P. M. Renal proximal tubular cell growth and differentiation are 
differentially modulated by renotropic growth factors and tyrosine kinase 
inhibitors. Eur J Clin Invest 31, 1029-39 (2001). 
335. Senthil, D., Choudhury, G. G., Abboud, H. E., Sonenberg, N. & Kasinath, B. S. 
Regulation of protein synthesis by IGF-I in proximal tubular epithelial cells. Am 
J Physiol Renal Physiol 283, F1226-36 (2002). 
336. Schuller, A. G., Groffen, C., van Neck, J. W., Zwarthoff, E. C. & Drop, S. L. 
cDNA cloning and mRNA expression of the six mouse insulin-like growth 
factor binding proteins. Mol Cell Endocrinol 104, 57-66 (1994). 
337. Rabkin, R. & Schaefer, F. New concepts: growth hormone, insulin-like growth 
factor-I and the kidney. Growth Horm IGF Res 14, 270-6 (2004). 
338. Gröne, H.-J. Experimentielle Modelle der renalen tubulären Inaktivitätsatrophie 
und der zystischen Tubuluszellhyperplasie. Funktionelle und morphologische 
Charakteristika und klinische  Relevanz. Verh Dtsch Ges Pathol 73, 706-721 
(1989). 
339. Konda, R., Sato, H., Hatafuku, F., Nozawa, T., Ioritani, N. & Fujioka, T. 
Expression of hepatocyte growth factor and its receptor C-met in acquired 
renal cystic disease associated with renal cell carcinoma. J Urol 171, 2166-70 
(2004). 
340. Dubey, R. K., Jackson, E. K., Rupprecht, H. D. & Sterzel, R. B. Factors 
controlling growth and matrix production in vascular smooth muscle and 
glomerular mesangial cells. Curr Opin Nephrol Hypertens 6, 88-105. (1997). 
341. Haas, C. S., Schocklmann, H. O., Lang, S., Kralewski, M. & Sterzel, R. B. 
Regulatory mechanism in glomerular mesangial cell proliferation. J Nephrol 
12, 405-15. (1999). 
342. Norstedt, G. & Palmiter, R. Secretory rhythm of growth hormone regulates 
sexual differentiation of mouse liver. Cell 36, 805-12 (1984). 
 
-152- 
References 
343. Johnson, D., al-Shawi, R. & Bishop, J. O. Sexual dimorphism and growth 
hormone induction of murine pheromone-binding proteins. J Mol Endocrinol 
14, 21-34 (1995). 
344. Cavaggioni, A. & Mucignat-Caretta, C. Major urinary proteins, alpha(2U)-
globulins and aphrodisin. Biochim Biophys Acta 1482, 218-28 (2000). 
 
 
 
 
 
 
 
-153- 
Appendix 
8 Appendix 
 
8.1 Staining procedures for paraffin embedded sections 
 
8.1.1 Hemalaun & Eosine (H&E) 
 
1. Mayer’s hemalaun (Applichem, Germany)    5 min 
2. Rinse in tap water   5 min 
3. 0.5% HCl-alcohol   until slides have cleared 
4. Rinse in tap water   5 min 
5. Eosine Y (Merck, Germany)   dip 2-7 times 
6. Rinse in distilled water   3 times, 3 sec 
 
8.1.2 Periodic acid-Schiff stain (PAS) 
 
1. 1% periodic acid (Applichem, Germany) 10 min 
2. Rinse in tap water 10 min 
3. Rinse in distilled water   3 times, 3 sec 
4. Schiff‘s reagent (Merck, Germany) 30 min 
5. Rinse in tap water   5 min 
6. Mayer‘s hemalaun (Applichem, Germany)   2 min 
7. Rinse in tap water   5 min 
8. 1% HCl alcohol   1 sec 
9. Rinse in tap water   5 min 
 
 
8.2 Staining procedures for plastic embedded sections 
 
8.2.1 Hemalaun & Eosine (H&E) 
 
1. Mayer‘s hemalaun (Applichem, Germany) 30 min 
2. Rinse in tap water 10 min 
3. 1% HCl-Alcohol   1 sec 
4. Rinse in tap water 10 min 
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5. Dry 
6. Eosine Y (Merck, Germany)   5 min 
7. Distilled water   3 times, 3 sec 
 
8.2.2 Periodic acid-Schiff stain (PAS) 
 
1. 1% periodic acid (Applichem, Germany) 15 min 
2. Distilled water   3 times, 3 sec 
3. Schiff‘s reagent (Merck, Germany) 30-60 min 
4. Rinse in tap water 30 min 
5. Dry 
6. Mayer‘s hemalaun (Applichem, Germany) 35 min 
7. Rinse in tap water 10 min 
8. 1% HCl alcohol   1 sec 
9. Rinse in tap water 10 min 
10. Dry 
 
8.2.3 Periodic acid silver methenamine (PASM) PAS stain 
 
1. 1% periodic acid (Applichem, Germany) 15 min 
2. Distilled water   3 times, 3 sec 
3. Dry 
4. Silver-methenamine solution containing: 
 3% Methenamine solution   50 ml 
 5% Silver nitrate (Applichem, Germany)  2.5 ml 
 2% Sodium tetraborate decahydrate (Borax)   6 ml 
 Distilled water   45 ml 
 Pre-heat to 60° C in a water bath     5 min 
 
Staining: shake in a closed water bath at 60°C  15-50 min 
(staining intensity has to be controlled repeatedly)  
5. Distilled water   3 times, 3 sec 
6. 1.5% Sodium thiosulphate solution    2 min 
7. Rinse in tap water   5 min 
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8. Dry 
9. Schiff‘s reagent (Merck, Germany) 60 min 
10. Rinse in tap water 30 min 
11. Dry 
12. Mayer‘s hemalaun (Applichem, Germany) 25 min 
13. Rinse in tap water 10 min 
14. 1% HCl alcohol   1 sec 
15. Rinse in tap water 10 min 
16. Dry 
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